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Abstract 
Mycobacterium tuberculosis (MTB) encodes three enzymes that are 
dependent on vitamin B12–derived cofactors for activity, including a B12-
dependent methionine synthase (MetH). Previously, work in the Molecular 
Mycobacteriology Research Unit (MMRU) demonstrated vitamin B12 
auxotrophy in a mutant strain disrupted in the alternative, B12-
independent methionine synthase, MetE. This observation established the 
ability of MTB to transport corrinoids despite the absence of an identifiable 
B12-specific transporter. In addition, it suggested that MTB does not 
synthesize vitamin B12 in vitro. Notably, bioinformatic analyses identified 
PPE2 as the only B12-related transport candidate in MTB, though as a 
putative B12-regulated cobalt transporter. PPE2 is unusual in possessing 
directly upstream of its predicted start codon one of only two B12-
dependent riboswitches in the MTB genome, and it lies in a putative 
operon with B12 biosynthetic genes, cobU and cobQ1. In this study, the 
possibility that PPE2 functions in the transport of vitamin B12 or cobalt was 
investigated. Transcriptional and phenotypic data suggested that PPE2 
was not involved in B12 transport. Instead, it was shown that cobalt can 
supplement the growth of an MTB metE mutant in liquid medium, strongly 
supporting the ability of MTB to synthesize B12 de novo. Moreover, the 
ability to utilise exogenous cobalt was dependent on functional PPE2, 
thereby establishing a role for a PPE-family member in cobalt assimilation 
in MTB. 
Vitamin B12 comprises a central corrin ring co-ordinated to 5,6-
dimethylbenzimidazole (DMB) as α-axial ligand. Substituting DMB with 
adenine yields the alternate form, pseudo-B12. The ability of mycobacteria 
to utilize pseudo-B12 precursors (cobinamide and adenine) to support full 
function of B12-dependent metabolic pathways was evaluated. Although 
the pseudo-B12 precursors appeared to complement chemically the 
mycobacterial B12 auxotrophs, growth of the mutants on cobinamide alone 
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complicated this interpretation. To address this limitation, DMB synthesis 
was targeted by disrupting the MTB bluB homologue, Rv0306. Neither 
site-directed mutagenesis of key Rv0306 residues, nor full-gene deletion 
was sufficient to eliminate growth on cobinamide. Instead, this 
observation highlights the need to establish biochemically the nature of 
the active B12 form synthesized and utilized by MTB under different 
conditions.  
In combination, the results presented here support the inferred 
flexibility of vitamin B12 biosynthesis in MTB, and reinforce the potential 
role of B12-dependent metabolism in mycobacterial pathogenesis. 
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1. Introduction 
 
1.1 Tuberculosis 
 
Mycobacterium tuberculosis (MTB) has long been the scourge of humanity 
as it causes one of the most devastating diseases, tuberculosis (TB). This 
air-borne bacterial pathogen claimed a staggering 1.7 million lives in 2009 
alone (WHO, 2009). Although statistics indicate that the global incidence 
and deaths due to TB are decreasing, this is sadly not true for developing 
countries which continue to shoulder the weight of this burden, 
accounting for more than 90% of all new cases as well as TB-related 
deaths (WHO, 2009). In resource-poor settings, poor socio-economic 
conditions are exacerbated by concurrent infection with human 
immunodeficiency virus (HIV); in fact, countries with the highest 
prevalence of HIV are the worst affected by the TB burden (WHO, 2009). 
Another primary source of concern is the rapid emergence globally of, and 
alarming increase in, drug resistant MTB strains which further threaten the 
control and elimination of TB. Despite on-going preventative measures 
including the administration of the BCG vaccine, the availability of effective 
chemotherapeutic regimens as well as worldwide support programs, TB 
continues to be a massive global health crisis.  
 
 
1.2 Prevention and chemotherapy 
 
1.2.1 The inadequacies of BCG 
 
The current TB pandemic is testament to the critical limitations of the only 
vaccine used to prevent TB, the live-attenuated bacille Calmette-Guérin 
(BCG). This vaccine was derived by in vitro passage of a Mycobacterium 
bovis isolate over a number of years. Despite the administration of BCG to 
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more than 3 billion people worldwide (Brosch et al., 2000), its efficacy 
remains inconsistent: the protective effect in various clinical trials ranged 
from 80% to nil (Fine, 1989), with several theories offered to explain this 
variability (Colditz et al., 1994; Fine, 1995; Brewer, 2000; Behr, 2001; 
Brosch et al., 2007). Whilst there is consensus that BCG is highly effective 
in protecting against severe childhood forms of TB (Colditz et al., 1995), it 
offers no protection against the most common form of the disease - that 
is, adult pulmonary TB which represents the main source of new infections 
and is the greatest contributor to mortality (WHO, 2009). In addition, 
there is a higher risk of vaccine-related complications such as 
disseminated BCG disease in HIV-infected children (Hesseling et al., 2007; 
Hesseling et al., 2009). This prompted the World Health Organization 
(WHO) Global Advisory Committee on Vaccine Safety to contraindicate 
BCG administration in HIV-infected and HIV-exposed children (WHO, 
2007). However, not vaccinating an HIV-exposed infant who remains 
uninfected increases the risk of disseminated TB; therefore, BCG continues 
to be administered in settings where TB and HIV are highly endemic 
(WHO, 2007; Hesseling et al., 2009). 
 
These concerns highlight the urgent need for safer and more effective 
vaccines which will aid in controlling the disease. Amongst the challenges 
facing new vaccine development is the need to design a vaccine that will 
not only elicit a strong host immune response to the initial infection (pre-
exposure vaccine), but will prevent progression to disease in those 
previously exposed (post-exposure vaccine) (Brennan, 2005). Perhaps 
even more challenging is the development of a vaccine that is safe for use 
in HIV-infected populations. It is encouraging, therefore, that the last few 
years have seen substantial progress in this area: there are several 
candidate TB vaccines in the pipeline, in clinical trials or on their way to 
preclinical development (Grode et al., 2005; Tullius et al., 2008; STOPTB, 
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2009; Aagaard et al., 2011). Ideally, new vaccines should complement 
drug regimens as this will significantly aid in the fight against this disease. 
 
 
1.2.2 Chemotherapy and drug resistance 
 
TB is curable; however, chemotherapy faces its own set of challenges that 
prevent the universal control of this disease. As part of an internationally 
recommended strategy to accelerate the control and eradication of TB 
worldwide, the WHO implemented directly observed therapy, short course 
(DOTS) in the early 1990’s. The foundation of this control strategy is a 
short-course treatment comprising a daily dose of a combination of drugs 
over a period of six months, with administration of each dose supervised 
by a health care worker. The short-course treatment regimen comprises 
an intense phase of isoniazid, rifampicin, pyrazinamide and ethambutol for 
two months, followed by a continuation phase of isoniazid and rifampicin 
for an additional four months (WHO, 2010). When all five elements 
(strong government support, effective case detection, standardized 
treatment with supervision, continued drug supply, and surveillance) are 
implemented in their entirety, chemotherapy under DOTS has been shown 
to achieve high cure rates for drug-sensitive TB (Murray, 1996). However, 
this requires substantial resources and a strong health infrastructure 
(Espinal and Dye, 2005). Moreover, in the context of high TB prevalance, 
the DOTS programme is probably inappropriate (Wood et al., 2011). 
 
A combination of inadequate drug regimens as well as the lengthy 
duration of therapy, results in inconsistent or even incomplete treatment, 
which in turn promotes the selection and spread of drug resistant strains 
that are difficult to treat. Multidrug resistant strains (MDR) are resistant to 
two of the most powerful first-line drugs - isonaizid and rifampicin - and so 
necessitate treatment with second-line drugs as part of the so-called 
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“DOTS plus” programme (WHO, 2010). An expansion of DOTS, this 
programme has been tailored to the management and treatment of MDR-
TB, specifically taking into account resource-poor countries with high HIV 
co-incidence. Treatment of MDR-TB is much more protracted, more 
expensive, more toxic and is considerably more complicated as some 
drugs are administered by injection; in combination, these factors result in 
lower cure rates and increased spread of the disease (Espinal and Dye, 
2005; Marahatta, 2010).  
 
Given these complexities in treating MDR, the emergence of extensively 
drug resistant (XDR) strains of TB, which are resistant to isonaizid, 
rifampicin, any fluoroquinolone, and at least one of the three injectable 
second-line drugs (amikacin, kanamycin and capreomycin) seems almost 
inevitable (CDC, 2006). That said, the rapid lethality observed in an 
outbreak of XDR-TB among HIV-positive individuals in the town of Tugela 
Ferry located in the central KwaZulu-Natal province, South Africa, was 
alarming (Gandhi et al., 2006). The startling report by Gandhi et al. (2006) 
revealed that, of the 475 confirmed TB cases, 53 individuals (of whom 44 
were HIV positive) had XDR-TB. Fifty-two of these died within 16 days of 
diagnosis. Notably, exogenous re-infection with MDR- or XDR-TB strains 
was implicated in the development of this outbreak (Andrews et al., 
2008), suggesting poor infection control practices, lack of proper 
diagnostic testing, and ineffective treatment of susceptible and MDR-TB 
(Jassal and Bishai, 2009). Sadly, XDR-TB is very difficult to treat, requiring 
extended therapy (18-24 months) with poor outcomes and significantly 
increased costs (Chan et al., 2008). Even more distressing are the recent 
reports describing the emergence of totally drug resistant (TDR) strains, 
and the possible catastrophic implications for treatment and control of this 
form of TB (Velayati et al., 2009). Another area of concern is the 
treatment of TB in patients receiving anti-retroviral therapy due to 
unfavourable drug interactions, overlapping toxicities, high pill burden and 
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the potential for the development of immune reconstitution inflammatory 
syndrome (IRIS) (McIlleron et al., 2007). 
 
In combination, these elements are driving the need for new TB drugs. 
This has mobilized organizations like the WHO and the Global Alliance for 
TB Drug Development to dedicate enormous efforts and funding towards 
the control and eradication of TB. The WHO implemented the “Global Plan 
to STOP TB 2006-2015” which is a program that aims to halve the global 
TB prevalence by 2015 relative to 1990, and to eliminate TB as a public 
health problem by 2050 (STOPTB, 2006). Additionally, the TB Alliance 
aims to reduce the duration of chemotherapy from 6-9 months to 2 
months or less, as this will improve patient adherence to therapy and 
thereby prevent further drug resistance (TBAlliance, 2005). Together, 
these organizations have been instrumental in stimulating and accelerating 
the discovery and development of new anti-tuberculosis drugs. Although 
no new drugs are expected at the dispensary soon, there are some 
promising candidates in the pipeline which include two nitroimidazole 
compounds (PA-824 and OPC-67683) and a diarylquinoline compound 
(R207910, also called TMC207) (Stover et al., 2000; Andries et al., 2005; 
Matsumoto et al., 2006; Koul et al., 2011). To ensure that this pipeline is 
populated, basic research is required that is aimed at further 
understanding TB biology at different stages of infection, as well as this 
pathogen’s extraordinary ability to subvert host immune responses.  
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1.3 Survival of MTB within the host 
 
1.3.1 Intramacrophage survival 
 
MTB’s success can be attributed to its ability to blunt the host immune 
response, and then establish a niche within the host for extended periods 
despite the hostile environments and continual immune surveillance 
(Nguyen and Pieters, 2005; Ahmad, 2011). By far the most common route 
of infection of MTB is through inhalation of aerosolized bacilli, which are 
subsequently ingested and enclosed within a phagosome within alveolar 
macrophages in the lower airways (Clark-Curtiss and Haydel, 2003). Entry 
of MTB into macrophages is facilitated through a variety of receptors 
including complement receptors (CR3, CR1, CR4), mannose receptors, Fc 
receptors and toll-like receptor (TLR) (Astarie-Dequeker et al., 1999; 
Hingley-Wilson et al., 2000; van Crevel et al., 2002; Pieters, 2008). It has 
been suggested that internalization of MTB through certain receptors is 
beneficial and may assist in circumventing immediate destruction once 
inside the macrophage. For example, ingestion through the Fc receptor 
triggers an inflammatory response, as opposed to entry via the CR3 
receptor which appears to avert macrophage activation (Caron and Hall, 
1998; Pieters, 2008). 
 
 
1.3.2 Immune evasion and granuloma formation 
 
Ingestion by activated macrophages results in the gradual acidification of 
the phagosome which fuses with lysosomes to form a phagolysosome 
(phagosome maturation) loaded with proteolytic enzymes. This is 
accompanied by a simultaneous increase in the generation of reactive 
oxygen and nitrogen intermediates which target multiple cellular 
structures and biochemical components to bring about the degradation 
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and death of the bacilli (Smith, 2003; Hestvik et al., 2005; Nguyen and 
Pieters, 2005). However, in the case of inactivated macrophages, MTB has 
evolved strategies that avoid destruction as well as allow survival and 
growth within the phagosome. These include prevention of phagosome-
lysosome fusion through a series of complex events that result in the 
retardation of phagosome maturation (Armstrong and Hart, 1971; Sturgill-
Koszycki et al., 1994; Via et al., 1997; Malik et al., 2000; Vergne et al., 
2005; Jayachandran et al., 2007), the use of specific receptors that do not 
trigger an oxidative burst upon entry into the phagosome (Wright and 
Silverstein, 1983; Schlesinger et al., 1990), resistance to reactive nitrogen 
intermediates (Miller et al., 2004), down-regulation of host immune 
modulators (Ting et al., 1999; Noss et al., 2000; Hickman et al., 2002; 
Nau et al., 2002), and blocking of apoptosis (Sly et al., 2003).  
 
As a result, MTB avoids elimination and continues proliferating 
intracellularly until phagosomal lysis occurs which releases viable bacilli 
into the surrounding lung tissue, where they are subsequently ingested by 
other macrophages (Clark-Curtiss and Haydel, 2003; Grosset, 2003). 
These immune cells similarly fail to control growth of MTB and are 
destroyed. Inflammatory cytokines and chemokines released by lysed 
macrophages stimulate the recruitment of additional monocyte-derived 
macrophages and dendritic cells to the site of infection where they readily 
ingest, but do not destroy, mycobacteria (van Crevel et al., 2002). During 
this time, dendritic cells with engulfed bacilli mature and migrate to lymph 
nodes where they prime T cells (CD4+ and CD8+) against mycobacterial 
antigens (Tufariello et al., 2003). Two to eight weeks post infection, a cell-
mediated immune response arises whereby primed T-cells migrate back to 
the site of infection in the lungs and activate defence mechanisms of 
macrophages containing MTB to destroy the invading bacilli or at least 
contain their growth (Saunders et al., 1999; Grosset, 2003; Ahmad, 2011). 
Moreover, T-cells strengthen antibacterial responses by recruiting and 
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activating additional immune cells, resulting in an influx of monocytes to 
the site of infection. The ensuing battle between the host immune system 
and MTB leads to the cessation of bacterial growth, and infiltration of 
immune cells that aggregate around the infected tissue to form a solid 
structure or a granuloma (Bloom and Murray, 1992; Clark-Curtiss and 
Haydel, 2003), that is sealed off from surrounding tissues by a fibrotic 
capsule (Stewart et al., 2003). Within the barricade-like structure of the 
granuloma, bacterial dissemination is prevented, and interactions between 
T-cells, macrophages and cytokines are facilitated which result in control 
of the infection in most immunocompetent individuals (Saunders et al., 
1999; Tufariello et al., 2003). 
 
 
1.3.3 Latent TB and metabolic readjustments 
 
In about 10% of infected individuals, bacilli continue to proliferate –
presumably due to ineffective T-cell responses – which results in the 
development of TB within 1-2 years (Caruso et al., 1999; Dye et al., 
1999). The remaining 90% successfully control the infection; however, a 
residual proportion of bacilli persist for extended periods within the 
granuloma (Ducati et al., 2006). The only clinical evidence of a latent TB 
infection (LTBI) is a delayed-type hypersensitivity response against 
mycobacterial antigens, demonstrated by the tuberculin skin test 
(Glickman and Jacobs Jr, 2001). Latently infected individuals are 
asymptomatic; however, several factors including HIV, cancer, diabetes, 
drug use, and malnutrition are known to favour reactivation and clinical 
manifestation of MTB (Parrish et al., 1998; Cosma et al., 2004).  
 
Although poorly understood, during LTBI bacilli within granulomas are 
thought to be characterized by decreased metabolic activity and limited or 
no replication (Hu et al., 2000; Muñoz-Elías and McKinney, 2005; Gill et 
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al., 2009). The environment within the granuloma is hostile with reduced 
availability of oxygen, acidic pH, the presence of toxic fatty acids, nitric 
oxide stress, and scarce supply of nutrients (Smith, 2003), all of which are 
thought to drive MTB into a non- or slowly replicating, drug-tolerant state. 
Several in vitro and in vivo models including the Wayne model (Wayne 
and Hayes, 1996; Wayne and Sohaskey, 2001), nutrient starvation model 
(Betts et al., 2002), Cornell mouse model (McCune et al., 1956), and low-
dose murine model (Orme, 1988) have been developed to recreate 
aspects of this state, as latency in the human host can take years to 
manifest and is not experimentally tractable. Although individually these 
models do not fully emulate the scenario between the host and bacterium 
during infection, they have proved very useful in investigating the 
metabolism and physiology of MTB under multiple conditions and stresses 
thought to prevail during chronic, persistent infection. 
 
Together with phenotypic, transcriptomic and proteomic analyses utilizing 
model systems, studies have identified various genes induced under 
conditions of non-replicating persistence. Overall, these observations 
indicate that under nutrient starvation, low oxygen, and nitrosative stress, 
MTB utilizes many mechanisms that allow it to undergo significant 
metabolic reprogramming to survive during chronic infection. Some of 
these include the induction of stress-related pathways including the 
dormancy regulon which is comprised of approximately 50 genes under 
the control of the dosR/S/T two-component regulatory system and is 
induced during hypoxia and upon exposure to low-dose nitric oxide or to 
carbon monoxide (Schnappinger et al., 2003; Voskuil et al., 2003; Kendall 
et al., 2004; Roberts et al., 2004; Voskuil et al., 2004a). The α-crystallin 
like protein hspX which is induced in response to stationary phase, low 
oxygen and nitrosative stress (Yuan et al., 1996); (Cunningham and 
Spreadbury, 1998; DesJardin et al., 2001) and the RelMtb-regulated 
stringent response to nutrient starvation (Primm et al., 2000; Betts et al., 
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2002). Additionally, mycobacterial factors involved in cell wall 
modifications (pcaA) (Glickman et al., 2000), anaerobic energy metabolism 
(narX) (Hutter and Dick, 1999; Sherman et al., 2001) and lipid metabolism 
(icl ) (Wayne and Lin, 1982) have also been identified as playing a role in 
persistence.  
 
 
1.4 Carbon metabolism in MTB 
 
Seminal experiments by Segal and Bloch (1956) suggested the importance 
of carbon metabolism to mycobacterial physiology; however, the extent of 
the role of alternate carbon sources in MTB has only been realized and 
fully appreciated recently. Like many bacterial species, MTB can 
metabolize a variety of carbon sources to generate energy during growth 
in synthetic media (Wheeler and Ratledge, 1994). This is consistent with 
the presence of enzymes required for glycolysis, the pentose phosphate 
pathway, the tricarboxylic acid (TCA) cycle, the glyoxlate cycle and the 
methylcitrate pathway in MTB (Cole et al., 1998). One of the main 
challenges faced by MTB during infection is the need to acquire nutrients 
from host cells. Even though carbohydrate and lipid metabolism genes 
have been shown to be transcribed during infection (Talaat et al., 2007), 
the types of nutrients available to MTB within the host remain unclear. 
However, emerging evidence has implicated lipids as the dominant carbon 
source.  
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1.4.1 Lipids as the dominant carbon source  
 
Early studies by Segal and Bloch (1956) demonstrated that bacteria 
isolated from mouse lung responded to substrates containing fatty acids, 
whereas broth-grown bacilli responded to a variety of carbon sources. This 
was the first indication that MTB obtained its energy from the metabolism 
of fatty acids as opposed to carbohydrates during infection. Subsequently, 
Wayne et al. (Wayne, 1977; Wayne and Hayes, 1996) developed the in 
vitro model of latency based on the idea that MTB adapts to the oxygen-
deficient environment within the granuloma. During the metabolic shift 
that occurs as a result of gradual oxygen depletion, enzymes involved in 
the glyoxlate shunt are up-regulated (Wayne and Lin, 1982). The 
glyoxylate shunt is an anaplerotic pathway that consists of two enzymes, 
isocitrate lyases (ICL) and a malate synthase (GlcB), which facilitate the 
conversion of fatty acids into carbohydrates by bypassing the two 
oxidative steps of the TCA cycle (Wayne, 1994). Furthermore, a complex 
repertoire of more than 250 genes involved in lipid metabolism is present 
in the MTB genome (Cole et al., 1998). Genes involved in lipid 
metabolism, together with those encoding glyoxylate cycle enzymes, are 
up-regulated during infection of macrophages (Schnappinger et al., 2003) 
and mice (Timm et al., 2003; Dubnau et al., 2005). 
 
Fatty acids can be catabolized via the glyoxylate shunt and the β-oxidation 
cycle; however, the latter is the dominant pathway utilized in bacteria 
(McKinney et al., 2000; Muñoz Elías and McKinney, 2006; Marrero et al., 
2010). Catabolism of fatty acids and lipids via β-oxidation generates 
acetyl-CoA that is shunted into the glyoxylate cycle to prevent carbon loss 
via the TCA cycle; this produces succinate which can be converted into 
glucose (Manabe and Bishai, 2000; Bentrup and Russell, 2001; Muñoz 
Elías and McKinney, 2006). Carbon flux into the glyoxylate cycle is 
mediated by ICL, which catalyzes the conversion of isocitrate to succinate 
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and glyoxylate and, in MTB Erdman, is encoded by two genes, icl1 and 
icl2. In contrast, H37Rv has a single ICL, encoded by icl1 (Muñoz-Elías and 
McKinney, 2005). When both isoforms, ICL1 and ICL2 were absent, the 
Erdman strain of MTB was able to grow on carbohydrates but incapable of 
growth on fatty acids or in macrophages, and was rapidly eliminated from 
the lungs of infected mice (Muñoz-Elías and McKinney, 2005). These data 
suggest that the glyoxlate shunt is essential for survival during murine 
chronic infection. In addition, oxaloacetate (OAA) from the glyxolate cycle 
can be fed into gluconeogensis, where it is converted to 
phosphoenolpyruvate (PEP) by the pckA-encoded phosphoenolpyruvate 
carboxykinase (PEPCK). A pckA deletion mutant of MTB was impaired for 
growth on fatty acids but not glucose in vitro (Marrero et al., 2010), 
indicating that this enzyme does not function in the reverse direction in 
MTB; that is, the conversion of PEP to OAA (Marrero et al., 2010). PEPCK 
was also shown to be required for growth and survival in macrophages 
and mice (Marrero et al., 2010), and was induced by fatty acids in vitro 
(Schnappinger et al., 2003; Dubnau et al., 2005), and during growth of 
MTB in mice (Timm et al., 2003). Together these data strenthen the idea 
that MTB subsists on fatty acids in vivo. 
 
 
1.4.2 Sources of lipids during infection 
 
The ability of MTB to shift its metabolism to utilize lipids as a carbon 
source appears to be a key strategy for persistence and survival during 
the chronic phase of infection. The types of lipids available to MTB within 
the varied microenvironments in the host remain undefined; however, 
possible sources of lipids include lung surfactant internalized by alveolar 
macrophages that is rich in long chain fatty acids (Muñoz Elías and 
McKinney, 2006), hydrolysis of lipids from the phagosomal membrane 
(Kondo et al., 1985; Muñoz Elías et al., 2006), macrophage triacylglycerol 
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(TAG) stores (Mason et al., 1972), or accumulated internal MTB TAG 
stores (Daniel et al., 2004).  
 
Emerging evidence suggests that cholesterol, a major sterol of the plasma 
membrane, is abundantly available as an alternate carbon source within 
the host. Studies have demonstrated that accumulation of cholesterol is 
necessary at the site mycobacterial entry (Gatfield and Pieters, 2000) and 
depletion inhibits cellular uptake into phagocytic cells (Nguyen and Pieters, 
2005), as well as stimulates phagosomal maturatation leading to 
decreased survival of bacilli (De Chastellier and Thilo, 2006). Pathogenic 
mycobacteria have been shown to induce the formation of foamy 
macrophages filled with lipid bodies which are known to accumulate in 
human and mouse granulomas (Cardona et al., 2000; Peyron et al., 2008; 
Russell et al., 2009). It was also demonstrated by electron microscopy 
that bacilli are positioned in proximity to lipid bodies within foamy 
macrophages and these are hypothesized to serve as a nutrient-rich 
reservoir during persistence (Peyron et al., 2008). Furthermore, 
biochemical anaylsis of the lipid species within the caseum revealed an 
abundance of cholesterol ester, cholesterol and triglycerol (Kim et al., 
2010).  
 
 
1.4.2.1 Evidence for cholesterol utilization 
 
Although several other lines of evidence have implicated cholesterol as a 
carbon source for MTB, an important study by Pandey and Sassetti (2008) 
provided the first genetic evidence that this pathogen mobilizes and 
catabolizes cholesterol from the host. With the aid of metabolic labelling 
studies, these authors reported that MTB can catabolize different portions 
of the cholesterol molecule for energy generation and the synthesis of the 
virulence factor, phthiocerol dimycocerosate (PDIM) (Pandey and Sassetti, 
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2008). Deletion of the mec4-encoded cholesterol transporter (Mohn et al., 
2008) resulted in poor growth in media containing cholesterol as a sole 
carbon source. More interestingly, a MTB mutant lacking mcec4 displayed 
impaired survival during the chronic phase of infection in mice, and in 
interferon-gamma activated macrophages (Pandey and Sassetti, 2008). 
Similar to the phenotype observed for the Δicl1 mutant of MTB Erdman 
(McKinney et al., 2000), loss of mce4 function had no effect on growth in 
non-activated macrophages or during the acute phase of murine infection. 
These data suggest that cholesterol is an important nutrient source during 
chronic infection when interferon-gamma macrophages are activated. 
However, it remains unclear what constitutes the major nutrient source for 
MTB during earlier stages of infection. 
 
Subsequently, a study by Chang and collegues (2009) found that deletion 
of the intracellular growth operon (igr) inhibited growth of MTB in 
cholesterol-containing media, whereas growth on short- and long- chain 
fatty acids was unaffected. Elimination of the Mce4 transporter in the ∆igr 
mutant partially reversed this cholesterol-dependent phenotype (Chang et 
al., 2009). Moreover, the ∆igr mutant displayed attenuation in mice during 
the early phase of infection, possibly due to accumulation of toxic 
intermediates produced by cholesterol catatabolism. Conversely, 
disruption of the cholesterol import system (mce4) in the ∆igr mutant 
resulted in attenuation during late phase murine infection, reinforcing the 
importance of cholesterol during infection. Recently, the igr operon was 
shown to be necessary for the degradation of the 2’-propanoate side chain 
of cholesterol metabolites by MTB (Thomas et al., 2011). These results are 
consistent with the idea that, in mice (Miner et al., 2009) and guinea pigs 
(Yang et al., 2011), cholesterol is avaliable throughout infection and only 
becomes limiting during the chronic phase – after the onset of adaptive 
immunity has altered the environment. Importantly, infection of guinea 
pigs with an MTB strain deficient in an iron-dependent extradiol 
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dioxygenase (hsaC), a key enzyme in cholesterol catabolism (Van der 
Geize et al., 2007), resulted in slower dissemination, decreased 
persistence, and reduced pathology in the lungs (Yam et al., 2009). 
Together, these studies confirm that cholesterol utilization by MTB is 
important in chronic disease as well as earlier in infection and suggest that 
this sterol is likely to contribute to the pathogen’s ability to disseminate in 
the host. This conclusion is supported by the recent identification of an 
expanded set of genes which are predicted to be essential for cholesterol-
dependent growth of MTB (Griffin et al., 2011). 
 
 
1.4.3 Toxicity associated with lipid metabolism 
 
Beta-oxidation of even-chain fatty acids yields acetyl-CoA, whilst β-
oxidation of cholesterol, odd- and branched- chain fatty acids produces 
propionyl-CoA in addition to acetyl-CoA (Muñoz Elías et al., 2006). 
Propionyl-CoA can be oxidized to pyruvate via the methylcitrate cycle, 
whose specific enzymes, methylcitrate synthase and methycitrate 
dehydrogenase, are encoded by prpC and prpD, respectively. Muñoz-Elías 
and McKinney (2006) observed that a MTB prpDC mutant was unable to 
grow on odd-chain fatty acids such as propionate and valerate, but was 
able to grow on even chain fatty acids. Together with their previous 
observation that a Δicl1 Δicl2 double mutant of MTB mutant was unable to 
grow on either odd- or even- chain fatty acids (Muñoz-Elías and McKinney, 
2005), this led the authors to conclude that ICL1 could function as 
methylisocitrate lyase. Together these results also demonstrated the 
essentiality of the methylcitrate cycle in MTB in detoxifying propionate, 
and reinforced the notion that, although propionate is a high-energy 
metabolite, its accumulation is toxic to the bacterial cell. For this reason, it 
is likely that propionate metabolism fulfils an essential function in 
16 
 
preventing the toxic build-up of propionyl-CoA within the cell. It was 
surprising, therefore, that a prpDC mutant of MTB Erdman showed no 
defect in growth or persistence in a mouse model of infection (Muñoz Elías 
and McKinney, 2006), in contrast to a Δicl1 mutant, which showed a 
persistence defect (McKinney et al., 2000) and a Δicl1 Δicl2 double 
mutant, which showed a dramatic phenotype, being unable even to 
establish an infection (Muñoz-Elías and McKinney, 2005). Besides 
confirming the critical role of ICL in disease pathogenesis, these findings 
suggested that propionyl-CoA detoxification in vivo could occur via a 
route(s) other than through the methylcitrate cycle (Muñoz-Elías and 
McKinney, 2005). That interpretation has gained greater credence with the 
recent demonstration that survival of an MTB prpDC mutant in a 
macrophage model of infection is enhanced by the addition of vitamin B12 
to the growth medium (Griffin et al., 2012). In particular, this result 
suggests that the B12-dependent methylmalonyl pathway might function to 
alleviate propionate stress in vivo, which in turn implies that MTB might be 
able to synthesize - or access - vitamin B12 during host infection. 
 
The first step in the methylmalonyl pathway involves the conversion of 
propionyl-CoA to (S)-methylmalonyl-CoA via the propionyl-CoA 
carboxylase (PCC) enzyme. This provides intermediates (methylmalonyl-
CoA) for the biosynthesis of methyl-branched lipids such as PDIM and 
sulfolipid (SL)-1 (Yang et al., 2009). These surface exposed lipids form an 
integral part of MTB’s cell wall as they provide protection against host-
induced damage, as well as modulate the immune response (Reed et al., 
2004; Rousseau et al., 2004), and so have been implicated in virulence. 
Recently, it was demonstrated that MTB grown on propionate or odd-
chain fatty acids displayed increased mass and abundance of PDIM and 
SL-1; however, no increase was observed when grown on short- and 
even- chain fatty acids (Jain et al., 2007). In fact, growth on propionate or 
odd- chain fatty acids resulted in the extension of PDIM mycocerosic acids 
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by 3-carbons, which in turn suggests the direct incorporation of the 
propionyl-CoA intermediate methylmalonyl-CoA. Interestingly, PDIM 
isolated from wild-type MTB in mouse lungs also displayed increased mass 
and lengthened mycocerosic acids. This result might indicate comparable 
propionyl-CoA build up as a result of β-oxidation of host lipids that 
increased the flux of methylmalonyl-CoA through lipid biosynthetic 
pathways which in turn increased virulence lipid biosynthesis. 
 
In another recent study, it was reported that MTB responds to redox 
fluctuations by selectively incorporating C3 compounds such as propionate 
or propionyl-CoA into cell wall lipids like polyacyltrehaloses (PAT), PDIM, 
SL-1 and the storage lipid TAG under the control of the DosR/S/T 
dormancy regulon (Singh et al., 2009). This C3 compound incorporation 
was observed in murine macrophage infections and was shown to be 
controlled by the transcriptional regulator WhiB3, which operates via a 
thiol-disulphide redox switch. Supporting the role of WhiB3 as a regulator 
of mycobacterial lipids, microarray data indicate up-regulation of WhiB3 
together with genes responsible for the production of SL-1, PAT, DAT and 
TAG in macrophages (Rohde et al., 2007). A MTB WhiB3 deletion mutant 
was able to grow even on toxic concentrations of propionate; in addition, 
this mutant was associated with increased levels of PDIM during growth in 
liquid (7H9/OADC) culture and within macrophages. Therefore, the 
possibility remains that MTB might differentially incorporate C3 
compounds into cell wall lipids as a means of detoxification. 
 
In addition to detoxifying excess intracellular propionate into cell wall 
lipids via the first steps of the methylmalonyl pathway, the last step of this 
pathway can be utilized to catabolise propionyl-CoA for energy generation. 
This step entails the isomerization of (R)-methylmalonyl-CoA to (S)-
methylmalonyl-CoA, which is converted to succinyl-CoA (Savvi et al., 
2008) in a reaction catalyzed by the mutAB-encoded methylmalonyl-CoA 
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mutase, a B12-dependent enzyme (Savvi et al., 2008). The succinyl-CoA 
can be fed into the TCA or glyoxylate cycles. Previously, Muñoz-Elías and 
McKinney (2005) demonstrated that treatment of MTB with the ICL 
inhibitor, 3-nitropropionate (3-NP), resulted in growth inhibition in media 
containing fatty acids, and that this phenocopied the Δicl1 Δicl2 deletion 
mutant. However, in work done in the MMRU, Savvi et al. (2008) 
subsequently demonstrated that the 3-NP-mediated growth inhibition of 
MTB on propionate could be alleviated by enabling the methylmalonyl 
pathway through addition of vitamin B12 to the growth medium (Savvi et 
al., 2008). This result demonstrated the functionality of the methylmalonyl 
pathway in vitro and so identified a third option available to MTB for the 
detoxification of propionate. It also reinforced the idea that the 
dispensability of the methylcitrate pathway observed in vivo (Muñoz Elías 
et al., 2006) could result from the functioning of the methylmalonyl 
pathway, and so confirmed the potential relevance of vitamin B12 to 
mycobacterial pathogenesis. The extent to which vitamin B12 availability 
dictates the functioning of this B12-dependent pathway remains unclear; 
however, it does raise important questions pertaining to MTB’s ability to 
access and/ or synthesize the cofactor in vivo. Previous studies have 
implicated other vitamins including vitamin B5 (Sambandamurthy et al., 
2002), and vitamin B6 (Dick et al., 2010) in MTB pathogenesis. However, 
the metabolically demanding biosynthesis of a cofactor of the structural 
complexity of vitamin B12 in MTB remains poorly explored by comparison. 
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1.5 Vitamin B12  
 
Vitamin B12, also known as cobalamin (Cbl), was first discovered when 
patients suffering from pernicious anaemia showed clinical as well as 
haematological improvements when they consumed a diet of raw liver 
(Whipple and Robscheit-Robbins, 1925; Minot and Murphy, 1926). This 
discovery earned Minot, Murphy and Whipple the Nobel Prize in Physiology 
and Medicine in 1934. Twenty years later, the anti-pernicious anaemia 
factor was independently isolated by Rickes et al. (1948) and Smith 
(1948) as a red crystalline compound from liver, and was named Vitamin 
B12. Owing to its importance for human health, vitamin B12 has been 
extensively studied ever since.  
 
 
1.5.1 Structure of vitamin B12 
 
In 1956, Dorothy Hodgkin and colleagues elucidated the complex, three-
dimensional structure of vitamin B12 (Hodgkin et al., 1956) and, together 
with Lenhert, later revealed the structure of the biologically active form of 
vitamin B12, adenosylcobalamin (AdoCbl) (Lenhert and Hodgkin, 1961). 
This earned Hodgkin the second Nobel Prize for B12-related research in 
1964, this time in the field of Chemistry. Cbl belongs to the same 
structurally complex prosthetic group as chlorophyll, heme, siroheme, and 
coenzyme F430, all of which are derived from the common macrocyclic 
biosynthetic intermediate, uroporphyrinogen III (Raux et al., 1998a; 
Rodionov et al., 2003). Structurally, Cbl is composed of a cobalt-centred 
corrin ring which is attached via an aminopropanol linker to a lower α-
ligand - 5,6-dimethylbenzamidazole (DMB) - and to an upper β-ligand 
comprising a methyl (methylcobalamin; MeCbl), adenosyl group (AdoCbl), 
or hydroxyl group (OHCbl) (Figure 1.1) (Raux et al., 1999). Naturally 
occurring analogues of vitamin B12 have either an adenosyl or methyl 
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group occupying the β-ligand: the adenosyl group is found in analogues 
involved in rearrangement or reductase reactions, while the methyl group 
is present in the cofactor that is involved in B12-dependent methionine 
synthesis (Marsh, 1999). Vitamin B12, or cyanocobalamin (CNCbl), is the 
industrially produced form that has a cyano group occupying the upper 
ligand as a result of the extraction procedure of the molecule from 
bacterial cultures (Martens et al., 2002). This form can be converted to 
either of the biologically active forms, AdoCbl or MeCbl (Martens et al., 
2002). Vitamin B12 and its analogues are often termed corrinoids and 
therefore, the abbreviation B12, will be utilized to refer to all forms of Cbl 
throughout this thesis.  
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Figure 1.1: Structure of vitamin B12 and derivatives. Vitamin B12 
(CNCbl) comprises a central corrin ring, a lower dimethylbenzimidazole 
(DMB) ligand, and an upper ligand containing a cyano group. CNCbl is the 
industrially produced form; the forms that occur in nature are 
methylcobalamin (MeCbl), hydroxocobalamin and adenosylcobalamin 
(AdoCbl; coenzyme B12), in which the cyano group is replaced as upper 
ligand (Martens et al., 2002; Warren et al., 2002). 
 
 
1.6 Vitamin B12 biosynthesis  
 
Vitamin B12 is an essential nutrient required by various forms of life; 
however, the de novo biosynthesis of this molecule is restricted to a select 
group of bacterial and archaeal species (Martens et al., 2002; Rodionov et 
al., 2003). It has been proposed by Roth and colleagues (1996) that the 
B12 biosynthetic pathway originally evolved to allow anaerobic 
fermentation of small molecules in the absence of an electron acceptor 
and, as the pathway continued to evolve, siroheme (allowing use of 
inorganic electron acceptors), chlorophyll (oxygen production), and heme 
(aerobic respiration) were produced. As the atmospheric levels of oxygen 
increased, many organisms lost fermentative functions and metabolic 
dependency on B12 decreased (Roth et al., 1996). However, both aerobic 
and anaerobic pathways for vitamin B12 biosynthesis have been identified 
in bacteria.  
 
A diverse set of enzymatic reactions involving the products of more than 
30 genes (denoted cob and cbi genes) is required for de novo biosynthesis 
of B12 (Roth et al., 1993). Previously, AdoCbl biosynthesis was divided into 
three discrete steps: CobI, which entails the conversion of 
uroporphyrinogen III to the AdoCbl intermediate cobinamide; CobII, which 
involves the synthesis of DMB from probable flavin precursors; and CobIII, 
in which the covalent joining of cobinamide, DMB, and a phosphoribosyl 
group completes synthesis of the cofactor (Roth et al., 1993; Lawrence 
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and Roth, 1996). However, this schematic was rejected when distinct 
routes for B12 biosynthesis were distinguished: an oxygen-dependent 
pathway characterized in Pseudomonas denitrificans (cob genes) 
(Stamford, 1994) and an oxygen-independent pathway characterized in 
Salmonella typhimurium (cbi genes) (Roth et al., 1993). Instead, the 
identification of these pathways resulted in the reclassification of the 
pathway to comprise two major parts (Rodionov et al., 2003). The first 
step is an energetically demanding process that involves corrin ring 
synthesis, and differs in the aerobic and anaerobic pathways in terms of 
cobalt insertion - that is, the two pathways diverge at the precorrin-2 step 
and merge again at adenosylcobyric acid (Raux et al., 1999; Warren et al., 
2002). In oxygen-dependent synthesis, precorrin-2 is methylated to 
precorrin-3A; in contrast, in oxygen-independent synthesis, precorrin-2 is 
chelated with cobalt to give cobalt-precorrin-2 (Raux et al., 1999). 
Therefore, these two pathways are quite distinct in that the oxygen-
independent pathway begins with the insertion of cobalt, while in the 
oxygen-dependent pathway, insertion of cobalt occurs much later - after 
nine further reactions. In addition, the cobalt-chelatases utilized in these 
pathways differ: in the oxygen-dependent pathway, CobNST requires ATP, 
whereas the oxygen-independent chelatase from S. typhimurium, CbiK, 
does not require any high-energy metabolites (Raux et al., 1997; 
Rodionov et al., 2003). The second part of the synthetic pathway is 
common to both aerobic and anaerobic routes, and comprises 
adenosylation, attachment of aminopropanol, and assembly of the 
nucleotide loop (Warren et al., 2002).  
 
Besides differing in the timing of cobalt insertion and the requirement for 
molecular oxygen, the aerobic and anaerobic synthetic pathways can be 
distinguished at the genetic level according to the presence or absence of 
hallmark genes. For example, aerobic ring contraction requires two 
enzymes, CobG and CobJ, the former requiring molecular oxygen for 
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activity. From comparative genetic studies, there seems to be no 
homologue of this monoxygenase in facultative anaerobes such as S. 
typhimurium (Roth et al., 1993) and Propionibacterium shermanii 
(Santander et al., 1997). Instead, organisms which synthesize B12 
anaerobically contain two other indispensable enzymes (Raux et al., 1996; 
Raux et al., 1998b): CbiD, which is involved in C-1 methylation (Roessner 
et al., 2005), and CbiG, a cobalt-precorrin-5A hydrolase (Kajiwara et al., 
2006). The anaerobic CbiD has been suggested to be a homologue of the 
aerobic methyltransferase CobF (Roper et al., 2000). Additionally, no 
homologues of P. denitrificans genes cobNST - which are required for late 
cobalt insertion - or cobF, cobE and cobW, were found in S. typhimurium 
(Raux et al., 1996; Warren et al., 2002). Conversely, S. typhimurium cbiK, 
which is required for cobalt chelation of precorrin-2, is not found in P. 
denitrificans (Raux et al., 1997). 
 
Although there appear to be certain hallmark features of the aerobic and 
anaerobic routes in terms of the presence or absence of specific genes, 
some bacteria have been shown to synthesize B12 under both conditions. 
Lawrence and Roth (1996) examined the B12 biosynthetic capability of 
enteric bacteria and found that most organisms belonging to this family 
are able to synthesize B12 both aerobically and anaerobically. However, S. 
typhimurium seems to be an exception in that it is only able to synthesize 
B12 de novo under strict anaerobic conditions (Jeter et al., 1984). Perhaps 
to compensate, this bacterium is able to take up incomplete corrinoids and 
the α-ligand DMB aerobically to synthesize B12 (Escalante-Semerena et al., 
1990). Uptake of only cobinamide, an incomplete corrinoid composed of 
the corrin ring plus aminopropanol side chain, generates only 100 
molecules of B12, which is apparently insufficient to support growth on 
ethanolamine; however, uptake of both cobinamide plus DMB markedly 
increases B12 production (Andersson and Roth, 1989; Carkeet et al., 
2006). Another enteric bacterium, E. coli, lacks the bulk of the genes 
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required for de novo B12 biosynthesis (Lawrence and Roth, 1996). This 
bacterium appears to possess remnants of the B12 pathway that allow it to 
synthesize a complete molecule by attaching upper and lower ligands to 
incomplete corrinoids (Lawrence and Roth, 1995). Therefore, in these 
organisms, an incomplete set of biosynthetic genes is compensated for by 
uptake utilizing an elaborate transport system.  
 
 
1.6.1 Synthesis of the lower ligand 5,6-dimethylbenzamidazole 
(DMB) 
 
Until recently (Gray and Escalante-Semerena, 2007; Taga et al., 2007), 
the synthesis of the α-axial ligand, DMB, was the one of the steps of the 
B12 biosynthetic pathway that remained a mystery. Previous studies 
demonstrated anaerobic synthesis of DMB in Eubacterium limosum from 
erythrose, glycine, formate, glutamine and methionine (Warren et al., 
2002); however, enzymes catalysing these reactions have not yet been 
identified (Escalante-Semerena, 2007; Taga and Walker, 2008). As with 
corrin ring synthesis, an aerobic DMB pathway was also elucidated which 
showed that DMB was derived from flavin mononucleotide (FMN) (Renz, 
1970; Höllriegl et al., 1982; Keck et al., 1998). Recent studies on the 
aerobic pathway in Rhodospirillum rubrum and Sinorhizobium meliloti 
found that the bluB gene was necessary for the formation of DMB from 
FMN in an oxygen dependent manner (Campbell et al., 2006; Gray and 
Escalante-Semerena, 2007; Taga et al., 2007). This was further confirmed 
in S. meliloti by introducing point mutations in two key residues commonly 
observed in bluB homologues (Taga et al., 2007). Mutation of aspartate at 
position 32 and the glycine at position 167 in the S. meliloti BluB, either 
individually or in combination, abrogated DMB synthesis. Interestingly, 
Salmonella enterica synthesizes the corrin ring anaerobically and derives 
DMB aerobically from FMN, yet no ortholog of bluB appears to exist in its 
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genome (Keck et al., 1998; Anderson et al., 2008). Bioinformatic analyses 
have revealed the Rv0306 gene in MTB as a putative homologue of S. 
meliloti bluB (Rodionov et al., 2003; Taga et al., 2007). A crucial similarity 
between S. meliloti BluB and Rv0306 is the conservation of the two key 
residues described above. 
 
 
1.6.2 Mycobacterial B12 biosynthesis 
 
The genome sequence of the commonly utilized laboratory strain, MTB 
H37Rv, was published in 1998 (Cole et al., 1998). Subsequent 
comparative bioinformatic analysis of genes involved in B12 biosynthesis 
has elucidated putative homologues in MTB (Figure 1.2), revealing that 
the organism possesses a near-complete B12 biosynthetic pathway 
(Rodionov et al., 2003; Dawes, unpublished). Key features of the 
predicted pathway are suggestive of aerobic B12 biosynthesis in MTB: the 
putative mono-oxygenase, CobG, which contains an iron-sulphur centre 
and is responsible for converting precorrin-3A into precorrin-3B, is of the 
type that requires molecular oxygen for activity (Debussche et al., 1993; 
Spencer et al., 1993a). In addition, MTB possesses an aerobic-type CobN. 
Moreover, it is predicted that cobalt insertion occurs late in the MTB B12 
biosynthetic pathway, and the MTB CobK and CobJ orthologues show 
conservation of residues commonly found in aerobic bacteria (Shearer et 
al., 1999; Warren et al., 2002). Interestingly, however, MTB appears to 
possess some features that are characteristic of anaerobic biosynthesis; 
for example, Rv0259c exhibits homology to CbiX, a cobalt chelatase (Raux 
et al., 1998b) that was identified in Bacillus megaterium and shown to 
chelate Co2+ into sirohydrochlorin - an intermediate of heme biosynthesis 
that can either be utilized in the synthesis of siroheme or AdoCbl (Leech et 
al., 2002; Raux et al., 2003). The functionality of this homologue is yet to 
be proven in MTB. Pseudomonas aeruginosa also possesses hallmarks of 
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both oxygen-dependent (CobG, CobN) and -independent (CbiD, CbiG) 
pathways, and is able to synthesize B12 aerobically and anaerobically 
(Raux et al., 2000). Therefore, the presence of these enzymes is 
consistent with the notion that MTB encounters oxygen-limiting 
environments in vivo to which it must adapt.  
 
Interestingly, other mycobacteria including Mycobacterium smegmatis 
(MSM), M. bovis and Mycobacterium avium also appear to have retained 
either all or parts of this pathway (Dawes, unpublished), with B12 
biosynthetic genes in MSM (Figure 1.2) indicative of aerobic synthesis 
(Rodionov et al., 2003; Dawes, unpublished). The predicted mycobacterial 
B12 biosynthetic pathways are consistent with results of a study by 
Karasseva et al. (1977) which used a microbiological assay to infer vitamin 
B12 biosynthesis by mycobacteria including M. bovis, M. phlei and MSM. 
This is despite the fact that no homologues of CobST - which in P. 
denitrificans, forms a complex with CobN and is responsible for cobalt 
insertion (Debussche et al., 1992) - could be identified by homology 
searches in mycobacterial genomes. Cobalt chelatase activity is only 
observed in the presence of the two component system (Warren et al., 
2002). It is possible that insertion of cobalt in mycobacteria is mediated by 
CysG which, in S. tyhphimurium, has been demonstrated to act as both a 
ferrochelatase for siroheme synthesis and a cobaltochelatase for B12 
biosynthesis (Fazzio and Roth, 1996). In E. coli, CysG is a multifunctional 
enzyme whose N-terminus is similar to that of CobA proteins which are 
responsible for methyltransferase activity, and whose C-terminus provides 
cobaltochelatase activity (Spencer et al., 1993b; Warren et al., 1994). MTB 
CysG exhibits homology to the E.coli protein over the entire length of the 
gene, including the NAD+ binding site in the N-terminus. In MTB and M. 
bovis, no homologue was found for CobF, which functions as a 
deacetylase and a methyltransferase in P. denitrificans (Debussche et al., 
1993; Min et al., 1993); however this enzyme is present in MSM 
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(MSMEG_5548) and M. avium (MAV_1065). In M. bovis, the 5’ region of 
cobL has been deleted in addition to two upstream genes (Brosch et al., 
2002), yet this mycobacterium still appears to be able to synthesize B12 
(Karasseva et al., 1977). Based on sequence comparisons, the bifunctional 
activity of CobL is predicted to be in the N- and C-terminal regions, which 
encode the methyltransferase and decarboxylase activities, respectively 
(Roth et al., 1993; Raux et al., 2000). In contrast, the equivalent protein 
in S. typhimurium is encoded by two separate genes, cbiT and cbiE (Raux 
et al., 2000; Rodionov et al., 2003). Interestingly, cbiE shows homology to 
cobI in addition to cobL suggesting that cobI may be able to substitute for 
cobL in mycobacteria.  
 
 
1.6.3 Vitamin B12 biosynthesis in MTB 
 
Putative homologues for most of the B12 biosynthetic genes have been 
identified in MTB. This near-complete B12 biosynthetic pathway appears 
not to contain homologues of cobF and cobST. CobF functions as a 
methyltransferase (Min et al., 1993) and, in MTB, a nonorthologous 
displacement of CobF is predicted to be encoded by Rv2067c, which 
houses a C-terminal methyltransferase domain (Figure 1.2) and has been 
designated as metZ (Rodionov et al., 2003). Late-stage cobalt insertion 
into hydrogenobyrinic-acid a,c-diamide is catalyzed by three subunits: 
CobN, CobS and CobT (Debussche et al., 1992). CobS and CobT are 
thought to form a complex that interacts with CobN to generate 
cob(II)yrinic acid a,c-diamide (Figure 1.2). The cobalt chelatase subunits 
CobN, CobS and CobT display significant homology to the magnesium 
chelatase subunits ChlH, ChlI and ChlD that function in bacteriochlorophyll 
biosynthesis (Gibson et al., 1995; Schubert et al., 1999). Therefore, it is 
hypothesized (Rodionov et al., 2003) that ChlD is the missing component 
of the cobaltochelatase complex which, in MTB, is encoded by Rv2850c 
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and is annotated as a magnesium chelatase (Figure 1.2). Notably, the 
gene encoding the cob(II)yrinic acid a,c-diamide reductase in the aerobic 
B12 biosynthetic pathway is yet to be identified in any organism. Although 
a NADH-dependent flavoprotein exhibiting cob(II)yrinic acid a,c-diamide 
reductase activity was purified in P. denitrificans (Blanche et al., 1992a). 
In MTB, Rv0306 was predicted to encode the cobalt reductase function 
(Rodionov et al., 2003). Despite the presence of the near-complete 
genetic repertoire for vitamin B12 biosynthesis, genetic evidence suggests 
that this pathway is not functional in vitro in MTB (Warner et al., 2007; 
Savvi et al., 2008). These observations appear to contradict the findings of 
Karasseva et al. (1977), and so demand further investigation.  
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Figure 1.2: Predicted pathway for AdoCbl biosynthesis in MTB. 
MTB H37Rv gene designations (http://genolist.pasteur.fr/Tuberculist/) are 
shown together with predicted Mycobacterium smegmatis mc2155 (MSM) 
homologues in green (all MSM gene names have the underscore removed 
for simplification). The pathway is adapted from Roth et al. (1993), 
Rodionov et al. (2003) and S. Dawes (unpublished); putative MSM 
homologues were identified by BLAST homology search (Altschul et al., 
1990) of the preliminary MSM database 
(http://tigerblast.tigr.org/cmr.blast/) using MTB query sequence. 
 
 
1.7 Alternate B12 cofactors: Pseudo-B12 
 
A spectrum of B12 analogues exists in nature whose functions are not yet 
fully understood. They share structural architecture with ‘orthodox’ B12 in 
the corrin ring with cobalt at the core and the β-axial ligand consisting of 
5’-deoxyadenosine, or a methyl group, but with a different α-axial ligand 
(Figure 1.1). Substituting DMB with phenolic compounds or, in the most 
common example, the purine nucleobase, adenine, generates an alternate 
B12 form known as pseudo-B12 (Figure 1.1). First reported in 1952 by 
Pfiffer and colleges, pseudo-B12 was isolated from an organism in the 
bovine rumen and was shown to be an inadequate substitute for vitamin 
B12 in small mammals and humans (Berman et al., 1956). However, E. coli 
mutants that responded to either methionine or B12 supplementation 
demonstrated the same response when supplemented with pseudo-B12 
(Davis, 1952). This alternate B12 was later identified by UV and visible 
(UV-Vis) spectroscopy to be the native cofactor of Clostridium 
tetannomorphum (Barker et al., 1958). Subsequently, this alternate form 
of vitamin B12 was found to be synthesized by a number of 
microorganisms such as Propionibacterium shermanii (Friedmann and 
Fyfe, 1969), Clostridium sticklandii (Stadtman, 1960), and Lactobacillus 
reuteri (Santos et al., 2007). 
  
32 
 
1.7.1 Role of alternate B12 cofactors 
 
More recently, Anderson and colleges (2008) demonstrated the ability of 
S. enterica to synthesize – and utilize – pseudo-B12. Specifically, these 
authors showed that pseudo-B12 could be used by all the B12- dependent 
enzymes of S. enterica raising the possibility that an “alternate” cofactor 
like pseudo-B12 might represent the preferred form under periods of high 
demand. Significantly, they also demonstrated that biosynthesis of 
pseudo-B12 from “incomplete” corrinoid precursors requires the same set 
of enzymes (CobT, CobU, CobS, and CobC) involved in the synthesis of 
“orthodox”, DMB-containing vitamin B12. This result indicated that 
nucleotide activation and attachment enzymes accommodate a variety of 
substrates. In addition, their results established that, S. enterica has the 
capacity to synthesize “complete” corrinoids aerobically by importing an 
incomplete corrinoid such as cobinamide and adding appropriate α- and β-
axial ligands, but is also able to generate B12 or pseudo-B12 de novo under 
anaerobic conditions. Subsequently, it was shown that Cyanobacterium 
synechocytis is able to synthesize pseudo-B12 de novo and this cofactor is 
utilized by the B12-dependent methionine synthase (metH) in this 
organism (Tanioka et al., 2009). Together, these observations suggest 
that the formation and utilization of pseudo-B12 is a natural physiological 
process and, further, that environmental conditions (for example, oxygen 
availability) might dictate the form of the cofactor synthesized (and 
utilized). 
 
The potential of pseudo-B12 to function in “classic” B12-dependent 
metabolism holds significant implications for MTB pathogenesis as well as 
the role of “alternate” B12 forms in other mycobacterial pathogens. For 
example, comparative genomic analyses have identified key B12 
biosynthetic and B12-dependent genes, as well as active pathways for the 
biosynthesis and scavenging of purines (including adenine) in M. leprae 
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(Wheeler, 1987; Dawes and Mizrahi, 2001), a pathogenic mycobacterium 
that has undergone extensive reductive evolution and is thought to 
approximate a minimal mycobacterial gene set (Cole et al., 2001). These 
observations raise questions as to what form of B12 might be utilized 
during host infection by MTB and other mycobacterial pathogens.  
 
 
1.8 Vitamin B12-dependent enzymes 
 
Despite the versatility of the cofactor, the actual number of known B12-
dependent enzymes remains small (Raux et al., 2000). Three classes of 
B12-dependent enzymes are known: the isomerases, the 
methyltransferases, and the reductive dehalogenases (Banerjee and 
Ragsdale, 2003). Members of all three classes of B12-dependent enzymes 
are important in microorganisms, as well as in human and animal 
metabolism; however, B12-dependent processes are yet to be identified in 
plants, fungi and insects (Croft et al., 2005). While mammals are 
restricted to two B12-dependent enzymes - methionine synthase and 
methylmalonyl-CoA mutase - prokaryotes harbour a variety enzymes 
requiring B12 cofactors (Roth et al., 1996; Banerjee and Ragsdale, 2003; 
Zhang and Gladyshev, 2009). For example, even though E. coli possesses 
relatively few B12 biosynthetic genes, it possesses four B12-dependent 
enzymes: ethanolamine ammonium lyase, epoxyqueuosine reductase, 
methylmalonyl-CoA mutase and a B12-dependent methionine synthase 
(Lawrence and Roth, 1996). 
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1.8.1 B12-dependent enzymes in MTB 
 
The MTB genome contains three enzymes which require vitamin B12 
derived cofactors for activity. These enzymes are predicted to participate 
in different aspects of cellular metabolism. The first, a methylmalonyl-CoA 
mutase encoded by mutAB (Rainwater and Kolattukudy, 1985; Savvi et al., 
2008), serves to catalyze the conversion of (R)-methylmalonyl-CoA – 
generated from β-oxidation of fatty acids – to succinyl-CoA. Intermediates 
from this pathway contribute to integral cell wall lipids which are thought 
to play a major role in survival of the bacterium in hostile in vivo 
environments. As described above, this pathway could also potentially 
present another route for propionyl-CoA detoxification, provided that 
sufficient B12 is available to satisfy the requirements of the enzyme. In 
humans, methylmalonyl-CoA mutase is required for the degradation of 
odd-chain fatty acids and certain branched-chain amino acids (Ledley, 
1990). Deficiency of the enzyme often results in fatal methylmalonoic 
acidemia as a result of the accumulation of propionyl-CoA and 
methylmalonyl-CoA (Allen et al., 1993; Qureshi et al., 1994). 
 
The second enzyme in MTB that requires a vitamin B12-derived cofactor is 
the B12-dependent methionine synthase, encoded by metH (Warner et al., 
2007). This enzyme has been shown to be functional in certain strains of 
MTB and comprises four functional units: an N-terminal homocysteine-
binding domain, methyltetrahydrofolate-binding domain, Cbl-binding 
domain and C-terminal S-adenosyl-L-methionine (SAM)-binding domain 
(Goulding et al., 1997; Warner et al., 2007). Interestingly, MetH in 
CDC1551 is truncated by 398 amino acids at the C-terminus, partially 
disrupting the Cbl-binding domain and completely eliminating the SAM-
binding domain which renders the enzyme non-functional and the clinical 
isolate a natural metH mutant (Warner et al., 2007). MetH catalyzes the 
transfer of a methyl group from N5-methyl-tetrahydrofolate to the thiolate 
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of homocysteine, thereby generating the essential amino acid, methionine 
(Banerjee and Matthews, 1990). The same reaction is also catalyzed by 
MetE a B12-independent methionine synthase that utilizes a different 
catalytic mechanism (Gonzalez et al., 1992; Matthews et al., 2003; Pejchal 
and Ludwig, 2004). Humans encode only the B12-dependent enzyme, 
while organisms that are unable to transport or synthesize the cofactor, 
such as yeasts, fungi, and plants, encode only the B12-independent 
enzyme (Hondorp and Matthews, 2004). However, many bacterial species 
that do not synthesize B12 de novo and some that synthesize B12 
exclusively under anaerobic conditions (e.g. S. typhimurium), encode both 
methionine synthase enzymes (Pejchal and Ludwig, 2004). In E. coli, 
these enzymes are differentially expressed; that is, MetH is only expressed 
in the presence of B12 which also serves to repress MetE while, in the 
absence of B12, MetE is the sole methionine synthase that is expressed 
(Greene, 1996). In humans, inhibition of methionine synthase results in 
the development of megaloblastic anaemia (Banerjee and Matthews, 
1990; Allen et al., 1993).  
 
The last of the three vitamin B12-dependent enzymes in MTB is a class II 
ribonucleotide reductase (RNR), encoded by nrdZ (Dawes et al., 2003). 
Ribonucleotide reductases are responsible for converting the pool of 
ribonucleosides to deoxyribonucleosides and therefore play an essential 
role in DNA repair and replication (Sjöberg and Sahlin, 2001). There are 
three classes of RNRs: the first can be subdivided into class Ia, Ib and Ic 
and require oxygen to generate radicals for catalysis; the second class 
(including NrdZ) does not require oxygen but is dependent on AdoCbl as a 
cofactor for radical generation; while the third class contains anaerobic 
enzymes that are inactivated by oxygen and generate a glycyl radical from 
S-adenosylmethionine and an iron-sulfur cluster (Jordan and Reichard, 
1998; Högbom et al., 2004; Nordlund and Reichard, 2006). MTB 
possesses a class Ib RNR which comprises nrdE-and nrdF2-encoded 
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subunits and has been shown to be essential under in vitro conditions 
(Dawes et al., 2003). Interestingly, the MTB genome also contains two 
other putative class Ib RNR small subunits NrdF1 and NrdB, but these are 
dispensable for growth in vivo and in vitro under various stresses (Mowa 
et al., 2009). The class II RNR is encoded by nrdZ which is part of the 
DosR/DevR regulon (Dawes et al., 2003; Voskuil et al., 2004b). In a 
mouse model of TB infection, a ΔnrdZ mutant displayed no in vivo growth 
phenotype, suggesting that the putative class II RNR does not play a role 
during infection, at least in the murine model (Dawes et al., 2003). 
 
Superficially, none of the B12-dependent functions in MTB appears to 
justify de novo synthesis of the cofactor. At least in the case of NrdZ and 
MetH, corresponding B12-independent enzymes are predicted to catalyze 
similar functions: that is, the MTB genome encodes a class Ib RNR 
encoded by nrdE and nrdF2 (Dawes et al., 2003) and a B12-independent 
methionine synthase encoded by metE (Warner et al., 2007). However, it 
has been shown that, in E. coli, the reaction catalyzed by vitamin B12-
dependent MetH is 100-fold faster than the reaction catalyzed by the 
vitamin B12-independent version, MetE (Greene, 1996). Furthermore, the 
B12-independent enzymes, NrdZ and MetH, have been shown to be non-
essential for growth of MTB in vitro (Dawes et al., 2003; Warner et al., 
2007). In the case of MutAB, dispensability of this enzyme is suggested by 
the alternate detoxification mechanisms of propionyl-CoA that exist in MTB 
(as discussed in section 1.4.3). These results are intriguing since they 
suggest redundancy of all three B12-dependent enzymes; however, it is 
possible that enzyme multiplicity signals the importance of the different 
pathways to the survival of the bacterium. That is, differential enzyme 
utilization might be demanded of MTB by the heterogeneous environments 
encountered during colonization of the human host (Warner and Mizrahi, 
2006). 
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1.9 Bacterial B12 regulation  
 
Vitamin B12 is known to repress the expression of genes required for its 
own biosynthesis and transport (Vitreschak et al., 2003). For example, the 
full cob operon that encodes the B12 biosynthetic genes of S. typhimurium, 
and the btuB genes in E. coli and S. typhimurium which encode the B12 
outer membrane transporter, are all repressed by exogenous B12 via a 
post-translational regulatory mechanism (Lundrigan et al., 1991; 
Richter‐Dahlfors and Andersson, 1992; Vitreschak et al., 2003). In 
addition, in bacteria that possess both B12-dependent and B12-independent 
enzymes, activity of the B12-independent enzyme is often subject to 
regulation by B12 (Vitreschak et al., 2003). Regulation occurs through the 
activity of B12 riboswitches - mRNA structural elements (Vitreschak et al., 
2003) that serve as ligand-responsive genetic controls to modulate the 
expression of certain genes in response to changing concentrations of 
metabolites (Nahvi et al., 2004). Typically, riboswitches are embedded 
within the 5’-untranslated region of the mRNA sequence and are 
composed of two functionally distinct domains (Nahvi et al., 2002; 
Santillán and Mackey, 2005). The aptamer domain provides a ligand 
binding pocket that binds the target metabolite with high selectivity 
(Mandal and Breaker, 2004). The other domain is an expression platform 
which is usually located downstream of the aptamer domain and controls 
the expression of adjacent genes or operon by harnessing allosteric 
changes in the RNA structure brought about by the aptamer-metabolite 
conformation (Nahvi et al., 2002; Barrick and Breaker, 2007). Vitamin B12-
sensing riboswitches are among the largest, with aptamer domains of 
about 200 nucleotides (nt) to accommodate this large metabolite (Gruber 
et al., 2011). The first direct evidence of riboswitches as regulatory 
elements was obtained utilizing a technique called in-line probing (Nahvi 
et al., 2002), which takes advantage of the spontaneous degradation of 
RNA due to internal transesterifications (Regulski and Breaker, 2008a). 
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Nahvi and colleagues (2002) demonstrated that the E. coli btuB mRNA 
leader sequence can bind directly to AdoCbl, resulting in conformational 
changes in the secondary and tertiary structure of the RNA. The possible 
mechanism of regulation involves the formation of two alternate RNA 
structures, repressing and anti-pressing, in the presence or absence of B12 
respectively (Nahvi et al., 2002). 
 
In a recent study, Gallo et al. (2008) used in-line probing to demonstrate 
the interaction of the E. coli btuB aptamer with various derivatives of B12. 
The 202 nt riboswitch is situated in the 5’-UTR of the btuB gene which 
encodes an outer membrane protein used for transport of B12 derivatives. 
The riboswitch underwent conformational change upon binding to AdoCbl, 
CNCbl, adenosyl factor A, and adenosyl-cobinamide (AdoCbi) provided 
that the ligand concentrations were high enough. This observation 
suggested that rather than the α- or β- ligands of the B12 molecule, the 
corrin ring was responsible for triggering the structural change of the 
aptamer domain (Gallo et al., 2008). 
 
The MTB genome contains two putative B12 riboswitch motifs which are 
located immediately upstream of the metE and PPE2 genes, respectively 
(Rodionov et al., 2003; Vitreschak et al., 2003). The riboswitch upstream 
of metE has been shown to regulate transcription of the B12-independent 
methionine synthase (metE) in response to increased B12 levels (Warner et 
al., 2007). Importantly, this study, as well as the related work by Savvi et 
al. (2008) revealed that MTB does not produce B12 under standard 
conditions in vitro. In addition, these publications also provided the first 
direct evidence of vitamin B12 transport in MTB (Warner et al., 2007).  
  
39 
 
1.10 B12 transport in bacteria 
 
Owing to its large size, B12 is unable to pass through the outer membrane 
porins (Nikaido, 1994) and, therefore, is actively transported across the 
outer and cytoplasmic membranes with the aid of highly effective and 
elaborate B12 uptake systems. The only known transport systems for B12 in 
bacteria are the btuBFCD systems in Gram-negative bacteria and the 
btuFCD system in Gram-positive bacteria (Vitreschak et al., 2003). In 
enteric bacteria including E. coli, vitamin B12, cobinamide, and other 
corriniods are actively transported using the TonB-dependent outer 
member receptor BtuB which forms a complex with the ABC transport 
system BtuFCD (Cadieux et al., 2002; Cadieux et al., 2003). BtuFCD 
belongs to a large superfamily involved in the uptake of iron, 
siderophores, and heme (Zhang and Gladyshev, 2009). Corriniods present 
in femtomolar (fM) concentrations in the environment (Bassford Jr and 
Kadner, 1977) are taken up by the BtuB protein which is a Ca2+-
dependent transporter located in the outer membrane (Heller et al., 1985; 
Bradbeer et al., 1986; Cherezov et al., 2006). Delivery of the corriniods to 
the periplasmic space by BtuB requires energy provided through 
interactions with TonB, which is located in the inner membrane (Ferguson 
et al., 2007; Postle and Larsen, 2007). Once in the periplasmic space, 
corrinoids are bound by the BtuF protein (Van Bibber et al., 1999; Cadieux 
et al., 2002) which facilitates delivery to the ABC transporter BtuCD - itself 
located in the inner membrane (DeVeaux and Kadner, 1985; Borths et al., 
2005) - in an ATP-dependent manner (Gruber et al., 2011).  
 
Based on comparative bioinformatic analysis, there appear to be no 
homologues of the E. coli B12 transport system components in MTB. The 
complete or partial lack of these btu-type B12-specific transporters in MTB 
is surprising given the demonstration by Warner et al. (2007) that the 
MTB ∆metE mutant was able to grow when supplemented with B12. For 
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this reason, and notwithstanding the absence of any supporting evidence, 
the presence of a B12 riboswitch directly upstream of PPE2 is at least 
strongly suggestive of the involvement of the gene in some aspect of B12 
or B12-dependent metabolism. For example, genes possessing B12 
riboswitch motifs in other bacteria include B12 or cobalt transporters, 
chelatases, and corrin ring methyltransferases (Rodionov et al., 2003). 
Interestingly, Rodionov et al. (2003) identified PPE2 as a putative B12-
regulated cobalt transporter that these authors termed CbtG. Notably, 
PPE2 appears to lie in a putative operon with two B12 biosynthetic genes, 
consistent with the observation that most B12-regulated genes are either 
found in B12 gene clusters or are scattered along the chromosome 
(Vitreschak et al., 2003). Recently, S. meliloti was shown to encode an 
ABC-type transport system possessing a B12 riboswitch in the 5’UTR that 
transports cobalt, and not Cbl (Cheng et al., 2011). Similarly, genes of the 
energy-coupling factor (ECF) cobalt transporter encoded by CbiMNQO in 
Rhodobacter capsulatus, are often co-localized with B12 biosynthetic genes 
or under the control of a B12 riboswitch (Rodionov et al., 2006; Zhang and 
Gladyshev, 2009).  
 
 
1.10.1 Cobalt transporters in bacteria 
 
Cobalt is utilized at very low concentrations but plays an important role in 
biological systems where it is predominantly incorporated into the corrin 
ring of the B12 molecule and in non-corrin cobalt-dependent enzymes 
(Komeda et al., 1997). Similar to the transport of B12, cobalt ions must be 
transported across the outer membrane into the periplasmic space, where 
they can be transported through the inner membrane into the cytosol. As 
noted above, this process can occur via an ABC transporter like the S. 
meliloti CbtJKL cobalt transporter (Cheng et al., 2011), or the CbiMNQO 
cobalt transporter found in Rhodobacter capsulatus (Rodionov et al., 
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2006). Alternatively, nickel-cobalt (NiCoT) permeases can facilitate 
transport of cobalt (Komeda et al., 1997). Cobalt can also be taken up via 
non-specific metal transport systems; for example, CorA proteins are 
generally associated with transport of magnesium ions but some members 
of the CorA family have also been shown to transport cobalt and nickel 
(Niegowski and Eshaghi, 2007; Zhang and Gladyshev, 2009).  
 
 
1.11 The PE and PPE multigene families  
 
The genome sequence of MTB contains two highly polymorphic sets of 
genes belonging to the PE and PPE families. These acidic, glycine rich 
proteins consume 10% of the coding capacity of the MTB genome (Cole et 
al., 1998) and have attracted considerable interest in the TB research field 
as their biological functions have not yet been fully elucidated (Sampson, 
2011). The PE/PPE genes are abundant in pathogenic mycobacteria such 
as MTB, M. bovis, M. ulcerans, M. Kansasii, and M. marinum, which is 
suggestive of a role in pathogenesis (Van Pittius et al., 2006; Bottai and 
Brosch, 2009). Furthermore, the non-pathogenic MSM - whose genome is 
considerably larger than MTB (7Mb versus 4Mb) - contains only two pairs 
of PE and PPE genes (Van Pittius et al., 2006).  
 
The names “PE” and “PPE” are derived from the presence of N-terminal 
proline-glutamate or proline-proline-glutamate motifs, respectively (Cole et 
al., 1998). Even though the PE/PPE genes appear to be scattered 
throughout the genome of MTB, detailed analysis has revealed that they 
are in fact arranged in organized operons. A total of 40 operons have 
been identified with 22 of these containing specific PE/PPE gene pairs, in 
which a PE coupled with a PPE gene (Strong et al., 2006; Tundup et al., 
2006). The remaining operons contain either a PE or PPE gene, with other 
genes including conserved hypotheticals, metabolic genes or ESAT-6 
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genes. It is notable, therefore, that PPE2 is located in a putative operon 
with B12 biosynthetic genes namely, cobU and cobQ1.  
 
The N-terminal domains are conserved within the respective PE and PPE 
families, whereas the C-terminal domains of both families are of variable 
size and sequence (Van Pittius et al., 2006). This has enabled the families 
to be divided into subfamilies based on sequence homology and 
characteristic motifs in their C-terminal domains. The PE family is 
composed of 99 members that have ~110 amino acids conserved in the 
N-terminal domains (Cole et al., 1998). The polymorphic GC-rich repetitive 
sequence (PGRS) subfamily is the largest within the PE family and is 
composed of 65 members with multiple tandem repeats of glycine-glycine-
alanine (Gly-Gly-Ala) or glycine-glycine-asparagine (Gly-Gly-Asn) motifs in 
the C-terminal domains (Cole et al., 1998; Van Pittius et al., 2006). The 
remaining subgroups of the PE family consist of proteins with C-terminal 
domains of low homology.  
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Figure 1.3: Diagrammatic representation of the PE and PPE 
subfamilies in MTB. The PE (a) and PPE (b) subfamilies possess 
conserved N-terminal domains of approximately 110 and 180 amino acids 
respectively, and variable C-terminal domains which allow classification of 
proteins into various subfamilies. X represents any amino acid. Adapted 
from van Pittius et al. (2006). 
 
 
The PPE family is made up of 68 members that have ~180 amino acids in 
the N-terminal domains and are divided into four subfamilies. The PPE-
SVP subfamily is the largest, with 24 members that are characterized by a 
conserved Gly-X-X-Ser-Val-Pro-X-X-Trp motif between position 300 and 
350 in the amino acid sequence (Adindla and Guruprasad, 2003; Van 
Pittius et al., 2006). The major polymorphic tandem repeats (MPTR) 
subfamily is the second largest, and consists of 23 members. The PPE-
MPTR subfamily is characterized by multiple repeats of Asn-X-Gly-X-Gly-
Asn-X-Gly in the C-terminal and is encoded by a consensus repeat 
sequence GCCGGTGTTG that is spaced by 5bp nucleotides (Hermans et 
al., 1992; Cole and Barrell, 1998). The third PPE subfamily consists of 12 
members that display low homology at the C-terminus (Van Pittius et al., 
2006). The final subfamily, PPE-PPW, consists of only 10 members and is 
PE
PGRS (GGAGGA)nPE
PPE
PPW (PxxPxxW)PPE
SVP (GxxSVPxxW)PPE
MPTR (NxGxGNxG)nPPE
~110 aa
~110 aa
0 to ~500 aimno acids
~180 aa
~180 aa
~180 aa
~180 aa
0 to >1400 aa
0 to ~400 amino acids
~200 to ~400 amino acids
~200 to ~400 amino acids
~200 to >3500 amino acids
a) PE subfamilies b) PPE subfamilies
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characterized by 44 amino acid residues at the C-terminus comprising of 
highly conserved Gly-Phe-X-Gly-Thr and Pro-X-X-Pro-X-X-Trp motifs 
(Adindla and Guruprasad, 2003). PPE2 falls within the PPE-PPW subfamily 
(Figure 1.3). 
 
 
1.11.1 Localisation and potential function of PE/PPE proteins 
 
Although it has been more than a decade since their discovery, the 
biological function of the PE/PPE proteins remains elusive (Sampson et al., 
2001). Of the 169 PE/PPE genes analysed in one study, 128 were shown 
to be differentially regulated under 15 different conditions (Voskuil et al., 
2004b). In addition, some PE/PPEs have been shown to be required for in 
vivo survival (Ramakrishnan et al., 2000; Sassetti et al., 2003; Singh et al., 
2008) suggesting their importance in infection. In a study by Brennan et 
al. (2001), it was demonstrated that a transposon mutant of PE-PGRS33 
(encoded by Rv1818c) was associated with dispersed growth in liquid 
medium and impaired ability to enter and survive within macrophages, 
suggesting a role for this protein in macrophage uptake. Further studies 
on PE-PGRS33 have implicated this protein in host cell apoptosis (Balaji et 
al., 2007; Basu et al., 2007) and necrosis of macrophages 
(Dheenadhayalan et al., 2006). In another study, PPE18 (Rv1196) was 
shown to interact with TLR2 receptors on macrophages and activate IL-10 
production, which has been shown to inhibit the host immune response 
and thereby promote replication and persistence of MTB inside the host 
cells (Redpath et al., 2001; Nair et al., 2009). Other PE/PPEs have been 
implicated in phagosome maturation arrest (Hestvik et al., 2005) and 
modulation of vacuole acidification (Li et al., 2005; Jha et al., 2010). 
Therefore, there appears to be growing evidence of a possible role for 
these proteins in interacting with host immune components, thereby 
altering and even enabling the bacterium to avoid innate immune 
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pathways. Consistent with this idea, studies have shown that PE/PPEs are 
cell wall-associated (Banu et al., 2002; Okkels et al., 2003; Le Moigne et 
al., 2005) or even partially exposed on the cell surface (Brennan et al., 
2001; Sampson et al., 2001) thereby allowing them to be secreted from 
the bacterium into the host cell. Further evidence of their surface 
exposure includes the observation that 40 PE/PPE proteins have β-barrel 
signatures, which are found in surface-exposed proteins having 
membrane-anchored regions (Pajon et al., 2006). Thus, they appear to be 
ideally positioned to interact with the host immune system. In fact, many 
studies have demonstrated that these proteins can elicit an immune 
response; for example, a humoral immune response was detected in 
infected mice against the PGRS domain of PE-PGRS33, and a cell-
mediated immune response was detected against the PE domain (Delogu 
and Brennan, 2001). Similarly, mice immunized with the PE25 and PPE41 
pair showed increased T-cell proliferation and higher levels of interferon 
gamma, tumor necrosis factor alpha, and IL-2 cytokines (Tundup et al., 
2008). Serology studies carried out by Espitia et al. (1999) and Singh et 
al. (2001), demonstrated antibodies against PE-PGRS81 (Rv1759c) and 
the PGRS domain of Rv3367, respectively, in sera of TB infected patients, 
suggesting that some proteins from this family are present during 
infection.  
 
M. marinum appears to have the largest number of PE/PPE genes (15 and 
106 respectively) (Stinear et al., 2008), of which two PE_PGRS genes were 
shown to be required for survival and persistence in macrophages, again 
supporting the idea that these proteins are virulence factors 
(Ramakrishnan et al., 2000). Other functions in which this family has been 
implicated include the up-regulation of a PPE37 gene (Rv2123) under low 
iron conditions, suggesting that this gene may encode a siderophore that 
is involved in iron uptake (Rodriguez et al., 1999; Rodriguez et al., 2002). 
Similarly, the PE_PGRS protein encoded by Rv1759c was found to display 
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fibronectin-binding properties (Espitia et al., 1999). Additionally, PE-PPE11 
(LipX) and PE_PGRS63 (LipY) demonstrated lipase activity (Deb et al., 
2006; Mishra et al., 2008), while PE_PGRS11 also exhibited 
phosphoglycerate mutase activity (Chaturvedi et al., 2010).  
 
Owing to the technical difficulties experienced when working with PE/PPE 
proteins, only one co-crystal structure has been solved thus far, that of 
the PE25/PPE41 complex (Strong et al., 2006). The structure revealed that 
the most conserved regions of the PE/PPE pair were responsible for 
protein-protein interactions, and also identified the presence of a possible 
docking site, which in turn suggested that other proteins could be 
recruited to the complex (Strong et al., 2006). Further analysis revealed 
that the PPE protein of the complex shared some features with a serine 
chemotaxis receptor; therefore, it was proposed that PE/PPE complexes 
may be involved in host immune sensing and signalling (Strong et al., 
2006). More structural data are clearly necessary in order to understand 
the function of these proteins. Overall, this intriguing family has been 
implicated in disease pathogenesis and other non-related areas; however 
complete understanding of their function remains a research priority. 
 
 
1.11.2 Association of PE/PPEs with esx regions 
 
Comparative genomic studies have revealed that the evolution and 
expansion of the PE/PPE gene families are coupled with the esx regions 
(van Pittius et al., 2001). The MTB genome contains five Esx gene clusters 
which encode the components of the Type VII or ESX secretion systems 
(van Pittius et al., 2001). The five ESX systems (ESX-1 to ESX-5) in MTB 
display a highly conserved gene organization that comprises a pair of esx 
genes in the centre of the cluster, accompanied by PE/PPE genes 
upstream and then flanked by membrane proteins and components of an 
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ATP-powered secretion machine (DiGiuseppe Champion and Cox, 2007; 
Bottai and Brosch, 2009). The best characterized of these is the ESX-1 
system, which is known to secrete the 6-kDa early secreted antigenic 
target (ESAT-6) and the 10-kDa culture filtrate protein (CFP-10), encoded 
by esxA and esxB, respectively (Sørensen et al., 1995; Berthet et al., 
1998). These highly immunogenic proteins have been shown to modulate 
TLR2 signalling and cytokine inhibition (Sørensen et al., 1995; Berthet et 
al., 1998; Skjot et al., 2000; Pathak et al., 2007). The ESX-1 system is 
located in the region of difference-1 (RD1), which is absent in the 
attenuated M. bovis BCG vaccine strain (Mahairas et al., 1996). The 
importance of the RD1 region in virulence has been established 
experimentally by deleting this region in H37Rv and confirming that it 
resulted in attenuation of the strain; conversely, incorporation of this 
region into the attenuated BCG vaccine strain resulted in expression of 
ESAT-6 and CFP-10 and increased virulence (Pym et al., 2002; Lewis et 
al., 2003; Pym et al., 2003). A functional ESX-1 system is required for the 
export of ESAT-6 and CFP-10, which have been demonstrated to be 
required for mycobacterial spread to uninfected macrophages (Guinn et 
al., 2004), inhibition of macrophage inflammatory response (Stanley et al., 
2003), cell lysis and tissue invasion (Hsu et al., 2003). 
 
In the MTB genome, the ESX-2 locus is located downstream of ESX-1; 
however, relatively few studies have focused on this system, or on ESX-4 
which represents the most ancestral system. As a result, nothing is 
presently known about their functions (van Pittius et al., 2001; Stinear et 
al., 2008). Genes in the ESX-3 cluster were shown to be regulated by iron 
and zinc in MTB (Maciag et al., 2007), suggesting involvement of this 
system in homeostasis of these metal ions. The faster growing MSM 
possesses ESX-1, ESX-4 and ESX-3 only (van Pittius et al., 2001), of which 
the latter cluster was shown to respond to iron and not zinc (Maciąg et al., 
2009). In a study utilizing MSM and M. bovis, it was demonstrated that the 
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ESX-3 secretion system responds to iron deprivation and is required for 
infection of macrophages (Siegrist et al., 2009). In addition, the ESX-3 
system was shown to be essential for growth in liquid medium using a 
tetracycline (Tet)-inducible conditional mutant (Serafini et al., 2009). The 
repression phenotype was reversed by addition of zinc, iron or 
supernatant from the parental strain, which led the investigators to 
conclude that ESX-3 might encode a novel metal uptake system. 
 
The final ESX system, ESX-5, has been studied in M. marinum. Abdullah et 
al. (2006) were the first to demonstrate a link between this system and a 
PPE protein. They showed that an ESX-5 mutant of M. marinum was 
unable to secrete the heterogeneously expressed MTB PPE41 protein; 
moreover, introduction of the ESX-5 cluster into MSM resulted in the 
secretion of PPE41 (Abdallah et al., 2006) confirming the involvement of 
the machinery encoded by this system in the secretion of the PPE protein. 
In addition, the ESX-5 system was found to be involved in modulating the 
immune response by suppressing proinflammatory cytokines and inducing 
1L-1β production (Abdallah et al., 2008). This PE-PGRS and PE-MPTR 
secretion pathway was also shown to be involved in suppressing cytokine 
secretion in a TLR-dependent manner (Abdallah et al., 2008; Abdallah et 
al., 2009). Although ESX-5 was shown to be a major secretion system for 
some PE and PPE proteins, the possibility that other PE/PPE proteins might 
be secreted via other systems including other ESX systems cannot be 
ruled out. In addition, this information was deduced in M. marinum; while 
these results might apply in MTB, this link is yet to be demonstrated 
formally.  
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1.12 Mycobacterial features examined in this thesis 
 
The biosynthesis of B12 is complex and requires an intricate pathway 
comprising 30 sequential enzymatic steps. For this reason, it is intriguing 
that MTB is included in a select group of microorganisms that appear to 
possess a near-complete biosynthetic pathway. Previous work in the 
MMRU has characterized B12-dependent metabolic processes (Dawes et 
al., 2003; Warner et al., 2007; Savvi et al., 2008). Amongst other findings, 
these studies surprisingly indicated that MTB does not synthesize B12 de 
novo despite possessing a near-complete biosynthetic pathway (Warner et 
al., 2007; Savvi et al., 2008). In addition, bioinformatic analysis revealed 
that there is a complete lack of typical B12 transport systems in the MTB 
genome, a result that is inconsistent with the ability of exogenous B12 to 
complement multiple growth phenotypes in MTB (Warner et al., 2007; 
Savvi et al., 2008). In addition, the presence of a B12 riboswitch upstream 
of PPE2, and the suggestion by Rodionov et al. (2003) that this gene 
might be a putative B12-regulated cobalt transporter, stimulated our 
interest in the potential role for PPE2 in B12 or cobalt transport in MTB. 
Furthermore, taking into account the versatility of MTB, we also sought to 
investigate whether MTB could synthesize and utilize alternate B12 
cofactors such as pseudo-B12 in B12-dependent metabolic processes. 
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1.13 Aims 
 
This study was initially directed towards investigating a role for PPE2 in B12 
metabolism in MTB, and to ascertaining the capacity of B12 precursors to 
function in B12 biosynthesis in mycobacteria. To this end, the project 
originally comprised two primary components:  
1. An investigation of the role of MTB PPE2 (Rv0256c) in vitamin B12 
or cobalt transport.  
2. An analysis of the ability of substrates like vitamin B12 (CNCbl), the 
B12 precursors cobinamide, DMB, adenine and cobalt to 
complement growth of MTB and MSM vitamin B12 auxotrophs. 
Subsequent observations in this study indicated that PPE2 did not have a 
role in B12 transport in MTB; however, its importance in either B12 
synthesis or cobalt transport still existed owing to the tantalising presence 
of a B12 riboswitch which indicated the likely B12-dependent regulation of 
PPE2 function. During the course of this project, it also became evident 
that MTB might be able to synthesize B12 de novo under certain in vitro 
conditions. Moreover, key questions arose pertaining to the precise form 
of B12 and B12-derived cofactors that mycobacteria utilize. The original 
aims of the project were therefore updated and expanded to include the 
following set of major aims that formed the basis of this dissertation: 
1. An analysis of the ability of substrates including vitamin B12 
(CNCbl), the B12 precursors cobinamide, DMB, adenine and cobalt 
to complement growth of MTB and MSM vitamin B12 auxotrophs 
already constructed within the laboratory (Warner et al., 2007; 
Dawes, unpublished). 
2. An investigation of the role of MTB PPE2 (Rv0256c) in cobalt 
transport or assimilation. 
3. An analysis of the ability of mycobcateria to synthesize and utilize 
pseudo-B12 as a functional equivalent of vitamin B12 in key B12-
dependent metabolic pathways. Abrogation of DMB synthesis by 
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eliminating the putative bluB (Rv0306) formed a core component of 
this aim as it enabled the genetic differentiation of vitamin B12 
biosynthesis (and utilisation) from the synthesis of pseudo-B12. 
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2. Materials and Methods 
 
All general procedures and DNA manipulations were performed according 
to standard protocols (Sambrook and Russell, 2001).  
 
 
2.1 Bacterial strains and culture conditions  
 
All bacterial strains utilized in this study were stored at -70°C in 30% (v/v) 
glycerol and are detailed in Table 2.1. 
 
 
 Escherichia coli DH5α  
Escherichia coli was cultured in Luria-Bertani broth (LB) at 37°C overnight 
with vigorous shaking (Labcon Shaking Incubator) or at 30°C for 48 h 
(New Brunswick Scientific Innova 400 incubator shaker), supplemented 
with appropriate antibiotics where necessary. Luria Bertani agar (LA) 
plates supplemented with appropriate antibiotics where necessary was 
used to culture E. coli containing plasmids, which were incubated at 37°C 
overnight (Incotherm Labotec Incubator) or at 30°C for 48 h (Heraeus 
Instrument Incubator). Strains carrying large plasmids (≥8000bp) were 
incubated at 30°C to minimise the risk of plasmid rearrangements. For 
selection purposes the following antibiotics were used at the indicated 
concentrations: ampicillin (Amp), 200µg/ml; hygromycin (Hyg), 100-200 
µg/ml; and kanamycin (Km), 50 µg/ml. For negative selection of clones 
that carry the sacB gene, 5% (w/v) sucrose was used. For positive 
selection of clones and/or to confirm disruption of the lacZ for cloning 
purposes, X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; 20 
mg/ml in deionised dimethyl formamide) was utilized. 
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Table 2.1: General strains used in this study 
 
Strain  Description Reference 
Escherichia coli  (Snapper et 
al., 1990) 
DH5α supE44 ∆lacU169 hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
Promega 
Mycobacterium smegmatis   
mc2 155 High-frequency transformation mutant of 
M. smegmatis ATCC 607 
(Snapper et 
al., 1990) 
∆metE::hyg metE deletion mutant in mc2 155; HygR (Dawes, 
unpublished) 
∆cobK cobK deletion mutant in mc2 155 (Dawes, 
unpublished) 
∆cobK ∆metE::hyg Double metE/cobK deletion mutant in mc2 
155 
(Dawes, 
unpublished) 
Mycobacterium tuberculosis   
H37Rv Virulent laboratory strain ATCC 25618 Laboratory 
collection 
∆PPE2 PPE2 deletion mutant of H37Rv This study 
∆metE::hyg metE deletion mutant of H37Rv; HygR (Warner et 
al., 2007) 
∆cobK ∆metE::hyg double metEcobK deletion mutant of 
H37Rv; HygR 
D. F. Warner, 
unpublished 
∆PPE2 ∆metE::hyg marked double metE/PPE2 deletion 
mutant of H37Rv; HygR 
This study 
∆cobU ∆metE::hyg marked double metE/cobU deletion 
mutant of H37Rv; HygR 
D. F. Warner, 
unpublished 
∆metE::hyg 
∆PPE2attB::PPE2 
∆PPE2 complemented with full-length 
PPE2 at attB site; HygR, KmR 
This study 
∆metE::hyg∆PPE2 
attB::PPE2-cobQ1-cobU 
∆PPE2 complemented with entire PPE2-
cobQ1-cobU locus; hygR, KmR 
This study 
∆metE::hyg∆cobU 
attB::PPE2-cobQ1-cobU 
∆metE::hyg∆cobU complemented with 
entire PPE2-cobQ1-cobU locus ; HygR, 
KmR 
This study 
∆Rv0306 Rv0306 deletion mutant of H37Rv This study 
∆metE::hyg ∆Rv0306 Double metE /Rv0306 deletion mutant of 
H37Rv; HygR 
This study 
∆Rv0306D32NS167G∆metE::hyg metE with site-directed point mutations in 
Rv0306;HygR 
This study 
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 Mycobacterium smegmatis 
Unless otherwise stated, MSM strains were cultured in Middlebrook 7H9 
liquid medium (Difco) supplemented with 0.1% Tween80, 0.2% glycerol 
and a glucose- salt solution (GS; 0.085% NaCl, 0.2% glucose). For growth 
on solid media, 7H10 Middlebrook (Difco) supplemented with 0.5% 
glycerol and glucose-salt (GS; 0.085% NaCl, 0.2% glucose) was used. 
Cultures were grown in Erlenmeyer flasks at 37°C shaking (Incotherm 
Labotec Incubator). Where necessary, antibiotics were used at the 
following concentrations: Km, 10 µg/ml or 25 µg/ml; and Hyg, 50 µg/ml. 
Unless otherwise indicated, the following supplements and cofactor 
precursors were used at the indicated concentrations: adenine (Sigma), 10 
µM; cobinamide (dicyanocobinamide, Sigma), 10 µM; 5,6-
dimethylbenzamidazole (Sigma), 10 µM; and vitamin B12 (cyanocobalamin, 
Sigma), 10 µg/ml (8 µM).  
 
 
 Mycobacterium tuberculosis 
Unless indicated, MTB strains were grown in Middlebrook 7H9 liquid 
medium (Difco) supplemented with 0.05% Tween80 and 0.2% glycerol, or 
on 7H10 Middlebrook solid medium (Difco) supplemented with 0.5% 
glycerol. 100 ml oleic acid-albumin-dextrose-catalase (OADC) enrichment 
(Difco) was added to both liquid and solid media (10% v/v). Culturing and 
manipulation of MTB strains was carried out in a biosafety level 3 
laboratory in a Class II flow cabinet at negative pressure of at least 160 
kPa. Cultures were grown at 37°C in tissue culture flasks that were placed 
flat or in roller bottles. For negative selection of clones that carry the sacB 
gene, 2% (w/v) sucrose was used. For positive selection of clones 
harbouring the lacZ gene, β-galactosidase activity (blue-white selection) 
was assessed by adding X-gal (Roche) at a standard concentration of 20 
mg/ml in deionised dimethyl sulfoxide (DMSO; Sigma) in 25 ml agar 
plates. Antibiotics were used at the following concentrations where 
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necessary: Km, 10 µg/ml or 25 µg/ml; and Hyg, 50 µg/ml. Unless 
otherwise indicated, the following supplements and cofactor precursors 
were used at the indicated concentrations: adenine, 10 µM; cobinamide, 
at 10 µM; 5,6-dimethylbenzamidazole (Sigma), 10 µM; 3-nitropropionate 
(3-NP; Sigma); 10 µM and Vitamin B12, 10 µg/ml (8 µM). 
 
 
2.2 Cloning vectors 
 
All plasmids utilized in this study are detailed in Table 2.2. 
 
Table 2.2: Plasmids used in this study 
 
Strain  Description Reference 
p2NIL E. coli cloning vector and mycobacterial suicide 
vector; KnR 
(Parish and Stoker, 
2000) 
pGEM3Z(+)f E. coli cloning vector; AmpR, lacZ Promega 
pGOAL17 Plasmid carrying lacZ and sacB genes as a 
PacI cassette; AmpR 
(Parish and Stoker, 
2000) 
pGOAL19 Plasmid carrying lacZ, hyg and sacB genes as 
a PacI cassette; AmpR 
(Parish and Stoker, 
2000) 
p2∆cobKU19 cobK knockout vector containing PacI cassette 
from pGOAL19; KnR, HygR, sucS 
K. Downing 
p2PPE2 P2NIL containing ∆PPE2 allele; KnR This study 
p2PPE2U17 PPE2 knockout vector containing PacI cassette 
from pGOAL17; KnR, HygR, sucS 
This study 
p2PPE2U19 PPE2 knockout vector containing PacI cassette 
from pGOAL19; KnR, sucS 
This study 
p2∆Rv0306 p2NIL containing ∆Rv0306 allele; KnR This study 
p2∆Rv0306U17 Rv0306 knockout vector containing PacI 
cassette from pGOAL17; KnR, HygR, SucS 
This study 
p2∆Rv0306U19 Rv0306 knockout vector containing PacI 
cassette from pGOAL19; KnR, sucS 
This study 
p2Rv0306D32NS167G 
U17 
p2NILcontaining Rv0306 with site-directed 
point mutations; KnR, HygR, sucS 
This study 
pMCPPE2comp PPE2 complementation vector- pMC1r carrying 
full length PPE2 ; KnR 
This study 
pMCPQUcomp Complementation  vector- pMC1r carrying 
entire PPE2-cobQ1-cobU locus ; KmR 
This study 
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2.3 DNA extraction 
 
2.3.1 Plasmid extraction and purification from E.coli 
 
 Small-scale plasmid DNA isolation 
Stationary-phase cultures were harvested by centrifugation in an 
Eppendorf 5415D microcentrifuge (15000 x g for 1 min) at room 
temperature in 1.5 ml microfuge tubes. The supernatant was discarded 
and the pellet resuspended in 100 µl of lysis solution I (0.5 M glucose, 50 
mM TrisHCl pH 8.0, 10 mM EDTA); thereafter, 200 µl of solution II (0.2 M 
NaOH, 1% SDS) was added and the suspension was mixed gently. After 5 
min of incubation at room temperature, 150 µl of neutralization solution 
III (3 M potassium acetate, pH 5.5) was added and gently mixed before 
centrifuging at 9000 x g for 5min at room temperature. The supernatant 
was transferred to fresh microfuge tubes and treated with 1 µl of 10 µg/ml 
RNase A (Sigma) for 10 min at 37°C. Plasmid DNA was precipitated by 
adding 350 µl of isopropanol, then incubated for 10 min at room 
temperature and collected by centrifugation at 15000 x g for 10 min. The 
pelleted DNA was washed with 70% ice-cold ethanol and dried at 45°C in 
a vacuum centrifuge (MiVac DNA concentrator, GeneVac). The DNA was 
resuspended in 20-30 µl of sterile distilled water (sdH2O). 
 
 
 Large-scale plasmid DNA extraction 
Cultures were grown overnight in 50 ml of LB and harvested by 
centrifugation in a Beckmann J2-21 centrifuge (1100 x g for 10 min). 
Thereafter the extraction method was exactly as described for the small-
scale extraction (above) except that the solution volumes were increased 
by a factor of 10. Once extracted and washed, the DNA was resuspended 
in a final volume of 500 µl of sdH2O and precipitated by adding 1/10
th 
volume 5.3 M sodium acetate (pH 5.3). The DNA was purified by adding 
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equal volumes of phenol:chloroform (1:1; v/v) solution, the suspension 
was mixed vigorously and then centrifuged at 15000 x g for 10 min at 
room temperature. The aqueous phase was added to an equal volume of 
chloroform: isoamyl alcohol (24:1; v/v), mixed vigorously, and centrifuged 
at 15000 x g for 10 min at room temperature. The aqueous phase was 
removed and the plasmid DNA was further precipitated by adding 2.5 
volumes of 100% ice-cold ethanol and incubating the solution at -20°C for 
30 – 45 min. DNA was collected by centrifugation at 15000 x g for 10 min 
at room temperature, and the pellet was washed with 70% ice cold 
ethanol, then dried in a vacuum centrifuge and resuspended in 50-200 µl 
sdH2O. 
 
 
2.3.2 Chromosomal DNA extraction from mycobacteria 
 
 Mycobacterium smegmatis 
Chromosomal DNA was isolated using a modified cetyltrimethylammonium 
bromide (CTAB; ICN Biomedicals, Aurora, Ohio) method (Larsen, 2000). 
Briefly, cells were heat-killed in microfuge tubes for 20 min at 65°C, then 
harvested by centrifugation at 13000 x g for 1 min. After resuspending the 
pellet in 500 µl TE buffer (10 mM Tris·HCl pH 8.0, and 1 mM EDTA), 50 µl 
of lysozyme (10 mg/ml) was added and the reaction incubated overnight 
at 37°C. The following morning, 70 µl of 10% SDS and 6 µl of proteinase 
K (10 mg/ml) was added and incubated at 37°C for 2 h. Thereafter, 80 µl 
of pre-warmed CTAB/NaCl mix (10% CTAB made in 0.7 M NaCl) and 100 
µl of 5M NaCl was added and the mixture was further incubated for 10 
min at 65°C. Subsequent to incubation, an equal volume of 
chloroform:isoamyl alcohol (24:1 v/v) was added to remove residual 
proteins. The aqueous phase was added to an equal volume of 
isopropanol and then put on ice for 30 min. After centrifugation for 20 min 
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at 9000 x g, the pellet was washed with ice cold 70% ethanol and dried in 
a vacuum centrifuge before resuspending in 100 µl of sdH2O.  
 
 
 Mycobacterium tuberculosis 
The method used for MTB DNA extraction was similar to that described 
above except for minor differences and that all procedures prior to the 
overnight lysozyme step were carried out in a biosafety level 3 laboratory 
in a class II flow cabinet at negative pressure of 160 kPa. Briefly, cells 
were heat killed in microfuge tubes for an hour at 80°C, then harvested by 
centrifugation at 13000 x g for 1 min. After resuspending the pellet in 500 
µl of TE buffer (10 mM TrisHCl pH 8.0, and 1 mM EDTA), 50 µl of 
lysozyme (10 mg/ml) was added and this was incubated overnight at 
37°C. Subsequent to incubation, 70 µl of 10% SDS and 50 µl of proteinase 
K (10 mg/ml) were added and this was incubated at 60°C for 1 h in a 
Thermomixer Compact (Eppendorf) set to low shaking mode (300 rpm). 
One hundred µl of pre-warmed CTAB/NaCl (10% CTAB, 0.7 M NaCl) and 
100 µl 5 M NaCl was added, mixed thoroughly and then returned to 60°C 
for 15 min in the Thermomixer. Thereafter, microfuge tubes were placed 
at -70°C for 15 min, then removed and allowed to thaw before incubating 
at 60°C in the Thermomixer for a further 15 min. An equal volume of 
chloroform:isoamylalcohol (24:1) was added and the mixture was inverted 
several times to mix, then harvested by centrifugation at 9000 x g for 10 
min. The aqueous phase was added to an equal volume of ice-cold 
isopropanol, mixed by inversion, and then stored at 4°C overnight. The 
following morning, chromosomal DNA was harvested by centrifugation at 
9000 x g for 10 min, the pellet was washed with 70% ice-cold ethanol and 
dried in a vacuum centrifuge before resuspending in 55 µl of sdH2O. 
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 DNA extraction from mycobacteria and E. coli for PCR 
screening using the colony boil method 
Bacterial colonies were picked from agar plates and resuspended in 200 µl 
of TE buffer (10 mM Tris·HCl pH 8.0, 0.1 mM EDTA) before being heat-
killed at 95°C for 5 min. An equal volume of chloroform was added, and 
the solution centrifuged at 15000 x g for 5 min. The aqueous phase was 
carefully extracted into fresh microfuge tubes and 2 µl was used for PCR. 
 
 
2.4 Agarose gel electrophoresis 
 
Standard electrophoretic techniques were applied when separating DNA 
fragments (Sambrook et al., 1989; Sambrook and Russell, 2001). High 
molecular weight DNA fragments were separated on agarose gels of 
0.8%-1% or 2%-4% agarose gels for low molecular weight fragments 
(≤1kb), all made in 1x TAE buffer (40 mM Tris-acetic acid, 1 mM Na2EDTA 
pH 8.0). DNA samples were loaded with tracking dye (0.025% 
bromophenol blue in 30% glycerol) into gels that contained 0.5 µg/ml 
ethidium bromide. Fragment sizes were assessed using lambda DNA 
molecular weight markers (BMII-BMVI; Roche). Agarose gels were 
electrophoresed in a Mini-Sub Cell GT mini gel horizontal submarine unit 
(Bio-Rad) between 80-100 volts and visualized under UV-light using the 
Gel Doc 2000 system (Bio-Rad). 
 
 
2.4.1 Recovery of DNA from agarose gels and quantification 
 
The required DNA fragments were excised from agarose gels and purified 
using the Nucleospin Extract II Kit (Macherey-Nagel) as per the 
manufacturer’s instructions. After purification, the eluted DNA was 
quantified either on an agarose gel by comparison to DNA molecular 
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weight markers, or on a NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific). 
 
 
2.5 DNA manipulations 
 
All DNA manipulations and molecular biology techniques were carried out 
according to standard protocols (Sambrook et al., 1989). 
 
 
 Restriction enzyme digests 
All restriction enzymes were obtained from Amersham Pharmacia Biotech, 
New England Biolabs Inc., or Roche. All restriction enzyme digests were 
performed at 37°C unless otherwise required by the manufacturer. 
Plasmid DNA of up to 1 µg was digested between 1-3 h at 37°C (unless 
otherwise required by the manufacturer) with the appropriate reaction 
buffer(s). Mycobacterial DNA of up to 5 µg was digested overnight at 37°C 
(unless otherwise required by the manufacturer) with the buffer(s). 
Digested DNA fragments were separated and analysed on agarose gels (as 
detailed in sections 2.4 & 2.4.1). 
 
 
 Dephosphorylation 
Linearized plasmid DNA was treated with Antarctic Alkaline Phosphatse 
(New England Biolabs) to ensure removal of the 5’-phosphate and thereby 
prevent vector re-ligation. Dephosphorylation was performed for 1 h at 
37°C after which the enzyme was heat inactivated for 20 min at 65°C (as 
per the manufacturer’s instructions). 
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 Ligation reactions 
Ligation reactions were carried out using either the Fast-link™ ligation kit 
(Epicentre ® Biotechnologies) or T4 DNA ligase (Roche) as per the 
manufacturer’s instructions. Ligations were then transformed into E. coli 
DH5α cells as detailed in section 2.7.1. 
 
 
2.6 Polymerase Chain Reaction (PCR) 
 
Screening and preliminary PCRs were carried out using FastStart Taq 
(Roche) as per the manufacturer’s instructions. Briefly, 20-50 µl reactions 
containing between 10-100 ng of plasmid or genomic DNA were set up 
with 1x reaction buffer, 200 µM of each dNTP, 0.5-1.0 µM of each primer, 
1.5 mM MgCl2, 1x GC-rich solution, and 2U/50 µl of DNA polymerase. 
Thermal cycler parameters used for DNA amplification were as follows: 
denature at 95°C for 4 min, followed by 30 cycles of denaturation (95°c 
for 30 s), annealing (60°C for 30 s), extension (72°C for 60s/kb), and a 
final extension at 72°C for 7 min. Fragments used for cloning purposes 
were amplified with Phusion High-Fidelity DNA polymerase (Finnzymes), 
which has a low error rate of 4.4 x10-7. As per the manufacturer’s 
instructions, 20-50 µl reactions contained: 1x reaction buffer, 200 µM of 
each dNTP, 0.5 µM of each primer, 3% DMSO or 1x GC rich solution, 0.02 
U/µl of DNA polymerase and between 10-100 ng of plasmid or genomic 
DNA. The DNA amplification parameters were: initial denaturation at 98°C 
for 3 min, followed by 30 cycles of denaturation (98°C for 10 s), annealing 
(60°C for 30 s), extension (72°C for 30s/kb), and final extension at 72°C 
for 7 min. All PCR reactions were carried out in the MyCycler™ thermal 
cycler (Bio-Rad) with oligonucleotide primers (Table 2.4 to 2.8) purchased 
from Inqaba Biotech Ltd. or Integrated DNA Technologies (IDT).  
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2.7 Bacterial transformation 
 
2.7.1 Chemical transformation of E. coli 
 
 Preparation of competent cells 
All competent cells were prepared using the rubidium chloride method 
obtained from Dr P. Stolt. Briefly, 1 ml of an overnight culture of E. coli 
DH5α was inoculated into 100 ml LB and grown to an OD600 of between 
0.48-0.55. The cells were kept on ice for 15 min then harvested by 
centrifugation at 3901 x g for 5 min at 4°C. The supernatant was 
discarded and the pellet resuspended in 20 ml transformation buffer (Tfb) 
I solution (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM 
calcium chloride, 50 mM manganese chloride, and 15% v/v glycerol – pH 
5.8). The suspension was chilled on ice for 15 min, and then harvested by 
centrifugation at 3901 x g for 5 min at 4°C. The pellet was then 
resuspended in 2 ml of TfbII solution (10 mM MOPS, 75 mM calcium 
chloride, 10 mM rubidium chloride and 15 % v/v glycerol – pH 6.5), and 
500 µl aliquots were flash-frozen in ice cold ethanol and stored at -80°C 
until required.  
 
 
 Transformation of E. coli with plasmid DNA 
The competent cells were thawed on ice, and 100 µl incubated with up to 
1 µg of pre-chilled DNA in microfuge tubes on ice. After 20 min, the cells 
were heat-shocked at 42°C for 90 s then chilled on ice for 1-2 min; 
thereafter, 4 volumes of 2TY (Tryptone Yeast broth) was added to rescue 
the cells at 37°C for 1 h. The cells were plated on LA plates containing 
appropriate antibiotics and incubated at 37°C overnight (Sambrook et al., 
1989) or for two days at 30°C for constructs larger than 8 000 bp.  
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2.7.2 Transformation of mycobacteria  
 
Mycobacteria were transformed by electroporation, which was performed 
according to previously published protocols, and as described briefly below 
(Larsen, 2000; Gordhan and Parish, 2001). 
 
 
 Electroporation into Mycobacterium tuberculosis 
Briefly, 1 ml of a log-phase pre-culture was inoculated into 75 ml of 
7H9/OADC media and grown to an OD600 0.8-1.0. At least 6 h before 
competent cells were prepared, glycine (30%; w/v) was added to a final 
concentration of 1.5% (w/v). Cells were harvested by centrifugation at 
1100 x g for 10 min at room temperature and the pellet was resuspended 
in 10% glycerol (w/v). Thereafter, cells were washed twice in 10% 
glycerol (w/v) then resuspended in 2-5 ml of 10% glycerol (w/v). Four 
hundred µl of competent cells were mixed with 2-5 µg of plasmid DNA in 
electroporation cuvettes (0.2 cm electrode gaps, Bio-Rad) and pulsed once 
in a GenePulser™ set at 2.5 kV, resistance 1000 Ω, capacitance 25 µF. 
Subsequent to electroporation, cells were rescued in 1 ml of 7H9/OADC 
then incubated overnight at 37°C. The following day, cells were spread on 
7H10/OADC plates containing appropriate antibiotics and/or supplements 
where necessary and then incubated at 37°C for 21-28 days. 
 
 
2.8 Southern blot analysis 
 
 Electroblotting 
Genomic DNA (2-5 µg) was digested overnight with appropriate restriction 
enzymes, separated by electrophoresis on a 0.8% agarose gel at 80 V 
(Section 2.4), and photographed with a ruler using the GelDoc 2000 
system (Bio-Rad). The DNA was depurinated by immersing the agarose 
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gels in 0.25 M HCl for 10-12 min, then denatured by soaking in 1.5 M 
NaCl/0.5M NaOH solution for 25 min, and then neutralized (1.5 M NaCl, 5 
M Tris·HCl, pH 7.5) for 30 min. Thereafter, the agarose gels were overlaid 
with Hybond™-N+ membrane (Amersham), and sandwiched in a TE 22 
Transphor cassette (Hoefer Scientific) between two pre-soaked 3 mm 
Whatmann (Merck) filter papers and two pre-soaked sponges. The 
cassette was placed in a TE 22 mini transfer unit (Hoefer Scientific) 
containing 1x Tris-Borate-EDTA (TBE) buffer (Sigma) and the DNA was 
transferred for 4 h at 0.4 A at 4°C. Once transferred, the DNA was cross-
linked to the membrane by irradiation in a UV Stratalinker 1800 
(Stratagene) at 1200 mJ/cm2, and membranes were either hybridized 
immediately or wrapped in saran wrap and stored at 4°C until required. 
 
 
 Synthesis and labelling of probes 
The probes (detailed in Table 2.3) utilized for Southern blots were 
synthesized by PCR using primers detailed in Table 2.4 or by restriction 
enzyme digests, and then labelled according to the ECL Direct Nucleic Acid 
Labelling and Detection System protocol (Amersham). Briefly, a maximum 
of 100 ng of probe DNA in 10 µl of dH2O was denatured by boiling for 5 
min at 95°C, and immediately cooled on ice for 5 min. Subsequently, 
equivalent volumes of DNA labelling agent (Amersham) and 
glutaraldehyde solution (Amersham) were added and mixed gently. The 
resulting mixture was incubated at 37°C for 10 min and then used 
immediately in hybridization experiments.   
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Table 2.3: Probes used in southern blot analysis 
 
Gene Probe description 
PPE2 860bp PCR product containing 170bp 3’ PPE2 coding 
sequence, generated using primer pair PPE2Fi/PPE2R1 
metE 1740 bp PCR product containing 562 bp 5’ metE coding 
sequence, generated using primer pair metEFR2 
cobK 1162 bp XhoI/SalI fragment from p2ΔcobK19 
cobU 1750 bp PCR product containing 113 bp 3’ cobU coding 
sequence, generated using primer pair cobUFR2 
Rv0306 811bp PCR product containing 224bp 5’ coding sequence, 
using primer pair Rv0306Fiseq/Riseq 
 
 
 Hybridization 
The hybridization buffer was prepared according to the ECL Direct Nucleic 
Acid Labelling and Detection System protocol (Amersham). Briefly, to 20 
ml of hybridization buffer, 5% w/v blocking agent and 0.5 M NaCl was 
added and this was stirred at room temperature for 1 h and then at 42°C 
for 1 h. Subsequent to cross-linking, the membrane was pre-hybridized in 
roller bottles in the Hybridisation oven/shaker SI3OH (Stuart) for 1 h at 
42°C, thereafter the labelled probe was added and this was hybridized 
overnight at 42°C.  
 
Table 2.4: Oligonucleotides used to synthesize Southern blot probes 
 
Name Sequence (5’-3’) 
PPE2 Fi CAGGGTGCCGTACACCCT 
PPE2 R1 AAGGAGCGGGATCCCTGG 
metE F2 GGGGGCCGGATCCAACTCTTCGAG 
metE R2 GCGCGGGAAGCTTCAACTTCGGGCA 
cobU F2 GGGGCGGGATCCCATTCTTCGGGCGT 
cobU R2 GGCGGCGGTACCAAGGGCGAGCTGAAGT 
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 Detection 
Following overnight hybridization, the membrane was washed in 5x SSC 
for 5 min at 42°C, then in primary wash buffer (6 M Urea, 0.4% SDS, 0.5x 
SSC) for 20 min at 42°C. The membrane was washed twice for 10 min in 
primary wash buffer at 42°C, and then twice for 5 min at room 
temperature in secondary wash buffer (0.5x SSC). Thereafter, detection 
reagents 1 and 2 (Amersham) mixed in equal quantities were overlaid 
over the membrane and incubated for 1 min at room temperature. The 
membrane was then drained, saran wrapped and exposed to X-ray film 
(Amersham Biosciences) in a cassette for time periods ranging from 1 min 
to 24 h at room temperature before developing. 
 
 
2.9 Sequencing 
 
All sequencing was performed as a pay-for-service by Inqaba Biotech Ltd, 
or the Central Analytical Sequencing Facility at Stellenbosch University.  
 
 
2.10 Construction of MTB deletion mutants and complemented 
derivatives  
 
 Construction of PPE2 deletion mutant of H37Rv 
The suicide vector used to generate the PPE2 deletion was constructed 
using primer pairs PPE2F1/PPE2R1 and PPE2F2/PPE2R2 (Table 2.5) that 
amplified 1400 bp upstream (PPE2FR1) and 1686 bp downstream 
(PPE2FR2) of PPE2 from H37Rv genomic DNA. Ligation of the resulting 
PCR products resulted in elimination of 1100 bp of the 1671 bp PPE2 gene 
sequence when cloned into the Asp718/HindIII-digested p2NIL (Parish 
and Stoker, 2001), to generate p2∆PPE2. Thereafter, the 7939 bp PacI 
marker cassette from pGOAL19 (Parish and Stoker, 2001) containing hyg-
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lacZ-sacB genes was cloned into the corresponding sites of p2∆PPE2 to 
generate p2∆PPE2U19. This suicide vector was electroporated into H37Rv 
and the resulting ∆PPE2 mutant was isolated by a two-step selection 
method as previously described (Gordhan and Parish, 2001). Genomic 
DNA from ∆PPE2 was digested with SalI and used in Southern blot 
analysis with the probe listed in Table 2.3 to confirm the genotype.  
 
 
Table 2.5: Oligonucleotides used to construct knockout vectors used in 
this study 
Name  Sequence (5’-3’) Comments 
PPE2 F1 GGCCACATGGTACCGAACA 1400bp sequence with 
naturally-occurring 
Asp718 site and 
introduced BamHI site 
in reverse primer 
sequence 
PPE2 R1 AAGGAGCGGGATCCCTGG 
PPE2 F2 GGCCTGGATCCACATCCG 1686bp sequence with 
introduced BamHI site 
in forward primer 
sequence  
PPE2 R2 CGCCGGTGAAGCTTGATCT 
Rv0306 F1 CTGCGTTGAAGCTGCAGGT 1599bp sequence with 
introduced PstI site in 
forward primer 
sequence  
Rv0306 R1 CGAGAATGCCCTCGACCTT 
Rv0306 F2 CCCGCGCTGGAACTGGAT Contains naturally- 
occurring EcoRI (after 
forward primer) and 
Asp718 restriction 
sites 
Rv0306 R2 GGTCACTGTGCGGTGACAA 
The underlined sequence represents incorporated restriction sites 
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 Generation of PPE2 knockout in ∆metE::hyg  mutant 
background 
The 6359-bp PacI marker cassette from pGOAL17 (Parish and Stoker, 
2000) containing lacZ-sacB genes was cloned into the corresponding sites 
of the p2∆PPE2 vector (described above) to generate p2∆PPE2U17. This 
suicide vector was electroporated into the hygromycin-resistant ∆metE 
mutant (Warner et al., 2007) and the resulting double ∆PPE2 ∆metE::hyg 
was phenotypically isolated by a two-step selection method previously 
described (Gordhan and Parish, 2001). Genomic DNA from the ∆PPE2 
∆metE::hyg double mutant was digested with SalI and used in Southern 
blot analysis with the probe listed in Table 2.3 to confirm the genotype. 
 
 
 Construction of ∆Rv0306 knockout in MTB (H37Rv) 
Two primer sets, Rv0306F1/Rv0306R1 and Rv0306F2/Rv0306R2 were 
designed for PCR amplification of the upstream and downstream 
fragments of the Rv0306 gene. The PCR products resulting from 
amplification of H37Rv genomic DNA - Rv0306FR1 (1599 bp) and 
Rv0306FR2 (1404 bp) - eliminated 313 bp of the 672 bp Rv0306 gene 
sequence. Using a three way cloning strategy, these PCR products were 
cloned into the relevant sites of suicide vector p2NIL to create the 
p2∆Rv0306 construct. Thereafter, the 7939 bp PacI marker cassette from 
pGOAL19 (Parish and Stoker, 2000) containing hyg-lacZ-sacB genes was 
cloned into the corresponding sites of p2∆Rv0306 to generate 
p2∆Rv0306U19. The resulting suicide vector was electroporated into 
H37Rv and the ∆Rv0306 mutant isolated by two-step selection as 
previously described (Gordhan and Parish, 2001). Genomic DNA from the 
∆Rv0306 was digested with StuI and used in Southern blot analysis with 
the probe listed in Table 2.3 to confirm the genotype.  
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 Construction of Rv0306 knockout in the ∆metE::hyg 
mutant background 
The 6359 bp PacI marker cassette from pGOAL17 (Parish and Stoker, 
2000) containing lacZ-sacB genes was cloned into the corresponding sites 
of the p2∆Rv0306 vector (described above) to generate p2∆Rv0306U17. 
This suicide vector was electroporated into the hygromycin-marked ∆metE 
mutant (Warner et al., 2007) and the resulting double mutant, ∆Rv0306 
∆metE::hyg was phenotypically isolated by a two-step selection method 
previously described (Gordhan and Parish, 2001). Genomic DNA from the 
∆PPE2 ∆metE::hyg was digested with StuI and used in Southern blot 
analysis with the probe listed in Table 2.3 to confirm the genotype. 
 
 
 Introduction of point mutations into Rv0306 by site-
directed mutagenesis  
A panel of synthetic genes comprising the entire MTB Rv0306 sequence 
with specific point mutations was synthesized by Sigma-Aldrich®. The 
alleles were provided in an ampicillin-resistant vector, pG04v. The 
engineered mutations in Rv0306 included D32N and G167S; the synthetic 
sequences were also designed to include FspI and StuI sites, both of 
which were used for rapid screening of putative transformants by 
restriction digest (detailed below). The pG04v vector was digested with 
Asp718 and the synthetic gene plus 336 bp of flanking sequence was 
cloned into the corresponding Asp718 site of p2NIL to create the 
p2Rv0306D32NS167GU17. Thereafter, the PacI marker cassette from 
pGOAL17 (Parish and Stoker, 2000) containing the lacZ-sacB genes was 
cloned into the corresponding sites of to generate p2Rv0306D32NS167GU17. 
The resulting suicide vector was electroporated into ∆metE::hyg. Mutants 
were screened and confirmed by PCR and restriction enzyme digests 
(detailed below). 
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 Screening of Rv0306 point mutations 
To aid in the screening process, each of the point mutations was 
engineered so as to introduce an artificial restriction site: the D32N 
mutation introduced an FspI site, and the G167S mutation introduced a 
StuI site. The screening process utilized was therefore two-fold: in the first 
step, the Rv0306 gene was amplified using the primer pair 
Rv0306Frs/Rv0306Rrs (Table 2.6), which generated a 854 bp fragment 
that included 672 bp of the gene together with upstream (190 bp) and 
downstream (50 bp) sequence. Then, in the second step the PCR product 
was digested with FspI and StuI, and positive transformants that 
harboured the point mutations generated 203 bp and 651 bp from the 
FspI digest; 597 bp and 257 bp from the StuI digest. 
 
 
Table 2.6: Oligonucleotides used in screening of Rv0306 point mutations 
in this study 
 
Name Sequence (5’-3’) Comments 
Rv0306 Frs CTACTCGACTAGCCCGTGA PCR product includes 
Rv0306 plus 190bp 
upstream and 50bp 
downstream 
Rv0306 Rrs CGTGCCGGCCGAATACGT 
 
 
 Complementation of ∆PPE2 mutant with the entire PPE2 
gene 
The PPE2 gene was amplified from genomic DNA using the 
PPE2compF/PPE2compR primer pair (Table 2.7). The resulting 2495 bp 
PCR product, which contained the entire H37Rv PPE2 plus 600 bp of 
upstream sequence, was digested with EcoRV and cloned into the blunted 
XmnI site of the pMC1r integrating vector (Ahidjo et al., 2011), generating 
the Km resistant pMCPPE2comp complementation vector. The 
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complementation vector was electroporated into the ∆PPE ∆metE::hyg 
double mutant and transformants selected on 7H10/OADC/B12 kanamycin 
plates. Putative complemented mutants were screened by PCR using attB 
primers (Barichievy, S., MSc dissertation, University of the Witwatersrand, 
2005) to confirm site-specific integration at the attB chromosomal locus. 
 
 
Table 2.7: Oligonucleotides used to construct complementation vectors  
 
Name Sequence (5’-3’) Comments 
PPE2compF GCAGACCCGATATCCGTCT 2495bp with 
introduced EcoRv 
site in forward 
primer; a  
naturally-occurring 
EcoRv site is 
located 
downstream of the 
reverse primer 
PPE2compR GCCCGACAATGCAGCGCT 
PQUcompF CGACGATCCGCGCGTTTAAATGCCGGTGTA 4580bp with DraI 
introduced in 
forward and 
reverse primer 
PQUcompR GGTCGCGGATATTTAAATGAGTAAGTCCTA 
The underlined sequence represents a restriction site 
 
 
 Complementation utilizing the putative PPE2-cobQ1-cobU 
operon 
A second strategy to complement PPE2 deletion entailed the introduction 
of the entire cobU-cobQ1-PPE2 (PQU) operon at the attB locus. The 
putative operon was amplified using the PQUcompF/PQUcompR primer 
pair (Table 2.7) which generated a 4580 bp PCR product that included all 
three genes and 688 bp of upstream sequence. The PCR product was 
digested with DraI and cloned into the relevant site of the pMC1r (Ahidjo 
et al., 2011) integrating vector, generating the Km resistant pMCPQUcomp 
construct. The complementation vector was electroporated into ∆PPE2 
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∆metE::hyg and ∆cobU ∆metE::hyg, then selected on 7H10/OADC/B12 Km 
plates. Transformants were screened for site-specific integration at the 
attB chromosomal locus with attB primers (Barichievy, S., MSc 
dissertation, University of the Witwatersrand, 2005). 
 
 
2.11 Validation of B12 and pseudo-B12 precursors utilizing S. 
enterica 
 
The ability of S. enterica to utilize exogenously-supplied cobinamide, 
adenine and DMB to synthesize B12 and pseudo-B12 was assessed 
according to previously described methods (Anderson et al., 2008). Briefly, 
a log-phase culture of S. enterica was harvested by centrifugation then 
resuspended in E media (Vogel and Bonner, 1956) that lacked citric acid 
but possessed ethanolamine (Sigma) as a carbon source hence Non-
Citrate Ethanolamine (NCE) media. Cells were inoculated into NCE media 
(see Appendix B) at an OD600 of 0.1 into the following combinations: 20 
nM cobinamide alone, 20 nM cobinamide plus 20 nM adenine, 20 nM 
cobinamide plus 20 nM DMB, 20 nM B12 and no supplement. Cultures were 
incubated at 37°C with shaking and OD600 was measured every 2.5 h. 
 
 
2.12 Phenotypic characterization of mycobacterial mutants 
 
Mycobacterial mutants were primarily characterized by comparing their 
growth kinetics in liquid media. The inability to complement growth on 
solid media with selected supplements (e.g. CoCl2) necessitated this. Once 
optimal precursor concentrations and growth kinetics was established in 
the fast-growing MSM mutants, this was applied to the panel of MTB.  
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2.12.1 Characterization of MSM B12 mutants  
 
 Complementation of MSM growth by various  
MSM B12 and methionine biosynthetic mutants; ∆metE::hyg, ∆cobK, ∆cobK 
∆metE::hyg (Dawes, unpublished) and mc2155 was assessed for their 
potential to utilize substrates such as vitamin B12 (CNCbl), the principal B12 
component, cobalt, and L-methionine to complement growth. Briefly, 1 ml 
of a log-phase culture was harvested by centrifugation at 15000 x g for 10 
min, then washed twice in 0.05% Tween80 and then resuspended in 
7H9/GS liquid media. Two hundred µl of 10-fold serial dilutions were 
plated on 7H10/GS agar plates containing the desired supplements. After 
72 h of incubation at 37°C, CFUs were enumerated. Vitamin B12 and L-
methionine were utilized at final concentrations of 10 µg/ml (8 µM) and 40 
µg/ml (32 µM), respectively. In addition to supplementing growth, a range 
of cobalt toxicity was established by spotting 10 µl of 10-fold serial 
dilutions on 7H10/GS agar plates containing either CoCl2 (Sigma-Aldrich) 
or CoSO4 (Sigma-Aldrich) ranging from 2 µM to 10 mM.  
 
 
 Assessment of B12 and pseudo-B12 synthesis  
The ability of MSM to utilize precursors to synthesize B12 and pseudo-B12 
was assessed by comparing growth kinetics of the MSM B12 auxotroph 
(∆cobK ∆metE::hyg) supplemented with cobinamide, adenine and DMB. 
Briefly, 50 ml of log-phase culture grown in 7H9/GS plus B12 (10 µg/ml), 
was harvested by centrifugation at 1100 x g for 10 min then washed twice 
in 0.05% Tween80 and resuspended in Sauton’s minimal liquid medium. 
Thereafter, cells were inoculated at an OD600 of 0.1 in 25 ml of Sauton’s 
medium in the following combinations: 10 µM cobinamide; 10µM 
cobinamide plus 10 µM adenine; 10 µM cobinamide plus 10 µM DMB; 10 
µg/ml B12 and no supplement. Cultures were incubated at 37°C with 
shaking. Optical density of the cultures was measured every 24 h, and 
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cultures were subsequently inoculated into fresh media containing the 
identical supplement. This process was repeated for up to 72 h. After 
inoculation at 72 h, the optical density of the cultures was measured every 
3 h and recorded.  
 
 
2.12.2 Characterization of MTB mutants 
 
 Assessment of B12 and pseudo-B12 synthesis 
The ability of a panel of MTB mutants to synthesis B12 and pseudo-B12 
from precursors was performed in a similar manner to MSM with a few 
exceptions. Briefly, a 50 ml log-phase culture grown in 7H9/OADC plus B12 
(10 µg/ml), where necessary, was harvested by centrifugation at 1100 x g 
for 10 min, then washed twice in 0.05% Tween80 and resuspended in 
Sauton’s medium. Thereafter, cells were inoculated at an OD600 of 0.1 in 
25 ml of Sauton’s in the following combinations: 10 µM cobinamide; 10 µM 
cobinamide plus 10 µM adenine; 10 µM cobinamide plus 10 µM DMB; 10 
µg/ml B12 and no supplement. Cultures were incubated flat in tissue 
culture flasks at 37°C with aeration every second day. Optical density was 
measured after 8 or 14 days and cultures were then inoculated into 
exactly the same combinations. Thereafter optical density was measured 
every second day and recorded.  
 
 
 Assessment of putative B12 transporter in valerate  
The role of PPE2 as a putative B12 transporter was assessed according to 
the ability of the mutant to transport B12 when grown on valerate in the 
presence of the isocitrate lyase inhibitor 3-NP, as previously described 
(Savvi et al., 2008). Briefly, a 50 ml culture (OD600 0.4-0.6) grown in 
7H9/OADC plus B12 (10 µg/ml) where necessary, was harvested by 
centrifugation at 1100 x g for 10 min then resuspended in valerate 
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(Appendix B). Cells were inoculated into 25 ml of media containing 
valerate plus 3-NP (10 µg/ml), valerate plus 3-NP plus B12, or valerate 
alone, at an OD600 of 0.02. Cultures were incubated in tissues culture 
flasks at 37°C and optical density was measured every 48 h.  
 
 
2.13 Semi-quantitative analysis of gene expression 
 
The primers used for semi-quantitative RT-PCR were designed using 
Primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and are shown in Table 2.8. All primers 
were designed to amplify DNA fragments that were internal to the open 
reading frames of the genes of interest. 
 
 
2.13.1 RNA isolation 
 
RNA isolation was carried out according to a modified protocol by K. 
Downing et al. (2004). Briefly, MTB cultures grown to an OD600 of 0.4-0.6 
were split into two equal aliquots, B12 (10 µg/ml) was added to one and 
cultures were returned to the incubator. Both cultures were harvested by 
centrifugation at 1100 x g for 15 min at 0 and 10 h post B12 addition. The 
pellet was resuspended in 2 ml of TRIzol (Sigma, USA), and then 
transferred to Lysing Matrix B tubes (Qbiogene, USA) and ribolysed three 
times for 20 s at speed 6 using the Savant Fastprep FP120 with 2 min 
intervals of cooling on ice between pulses. Samples were centrifuged at 
15000 x g for 45 s and supernatants were transferred to Phase Lock gel 
tubes (Merck) containing 300 µl of chloroform:isoamyl alcohol (24:1). The 
solution was inverted rapidly for 15 s to mix, then periodically for 2 min 
thereafter, and centrifuged at 15000 x g for 5 min. The aqueous phase 
was transferred to microfuge tubes containing an equal volume of 
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isopropanol and samples were precipitated overnight at 4°C. Nucleic acids 
were collected by centrifugation at 15000 x g for 20 min, and pellets were 
washed with 70% ethanol, air-dried and then resuspended in 
Diethylprocarbonate (DEPC) treated water. Samples were treated with 
DNase I (Ambion) to eliminate contaminating genomic DNA and then 
purified with the RNeasy kit (Qiagen) according to the manufacturer’s 
instructions. The samples were further treated with Turbo DNase I 
(Ambion) according to the manufacturer’s instructions. The RNA quality 
was assessed by electrophoresis on a 2% agarose gel containing 0.1% 
SDS and quantified using the Nanodrop ND-1000 Spectrophotometer. 
 
 
2.13.2 Reverse transcription 
 
Reverse transcription reactions were carried out using the Enhanced Avian 
HS RT-PCR kit (Sigma) as per the manufacturer’s instructions. Briefly, 
primers were annealed to the RNA in a 21 µl reaction consisting of 1 µg of 
RNA and 0.5 µM of each reverse primer (Table 2.8). The RNA was 
denatured at 94°C for 90 s, and then annealed at 65°C for 3 min followed 
by 3 min at 57°C. Thereafter, 10 µl of the annealing mixture was added to 
the RT reaction which consisted of 1x Avian Myeloblastoma Virus (AMV) 
RT buffer, 4 mM MgCl2, 200 µM of each dNTP, 0.6 µl of dimethyl 
sulphoxide (DMSO), and 2U of Enhanced AMV RT (Sigma). The RNA was 
reverse transcribed at 60°C for 30 min, denatured at 95°C for 5 min and 
then cooled to 4°C. Control reactions that lacked the RT enzyme were run 
in parallel to monitor DNA contamination.  
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Table 2.8: Oligonucleotides used in RT-PCR 
 
Name Sequence (5’-3’) 
metE L TGGTTCGACACCAACTACCA 
metE R GCCCTAACGCCTCTTTGAGT 
sigA L CCTACGCTACGTGGTGGATT 
sigA R CTTGTTGATCACCTCGACCA 
 
 
2.13.3 PCR 
Two µl of the synthesized cDNA (described above) was used as template 
in a 50 µl PCR reaction that consisted of 1x FastStart PCR buffer without 
MgCl2 (Roche), 4 mM MgCl2 (Roche), 200 µM of each dNTP (Roche), 5 µl 
of DMSO (Sigma), 0.5 mg/ml Bovine Serum Albumin (BSA, Roche), 0.2 µM 
of each primer and 2.5 U of FastStart Taq DNA Polymerase (Roche). The 
reaction was denatured at 94°C for 10 min, followed by 14 cycles of 94°C 
for 30 s, 65°C for 30 s, 72°C for 30 s and then 24 cycles of 94°C for 30 s, 
57°C for 1 min and 72°C for 30 s. PCR products were separated on a 4% 
agarose gel. 
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3. Results 
 
The genome sequence of MTB H37Rv (Cole et al., 1998) provided a crucial 
resource to investigate the biology of this formidable pathogen. Among 
other previously unknown physiological traits, comparative genomic 
analysis revealed that MTB possesses a near-complete genetic repertoire 
for the biosynthesis of B12 (Rodionov et al., 2003). This was intriguing as 
vitamin B12 biosynthesis represents one of the most complex pathways in 
nature, and is restricted to certain prokaryotes only. Although consistent 
with the presence in the genome of three B12-dependent enzymes (Dawes 
et al., 2003; Warner et al., 2007; Savvi et al., 2008), the inclusion of MTB 
among the select group of organisms predicted to catalyze de novo B12 
biosynthesis suggested that vitamin B12 metabolism might be critical for 
pathogenesis. Previous studies in the MMRU demonstrated that MTB does 
not synthesize B12 de novo (Warner et al., 2007; Savvi et al., 2008); 
however, the possibility exists that transport of the complete cofactor - or 
salvage and utilization of vitamin B12 precursors from host sources, as well 
as alternate forms such as pseudo-B12 – might assume increased 
importance during growth or survival under unfavourable conditions 
encountered through the course of host infection. Therefore, this study 
aimed to investigate the functionality of the vitamin B12 biosynthetic 
pathway in MTB by testing the ability of a panel of mycobacterial mutants 
to utilize specific B12 precursors and building blocks, including those 
required for the synthesis of alternate B12 forms. In addition, the presence 
of a B12-responsive regulatory element – a riboswitch – directly upstream 
of a putative operon containing PPE2 prompted an investigation of the 
potential role of the encoded PPE-family protein in B12 homeostasis. 
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3.1 Investigation into mycobacterial B12 metabolism utilizing 
MSM as a surrogate for MTB 
 
3.1.1 Identification of putative homologues of the B12 
biosynthetic pathway and B12-dependent enzymes in MSM 
 
Previous studies in the MMRU (Warner and Dawes, unpublished) identified 
putative homologues of B12 biosynthetic genes in MTB, which enabled the 
construction of a proposed B12 biosynthetic pathway utilizing a 
combination of bioinformatics tools (Figure 3.9). In order to establish the 
appropriateness of MSM as a model for vitamin B12 biosynthesis in MTB, 
this study was initiated by identifying putative MSM homologues of the 
predicted MTB B12 biosynthetic genes. To this end, a BLAST homology 
search (Altschul et al., 1990) of the MSM database 
(http://tigerblast.tigr.org/cmr.blast/) was performed using MTB query 
sequences. This analysis revealed minor differences between the B12 
biosynthetic gene complements of MSM and MTB. For example, the 
precorrin-6A synthase encoded by CobF in P. denitrificans (Debussche et 
al., 1993; Min et al., 1993) is absent in MTB and M. bovis, but there is a 
putative homologue in MSM that is encoded by MSMEG_5548. In addition, 
the aminotransferase encoded by CobC in MTB appears to have no 
homologue in MSM, though it is possible that a non-orthologous protein 
fulfils this function. Similar to MTB, the MSM B12 biosynthetic pathway 
contains signatures of aerobic B12 biosynthesis including CobG 
(MSMEG_3871) which requires molecular oxygen for activity, as well as 
CobK (MSMEG_3875) and CobJ (MSMEG_3873) which contain conserved 
residues that are associated with aerobic B12 synthesis (Shearer et al., 
1999). In a parallel analysis of B12-dependent enzymes in the different 
mycobacteria, it was notable that there appeared to be no homologue of 
NrdZ in MSM: only MetH and MutAB were found. Furthermore, MSM 
possesses putative homologues of additional B12-dependent enzymes that 
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are not present in MTB: specifically, glutamate mutase (MSMEG_0969), 
dioldehydratase (MSMEG_6318), small and large subunits of ethanolamine 
ammonium lyase (MSMEG_1553-1554) and three glycerol dehydratases 
made up of large and small subunits (MSMEG_1547-1548, MSMEG_6320-
6321 and MSMEG_0496-0497). Therefore, while MSM does not possess 
the same vitamin B12-dependent complement that characterizes the MTB 
genome, this non-pathogenic mycobacterium appears to encode the full 
machinery required to synthesize B12 de novo.  
 
Based on these genetic similarities, MSM was initially used as a surrogate 
(1) to investigate the ability of vitamin B12 (CNCbl) and L-methionine to 
complement growth of mutants containing disruptions in B12 and 
methionine biosynthesis pathways; and (2) to assess the ability of MSM to 
utilize vitamin B12 precursors and building blocks including cobinamide, 
DMB, and adenine to synthesize different forms of B12, as well as to 
optimize the precursor concentrations and experimental conditions before 
proceeding into MTB.  
 
 
3.1.2 Complementation of MSM mutants with vitamin B12 and L-
methionine 
 
Mutants of the enteric bacteria, S. typhimurium and E. coli, which contain 
disruptions in their B12-independent methionine synthases, encoded by 
metE in both cases, are unable to grow unless supplemented with either 
L-methionine or vitamin B12 (Davis and Mingioli, 1950; Jeter et al., 1984). 
This methionine – and, indirectly, vitamin B12 – auxotrophy established 
that the alternative, vitamin B12-dependent methionine synthase, MetH, 
was not able to complement loss of the B12-independent enzyme in these 
organisms. In turn, it also suggested that S. typhimurium and E. coli could 
not synthesize B12 de novo under standard laboratory conditions. This was 
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subsequently verified with the demonstration that both organisms 
synthesize B12 under anaerobic conditions only; however, it established an 
assay – chemical complementation with methionine or vitamin B12 – that 
could be usefully applied to other organisms including MTB (Warner et al., 
2007; Savvi et al., 2008).  
 
To investigate the ability of MSM to synthesize vitamin B12, a panel of B12 
and methionine biosynthetic mutants was constructed (Dawes, 
unpublished) and their ability to utilize B12 and L-methionine was assessed 
in a range of in vitro assays. As expected, a ∆cobK mutant grew in the 
absence of B12 supplementation (Figure 3.1), owing to the function of the 
B12-independent methionine synthase, MetE. Unlike the corresponding 
MTB mutant (Warner et al., 2007), the MSM metE knockout was able to 
grow with similar kinetics to the parental mc2155 (Figure 3.1). This was 
surprising and suggested that, in contrast to MTB (as well as S. 
typhimurium and E. coli), MSM is capable of de novo B12 biosynthesis in 
vitro under standard (aerobic) culture conditions. Confirming this 
interpretation, the double ∆cobK ∆metE::hyg mutant was unable to grow 
in the absence of exogenous vitamin B12. As a strict B12 auxotroph, the 
MSM ∆cobK ∆metE::hyg double mutant therefore phenocopies the MTB 
∆metE::hyg mutant (Warner et al., 2007). An interesting feature of the 
MTB ∆metE::hyg mutant is that it cannot be supplemented with L-
methionine on solid 7H10 agar (Warner, 2006). In another departure from 
the MTB phenotype, the MSM ∆cobK ∆metE::hyg double mutant was able 
to utilize exogenous methionine for growth in vitro on 7H10 agar (Figure 
3.1). However, the colonies of the ∆metE::hyg and ∆cobK ∆metE::hyg 
mutants appeared significantly smaller in size compared to the wild–type 
strain, which suggested that methionine could only partially restore 
growth in strains lacking metE.  
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Figure 3.1: Growth of MSM B12 and methionine biosynthetic 
mutants. A 200 µl aliquot of a 10-fold serial dilution of a log phase 
culture of each strain was plated on 7H10+GS, 7H10+B12 (10 µg/ml), and 
7H10+L-methionine (40 µg/ml) and growth was scored after 72 h. Growth 
of ∆metE::hyg and ∆cobK mutants was comparable to mc2155 on all 
substrates, whereas the ∆cobK ∆metE::hyg double mutant was unable to 
grow without B12 or L-methionine supplementation. 
  
7H10+GS 7H10+B12 7H10+L-Methionine
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3.2 Can MSM and MTB synthesize alternate forms of the B12 
cofactor? 
 
3.2.1 Synthesis of B12 and pseudo-B12 by mycobacterial B12 
auxotrophs 
 
Subsequent to the initiation of this project, Anderson et al. (2008) 
demonstrated the ability of S. enterica to synthesize and utilize an 
alternate form of B12 known as pseudo-B12. The key difference between 
B12 and pseudo-B12 lies in the α-axial ligand: in canonical (“orthodox”) 
vitamin B12, this position is occupied by DMB. Substituting DMB with the 
purine nucleobase, adenine, generates pseudo-B12. Under strict anaerobic 
conditions, S. enterica is able to synthesize either form - DMB-containing 
“orthodox” B12 or pseudo-B12. However, during aerobic growth, it must be 
provided with cobinamide (the corrin ring plus aminopropanol side chain) 
and DMB in order to synthesize B12. Notably, Anderson and colleagues 
also showed that the synthesis of pseudo-B12 requires the same set of 
enzymes (CobT, CobU, CobS and CobC) that are involved in the synthesis 
of DMB-containing B12 (Anderson et al., 2008). Their results raised the 
possibility that mycobacteria might possess a similar ability to synthesize 
either B12 or pseudo-B12, depending on whether bacilli are provided with 
cobinamide plus DMB (for orthodox B12) or cobinamide plus adenine 
(pseudo-B12). If so, this would imply that pseudo- B12 could act as a 
functional equivalent of B12 in B12-dependent pathways, thereby enabling 
MTB to utilize alternate B12 forms depending on prevailing environmental 
(host) conditions.  
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Figure 3.2: Schematic illustrating predicted phenotypes in 
assessment of pseudo-B12 synthesis in mycobacteria. MSM ∆cobK 
∆metE::hyg and MTB ∆metE::hyg both require B12 for growth. Both strains 
are predicted to grow when supplemented with ‘orthodox’ B12 precursors 
(cobinamide plus DMB), pseudo-B12 precursors (cobinamide plus adenine) 
and cobinamide. However, growth on cobinamide alone is indicative of 
endogenous DMB synthesis. Thus, it is predicated that abrogation of DMB 
synthesis in MTB will result in the inability of Rv0306D32NS167G ∆metE::hyg 
and ∆Rv0306 ∆metE::hyg to utilize cobinamide alone. Symbols: = 
equivalent;  growth;  no growth.  
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∆Rv0306 ∆metE::hyg
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3.2.2 Aerobic growth of S. enterica supplemented with B12 and 
pseudo-B12 precursors 
 
Before testing the hypothesis that MTB might be able to utilize alternate 
B12 forms, the ability to reproduce the experimental protocol developed for 
S. enterica by Anderson et al. (2008) was validated. To this end, the 
growth kinetics of S. enterica were assessed using a variation of Vogel and 
Bonner’s (1955) E media. In their study, Anderson et al. (2008) referred 
to this medium as Non-Citrate E (NCE) media, as it is a minimal medium 
that is deficient in citrate but contains ethanolamine as carbon source. S. 
enterica utilizes ethanolamine as the sole carbon and nitrogen source 
under aerobic conditions only if B12 or, in this case, B12 precursors are 
provided (Chang and Chang, 1975). After growth to log phase in LB broth, 
cultures were harvested and washed before inoculating into NCE medium 
at an OD600 of 0.1. Growth was recorded every 2.5 h. As indicated in 
Figure 3.3A, S. enterica was able to utilize cobinamide plus DMB to 
synthesize B12 under aerobic conditions; cobinamide alone was not 
sufficient for growth. Moreover, an adenine titration was performed which 
established that the growth of S. enterica improved with increasing 
concentrations of adenine (Figure 3.3B). These data were consistent with 
the results of Anderson et al. (2008), and confirmed that the cobinamide, 
DMB and adenine supplements provided were active and capable of 
supporting bacterial growth.  
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Figure 3.3: Aerobic synthesis of B12 and pseudo-B12 by S. 
enterica. S. enterica was grown in NCE minimal medium with 
ethanolamine as the sole carbon and nitrogen source (A) without any 
supplement ( ), with 20 nM cobinamide ( ), and with 20 nM cobinamide 
plus 20 nM DMB ( ), and (B) with a fixed concentration of 20 nM 
cobinamide plus increasing concentrations of 0.1 µM adenine ( ), 1 µM 
adenine ( ), 10 µM adenine ( ), 100 µM adenine ( ) and 20 nM DMB (
). Abbreviations: cbi - cobinamide, AD - adenine. 
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3.2.3 MSM utilizes B12 and pseudo-B12 precursors 
 
In addition to assessing the ability of MSM to utilize B12 and pseudo-B12 
precursors, this faster growing mycobacterium was used to determine the 
optimal concentrations of pseudo-B12 (cobinamide and adenine) and B12 
(cobinamide and DMB) precursors for use in MTB. As noted in Figure 3.9, 
comparative bioinfomatic analyses identified a near-complete B12 
biosynthetic pathway in MSM, including homologues of enzymes required 
for DMB - and, by inference, adenine - attachment (CobT, CobU, CobS). 
Rv2228c and MSMEG_4305 are the putative homologues of S. enterica 
CobC in MTB and MSM, respectively. The gene annotated as cobC in MTB 
is homologous to the aminotransferase encoded by cobD in S. enterica.  
As MSM synthesizes B12 in vitro (Figure 3.1), the ∆cobK ∆metE::hyg 
double mutant containing disruptions in both B12-independent methionine 
synthase (metE) and Cbl biosynthesis (cobK) genes were used as the 
experimental strain. Deletion of cobK was predicted not to impact the 
ability of MSM to utilize the supplied cobinamide and DMB supplements for 
B12 (or pseudo-B12) synthesis since this strain retains all components of 
the late-stage B12 biosynthetic pathway (Figure 3.9). This includes CobT 
which possesses a broad specificity (Cheong et al., 2001) and can 
phosphoribosylate a wide variety of aromatic substrates giving rise to a 
variety of lower B12 ligands. When S. enterica is grown under aerobic 
conditions, DMB occupies the β-ligand (Johnson and Escalante-Semerena, 
1992) whereas, under anaerobic conditions, it is replaced by adenine 
(Keck and Renz, 2000). In both cases, this transfer is carried out by CobT. 
Therefore, CobT should facilitate the assimilation of DMB or adenine into 
the α-ribazole moiety of adenosyl-cobinamide-GMP (utilizing exogenous 
supplied cobinamide) (Taga et al., 2007).  
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As a strict auxotroph, the ∆cobK ∆metE::hyg mutant could be propagated 
only when grown in media supplemented with vitamin B12 (Figure 3.1 & 
3.4A). Therefore, for growth assays in liquid media, cells were harvested 
during log-phase growth in B12-supplemented medium before washing 
them to remove any residual B12. Thereafter, the cells were re-inoculated 
at a starting OD600 of approximately 0.1 in fresh Sauton’s minimal 
medium. However, for the first generation, this proved insufficient: growth 
was observed in all media even in the absence of supplement (data not 
shown). This was presumably because cells retained sufficient quantities 
of residual (intracellular) B12. Therefore, a modified protocol was adopted 
for all subsequent experiments in which all cultures were serially re-
inoculated into fresh Sauton’s medium containing the identical supplement 
combinations; that is, a culture grown in Sauton’s plus B12 was serially re-
inoculated into fresh Sauton’s medium containing B12, another culture 
grown in Sauton’s only was serially re-inoculated into fresh Sauton’s 
medium lacking any supplement, etc. This process was repeated every 24 
h for a duration of 72 h until all residual (internal) B12 was utilized, as 
determined by the inability of the ∆cobK ∆metE::hyg mutant to grow in 
supplement-free medium (Figure 3.4A). It should be noted that, in all 
MSM growth curves, only three time points are shown for samples grown 
in medium containing B12 (Figures 3.4A&B and Figures 3.5A&B). This is 
because the B12-supplemented samples were characterized by robust 
growth whereas those strains supplemented with other compounds grew 
with much slower kinetics. Therefore, for easier visualization of the data, 
the optical density readings for the B12-supplemented samples were 
excluded from the growth curves after the third time point. 
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Figure 3.4: Growth kinetics of MSM ∆cobK ∆metE::hyg mutant 
when supplemented with B12 and B12 precursors. A log phase 
culture of ∆cobK ∆metE::hyg was washed before being inoculated at an 
OD600 of 0.1 into Sauton’s minimal medium, and then serially re-inoculated 
into the same medium to deplete internal B12 levels. Optical densities were 
measured every 3 h for approximately 5 days. A) The ∆cobK ∆metE::hyg 
mutant is a B12 auxotroph that requires exogenous B12 (10 µg/ml) ( ) for 
growth, and is unable to grow in media lacking B12 ( ). B) Growth of the 
∆cobK ∆metE::hyg mutant in medium supplemented with cobinamide only 
( ), with lower concentrations of cobinamide and DMB ( ), with higher 
concentrations of cobinamide and DMB ( ), and with vitamin B12 ( ) or 
no supplement ( ). Data are representative of a single experiment from 
two independent biological replicates. OD600 readings of B12 supplemented 
media were curtailed at 94 h. Abbreviations: cbi- cobinamide, AD- 
adenine.  
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Importantly, the ∆cobK ∆metE::hyg mutant was able to grow when 
supplemented with B12 precursors (cobinamide plus DMB), strongly 
suggesting the ability of MSM to assimilate these into vitamin B12 (Figure 
3.4B). Similar growth was observed when the mutant was supplemented 
with the pseudo-B12 precursors, cobinamide plus adenine (Figure 3.5A). 
Although this hinted at the possible synthesis (and utilization) of pseudo-
B12 by MSM, this observation was not conclusive since the mutant was 
able to grow on cobinamide alone, perhaps indicating the endogenous 
production and attachment of DMB to the supplemented cobinamide to 
produce “orthodox” vitamin B12. That is, because the late stage of the B12 
biosynthetic pathway is retained in the ∆cobK ∆metE::hyg mutant, it was 
not possible to determine unequivocally whether cobinamide plus adenine, 
or cobinamide alone, was utilized as the active cofactor. To resolve that 
question, an adenine titration was performed utilizing increasing amounts 
of adenine in combination with a fixed concentration of cobinamide, as 
described by Anderson et al. (2008). Increasing concentrations of adenine 
appeared to correlate with improved growth of the ∆cobK ∆metE::hyg 
double mutant (Figure 3.5B). Although suggestive of pseudo-B12 
synthesis, this result was not sufficiently conclusive since the stepwise 
trend was not perfect and, as observed above, cobinamide alone was 
associated with good growth. Moreover, the exact nature of the individual 
chemical species being synthesized cannot be determined utilizing our 
genetic approach. Instead, a more precise method like high-performance 
liquid chromatography (HPLC) is required to determine the specific 
cofactor form, and thus establish whether MSM can indeed synthesize and 
utilize pseudo-B12 as a functional equivalent of B12 in key B12-dependent 
metabolic pathways.  
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Figure 3.5: Growth kinetics of MSM ∆cobK ∆metE::hyg when 
supplemented with B12 and pseudo-B12 precursors. A log phase 
culture of ∆cobK ∆metE::hyg was washed before being inoculated at an 
OD600 of 0.1 into Sauton’s minimal medium, and then serially re-inoculated 
into the same medium to deplete internal B12 levels. Optical densities were 
measured every 3 h for approximately 5 days. A) Growth with cobinamide 
only ( ), with lower concentration cobinamide plus adenine ( ), with 
higher concentration cobinamide plus adenine ( ), and with vitamin B12 (
) versus no supplement ( ). B) Differential response to increasing 
concentrations of adenine: 0.1 µM adenine ( ), 1 µM adenine ( ), 10 µM 
adenine ( ), 25 µM adenine ( ), 50 µM adenine (+), 100 µM adenine (
), plus fixed concentration of cobinamide at 10 µM ( ), no supplement (
), and 10 µg/ml vitamin B12 ( ). Data are representative of a single 
experiment from two independent biological replicates. OD600 readings of 
B12 supplemented media were curtailed at 94 h (A) and 78 h (B). 
Abbreviations: cbi- cobinamide, AD- adenine.  
 
 
3.2.4 Synthesis of B12 and pseudo-B12 in MTB 
 
Having established effective B12 precursor concentrations in MSM, these 
were applied to the MTB ∆metE::hyg mutant (Warner et al., 2007). 
Analogous to the MSM ∆cobK ∆metE::hyg double knockout, MTB 
∆metE::hyg can only be propagated in media containing B12. Therefore, 
cells were first washed before inoculating at an OD600 of 0.1 into Sauton’s 
minimal medium. Cultures were grown for 8 to 14 days to allow depletion 
of internal B12, and then re-inoculated into fresh Sauton’s medium 
containing the same supplement(s). The ∆metE::hyg mutant was able to 
grow in medium supplemented with cobinamide alone, as well as 
cobinamide plus DMB (Figure 3.6A). When supplemented with pseudo-B12 
precursors (cobinamide plus adenine) the MTB B12 auxotroph was also 
able to grow, as shown in Figure 3.6B.   
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Figure 3.6: Growth kinetics of MTB ∆metE::hyg mutant when 
supplemented with B12 and pseudo-B12 precursors. A log-phase 
culture of MTB ∆metE::hyg was washed then inoculated at an OD600 of 0.1 
into Sauton’s medium containing the following: no supplement ( ), 
cobinamide only ( ), 10 µM cobinamide plus 10 µM DMB ( ), 10 µM 
cobinamide plus 10 µM adenine ( ) and vitamin B12 ( ). Cultures were 
grown for 8-14 days to allow internal B12 to be depleted before re-
inoculating into fresh Sauton’s containing the same supplement(s). (A) 
Growth with B12 precursors, cobinamide plus DMB and (B) growth with 
pseudo-B12 precursors, cobinamide plus adenine. Data are representative 
of a single experiment from three independent biological replicates. 
Abbreviations: cbi- cobinamide, AD- adenine. 
 
 
The ability of B12 and pseudo-B12 precursors to support the function of 
other B12-dependent enzymes which require different forms of the cofactor 
for activity was also investigated. MetH utilizes MeCbl while both MutAB 
and NrdZ require AdoCbl. To determine the ability of pseudo-B12 to 
support AdoCbl-dependent growth, an assay was employed that was 
developed previously in the MMRU (Savvi et al., 2008), and involves the 
use of the succinate analogue, 3-NP, to inhibit ICL function. Among 
various alternative odd-chain fatty acids, the catabolism of the five carbon 
(C5) compound, valerate, as an alternative carbon source generates an 
equimolar ratio of acetyl-CoA and propionyl-CoA subunits. Propionyl-CoA is 
metabolized through the methylcitrate and glyoxylate pathways, and its 
accumulation is toxic to MTB. Wild-type MTB H37Rv is unable to grow on 
valerate as a sole carbon source in the presence of 3-NP due to toxic 
build-up of propionyl-CoA (Figure 3.7). However, Savvi et al. (2008) 
demonstrated that 3-NP-mediated growth inhibition is alleviated by the 
addition of B12 which allows the propionyl-CoA to be metabolized through 
the MutAB-containing methylmalonyl pathway. Supplementation of the 
medium with various B12 precursors resulted in growth of H37Rv grown in 
valerate plus 3-NP (Figure 3.7). This suggested that MutAB was functional 
in these conditions, thereby reinforcing the conclusion that MTB can utilize 
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exogenous B12 or cobinamide to support the function of both AdoCbl-
dependent (MutAB) and MeCbl-dependent (MetH) pathways. 
 
 
Figure 3.7: Growth kinetics of MTB H37Rv in valerate plus the ICL 
inhibitor, 3-NP, and supplemented with B12 and pseudo-B12 
precursors. H37Rv was grown in medium containing valerate as the sole 
carbon source in the presence of 3-NP with vitamin B12 ( ), without 
vitamin B12 ( ), with 10 µM cobinamide ( ), with 10 µM cobinamide plus 
10 µM DMB ( ), and with 10 µM cobinamide plus 10 µM adenine (X). 
Data are representative of a single experiment from three independent 
biological replicates. Abbreviations: cbi- cobinamide, AD- adenine. 
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As with MSM, growth of MTB ∆metE::hyg with cobinamide plus adenine 
could not be attributed to pseudo-B12 biosynthesis since this mutant was 
also able to grow in media containing cobinamide alone (Figure 3.6A). 
Again, this suggested the possibility of endogenous DMB biosynthesis. To 
assess whether increasing concentrations of adenine would influence 
growth, titrations with fixed concentrations of cobinamide (5 µM or 10 µM) 
were performed. Unlike MSM (Figure 3.5), no differential growth was seen 
in MTB in response to increasing concentrations of adenine with 10 µM 
cobinamide (Figure 3.8B). However, decreasing the cobinamide 
concentration to 5 µM appeared to correlate with improved growth of 
∆metE::hyg in the presence of elevated adenine concentrations (Figure 
3.8A). These data also suggest that the higher concentration of 
cobinamide (10 µM) might exceed the requirements for growth, and so 
might conceal the benefits to the bacillus of increasing adenine 
concentrations in this assay. 
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Figure 3.8: Assessment of pseudo-B12 synthesis by MTB 
∆metE::hyg by adenine titration. A log-phase culture of MTB 
∆metE::hyg was washed then inoculated at an OD600 of 0.1 into Sauton’s 
minimal media, grown for 8-14 days until internal B12 was depleted, and 
then re-inoculated into media containing the exactly same supplement(s). 
Titrations were performed with fixed concentrations of either (A) 5 µM 
cobinamide or (B) 10 µM cobinamide, plus increasing concentrations of 
adenine. Data are representative of a single experiment from three 
independent biological replicates Abbreviations: cbi-cobinamide, AD-
adenine.  
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3.2.5 Investigation of pseudo-B12 synthesis in MTB by abrogation 
of DMB biosynthesis 
 
To determine whether MTB was able to utilize exogenous DMB (or 
adenine) for the synthesis of B12 (or pseudo-B12), a genetic approach was 
adopted that entailed the abrogation of DMB biosynthesis. The rationale 
for this approach was that, by eliminating the ability of ∆metE::hyg to 
synthesize its own DMB, the mutant could be “forced” to utilize exogenous 
B12 (cobinamide plus DMB) or pseudo-B12 (cobinamide plus adenine) 
precursors. To date, no biosynthetic genes have been identified in MTB for 
the synthesis of the lower ligand, DMB. However, recent studies have 
implicated BluB in the synthesis of DMB in S. meliloti (Campbell et al., 
2006; Taga et al., 2007).   
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Figure 3.9: Putative AdoCbl biosynthetic pathway in MTB and 
MSM incorporating the proposed pathway for DMB biosynthesis. 
The putative AdoCbl biosynthetic pathway from Figure 1.2 is expanded 
here to include the predicted pathway for DMB biosynthesis (shaded 
panel). H37Rv Rv0306 (http://genolist.pasteur.fr/Tuberculist/) is shown 
together with predicted S. meliloti homologue bluB. The pathway is 
adapted from Metacyc reference pathway (http://metacyc.org/META/new-
image?object=PWY-5523); a putative MSM homologue of bluB was 
identified by BLAST homology search (http://tigerblast.tigr.org/cmr.blast/) 
using S. meliloti query sequences.  
 
 
Rv0306 was originally predicted to be a cob(II)yrinic acid a,c-diamide 
reductase (“cobalt reductase”) in the B12 biosynthetic pathway (discussed 
in section 1.6.3). However, bioinformatic analyses (Rodionov et al., 2003; 
Campbell et al., 2006; Taga et al., 2007), identified Rv0306 as the 
putative MTB homologue of S. meliloti BluB (Figure 3.9). Further 
examination of the Rv0306 protein sequence confirmed the conservation 
of two key residues required for BluB activity: the aspartate at position 32 
and the glycine at position 167 (Figure 3.10). Taga et al. (2007) showed 
that mutations in these residues, either individually or in combination, 
abrogated DMB synthesis in S. meliloti. Although Rv0306 is annotated as 
an oxidoreductase, it is noteworthy that these residues are more 
commonly observed in nitroreductases, and the BluB enzyme belongs to a 
subfamily of the nitroreducatase family.  
  
101 
 
 
Figure 3.10: Sequence alignment of S. meliloti BluB and MTB 
Rv0306. Protein sequences were aligned utilizing the PROMALS3D 
multiple sequence and structure alignment server 
(http://prodata.swmed.edu/promals3d/promals3d.php). Critical residues 
mutated by Taga et al. (2007) are indicated by black arrows. 
 
 
 Targeting of DMB biosynthesis in MTB by site-directed 
mutagenesis of key residues 
 
DMB biosynthesis in MTB was targeted by a twofold approach: (1) site-
directed mutagenesis of the key residues in Rv0306 (Taga et al., 2007), 
and (2) targeted knockout of Rv0306. The Rv0306 allele was custom 
synthesized by Sigma and included the full-length Rv0306 plus 
substitutions of the key residues: that is, switching the aspartate at 
position 32 to asparagine (D32N) and glycine at position 167 to serine 
(S167G) (Figure 3.10). The mutant allele was synthesized with sufficient 
flanking sequence for homologous recombination and was utilized to 
construct the p2Rv0306D32NS167GpG17 suicide vector (Table 2.2), which 
was electroporated into the MTB ∆metE::hyg mutant. The screening 
process applied to identify putative Rv0306D32NS167G∆metE::hyg mutants 
entailed first amplifying the 672bp Rv0306 gene together with 190bp 
 
S. meliloti bluB             MLPDPNGCLTAAGAFSSDERAAVYRAIETRRDVRDEFLPEP-LSEELIARLLGAAHQAPS 
M. tuberculosis H37Rv|Rv0306 -------------MFSAPERRAVYRVIAERRDMR-RFVPGGVVSEDVLARLLHAAHAAPS 
                                           **: ** ****.*  ***:* .*:*   :**:::**** *** *** 
 
 
S. meliloti bluB             VGFMQPWNFVLVRQDETREKVWQAFQRANDEAAEMFSGERQAKYRSLKLEGIRK-APLSI 
M. tuberculosis H37Rv|Rv0306 VGLMQPWRFIRITDETLKRRIHALVDDERLLTAEAL-GAREEEFLALKVEGILDCAELLV 
                             **:****.*: : ::  :.::   .:  .  :** : * *: :: :**:*** . * * : 
 
 
S. meliloti bluB             CVTCDRTRGGAVVLGRTHNPQMDLYSTVCAVQNLWLAARAEGVGVGWVSIFHESEIKAIL 
M. tuberculosis H37Rv|Rv0306 VALCDRR--GSYIFGRRTLPQMDLASVSCAIQNLWLAARSEGLGMGWVSLFDPQRLAALL 
                              . ***   *: ::**   ***** *. **:********:**:*:****:*. ..: *:* 
 
 
S. meliloti bluB             GIPDHVEIVAWLCLGFVDRLYQEPELAAKGWRQRLPLEDLVFEEGWGVR----------- 
M. tuberculosis H37Rv|Rv0306 AMPADAEPVAILCLGPVPEFPDRPALELDGWAYARPLAEFVSENRWSYPSALATDHHHGE 
                             .:* ..* ** **** * .: :.* *  .**    ** ::* *: *.              
S167G
D32N
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upstream and 50 bp downstream sequence by PCR, and then digesting 
the resulting PCR product with FspI and StuI restriction enzymes in order 
to exploit the restriction sites engineered into each point mutant (Figure 
3.11A & B). Positive transformants harbouring both point mutations were 
confirmed by the presence of 203 bp and 651 bp fragments following FspI 
digest; and 597 bp plus 257 bp from the StuI digest (Figure 3.11D & E). 
The deletion of the metE gene in the putative Rv0306D32NS167G ∆metE::hyg 
mutant was re-confirmed by Southern blot (Figure 3.17C).  
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Figure 3.11: Rv0306 with introduced point mutations. Protein 
sequences with corresponding nucleotide sequences showing that (A) the 
D32N mutation introduces FspI restriction site, and (B) the S167G 
mutation introduces StuI restriction site, along with a (C) diagrammatic 
representation of Rv0306 illustrating point mutations and corresponding 
restriction sites. Restriction digests confirming point mutations in Rv0306, 
Lane 1: molecular weight marker VI (Roche), Lane 2: H37Rv, Lane 3: 
p2Rv0306D32NS167GpG17, Lane 4: Rv0306D32NS167G∆metE::hyg (D) FspI 
digest confirming Rv0306 with aspartate to asparagine point mutation. (E) 
StuI digest confirming Rv0306 with serine to glycine point mutation. 
 
 
It was hypothesized that abrogation of DMB biosynthesis in 
Rv0306D32NS167G∆metE::hyg would render the mutant unable to grow on 
cobinamide alone and instead dependent on a combination of cobinamide 
plus DMB (to yield B12) or cobinamide plus adenine (pseudo-B12). 
However, as shown in Figure 3.12, the Rv0306D32NS167G ∆metE::hyg 
mutant was able to grow when supplemented with cobinamide alone. The 
mutated residues had been selected based on the observations of Taga et 
al. (2007); the formal possibility remained, therefore, that the point 
mutations introduced into MTB Rv0306 were not sufficient to abrogate 
BluB function and thus DMB biosynthesis.   
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Figure 3.12: Mutation of Asp32 and Ser167 does not affect 
growth of MTB Rv0306D32NS167G ∆metE::hyg on cobinamide. A log-
phase culture of MTB Rv0306D32NS167G ∆metE::hyg was washed then 
inoculated at an OD600 of 0.1 into Sauton’s minimal medium, grown for 8- 
14 days until internal B12 was depleted, and then re-inoculated into 
medium containing exactly the same supplement(s). Growth of 
Rv0306D32NS167G ∆metE::hyg in Sauton’s medium with no supplement ( ), 
with B12 (10 µg/ml) ( ), with 10 µM cobinamide (X), with 10 µM 
cobinamide plus 10 µM adenine ( ), and with 10 µM cobinamide plus 10 
µM DMB ( ). Data are representative of a single experiment from three 
independent biological replicates. Abbreviations: cbi - cobinamide, AD - 
adenine.  
 
 
 Targeting of DMB biosynthesis by deletion of Rv0306  
 
Site-directed mutagenesis of two key residues in Rv0306 did not affect 
growth on cobinamide (Figure 3.12). To investigate the possibility that 
these mutations were insufficient to eliminate Rv0306 function, a double 
mutant was constructed by deleting the Rv0306 gene in the ∆metE::hyg 
background (Figure 3.13). The deletion of metE in the ∆Rv0306 
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∆metE::hyg double mutant was also confirmed genotypically (Figure 
3.17C).  
 
 
Figure 3.13: Genotypic analysis of the ∆Rv0306 ∆metE::hyg 
double mutant. (A) Deletion of Rv0306 in the ∆metE mutant background 
was confirmed by digesting genomic DNA isolated from H37Rv and 
∆Rv0306 ∆metE::hyg with restriction enzyme StuI and probing with the 
Rv0306 probe described in Table 2.3. Construction of the mutant allele 
eliminated 313bp of Rv0306 coding sequence, and hybridization with the 
Rv0306 probe identified 5370 bp and 1871 bp fragments in the parental 
H37Rv and 6899 bp fragment in the ∆Rv0306 mutant allele. (B) Schematic 
representation of the parental and mutant allele plus restriction sites; the 
probe is represented by an open box.  
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The ∆Rv0306 ∆metE::hyg double mutant grew with wild-type kinetics in 
Sauton’s minimal medium supplemented with cobinamide alone (Figure 
3.14). This result was surprising, and suggested a number of possibilities: 
for example, MTB might possess an alternative pathway(s) for DMB 
biosynthesis, or Rv0306 might not be the only enzyme capable of 
catalysing the flavin destructase reaction. Alternatively, it is possible that 
an alternate form of B12 is synthesized by MTB using an endogenous α-
ligand, such as adenine. This result reinforced the conclusion that 
detection of B12 or pseudo-B12 synthesis was not possible utilizing a 
genetic assay alone, and suggested that a more precise biochemical assay 
would be required to determine the nature of the active cofactor. 
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Figure 3.14: Phenotypic analysis of the ∆Rv0306 ∆metE::hyg 
double mutant. ∆Rv0306 ∆metE::hyg was phenotypically assessed by 
growing to log-phase then washing and inoculating the culture at an OD600 
of 0.1 into Sauton’s minimal media, with no supplement ( ), with B12 (10 
µg/ml) ( ), with 10 µM cobinamide ( ), with 10 µM cobinamide plus 10 
µM adenine ( ), and with 10µM cobinamide plus 10 µM DMB ( ). 
Cultures were grown for 8-14 days until internal B12 was depleted, then 
re-inoculated into media containing the same supplement(s) and then 
OD’s were taken. Data are representative of a single experiment from 
three independent biological replicates. Abbreviations: cbi- cobinamide, 
AD- adenine.  
 
 
3.3 Cobalt supplementation enables growth of a MTB B12 
auxotroph 
 
MTB encodes a near-complete B12 biosynthetic pathway (discussed in 
section 1.6.3), and appears to lack homologues of cobF and cobST. 
However, B12 biosynthesis has been microbiologically demonstrated in the 
closely related M. bovis (Karasseva et al., 1977) which, like MTB, appears 
to lack CobF and CobST but, unlike MTB, also possesses a truncated CobL 
(Brosch et al., 2002). Therefore, the inability of the ∆metE::hyg mutant 
(Warner et al., 2007) to grow without B12 supplementation (Figure 3.15A) 
was intriguing.  
 
Industrial production of B12 by various bacterial species is influenced by a 
variety of conditions; for example, the addition of key precursors to the 
culture medium has been shown to increase B12 yields (Halbrook et al., 
1950; Kamikubo et al., 1978; Riaz et al., 2007). Some of these precursors 
(as seen in section 3.2) also facilitated synthesis of B12 in MTB, but the 
results did not address the question of whether the bacillus is capable of 
corrin ring synthesis. At the heart of the corrin macrocycle lies a cobalt 
ion; the supplementation of growth media with cobalt is an absolute 
requirement in the industrial synthesis of B12, as it enhances yields. 
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Therefore, it was speculated that cobalt availability might be a limiting 
factor for MTB B12 biosynthesis under standard in vitro conditions. To 
investigate this possibility, the ∆metE::hyg mutant was grown in Sauton’s 
minimal medium containing cobalt. As shown in Figure 3.15B, 5 µM cobalt 
can supplement growth of the MTB B12 auxotroph. Although B12 
biosynthesis had not been demonstrated biochemically, this was a 
significant result since it suggested corrin ring synthesis in MTB.  
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Figure 3.15: Exogenous cobalt supports growth of MTB B12 
auxotroph. A log-phase culture of the ∆metE::hyg mutant was washed 
then inoculated at an OD600 of 0.1 in Sauton’s minimal medium, and 
grown for 8 to 14 days to allow depletion of internal B12. Cultures were re-
inoculated into fresh medium containing the identical supplement, and 
optical densities measured. Growth of ∆metE::hyg mutant in minimal 
medium supplemented with (A) 10 µg/ml B12, and (B) 5 µM cobalt. Data 
are representative of a single experiment from three independent 
biological replicates. 
 
 
The near-complete B12 biosynthetic pathway in MTB exhibits 
characteristics of aerobic biosynthesis. As a result, the insertion of cobalt 
into the corrin macrocycle is predicted to occur late in the pathway. To 
confirm the notion that cobalt was limiting in standard growth media, and 
that supplementation with cobalt enabled de novo B12 biosynthesis in MTB, 
a panel of mutants was constructed containing disruptions in key B12 
biosynthetic genes. An early step in the pathway that involves the 
conversion of precorrin-6x to precorrin-6y is catalyzed by the CobK-
encoded precorrin-6x reductase (Figure 3.9). Deletion of cobK in the 
∆metE::hyg background eliminated the ability of the resulting ∆cobK 
∆metE::hyg double mutant (Figure 3.17A & C) to grow in minimal medium 
supplemented with cobalt (Figure 3.16A). In contrast, supplementation 
with cobinamide, a late-stage product of the pathway, enabled growth 
(Figure 3.16A)  
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Figure 3.16: Abrogation of predicted early- (CobK) and late- 
stage (CobU) vitamin B12 biosynthetic steps in MTB ΔmetE::hyg 
suggests the incorporation of cobalt into vitamin B12. Log-phase 
cultures of ∆cobK ∆metE::hyg and ∆cobU ∆metE::hyg were washed then 
inoculated at an OD600 of 0.1 into Sauton’s minimal medium, and grown 
for 8 to 14 days to allow internal B12 depletion. Cultures were re-
inoculated into fresh media containing the same supplement and optical 
densities were measured. (A) Inability of ∆cobK ∆metE::hyg to grow in 
unsupplemented medium ( ) and medium containing 5 µM cobalt ( ) 
contrasts with growth of this mutant in medium supplemented with 10 µM 
cobinamide ( ), 10 µM cobinamide plus 10 µM DMB ( ), and 10 µg/ml 
B12 ( ). (B) The ∆cobU ∆metE::hyg mutant is able to grow only when 
supplemented with 10 µg/ml B12, but not in medium supplemented with 5 
µM cobalt ( ), 10 µM cobinamide ( ), or 10 µM cobinamide plus 10 µM 
DMB ( ). Data are representative of a single experiment from three 
independent biological replicates. Abbreviations: cbi- cobinamide, AD- 
adenine.  
 
 
One of the final steps in B12 biosynthesis involves the conversion of 
adenosylcobinamide to adenosyl-cobinamide-GDP in a reaction catalyzed 
by the bifunctional enzyme, CobU (Figure 3.9). This enzyme represents a 
crucial step in the synthesis of B12 because it functions as both a kinase 
and guanylyltransferase in AdoCbl biosynthesis. To investigate the effects 
of late-stage disruptions on the ability of the ∆metE::hyg mutant to utilize 
exogenous cobalt, a double mutant was constructed (Warner, 2006) by 
deleting metE in the cobU background (Figure 3.17B & C). In contrast to 
∆cobK ∆metE::hyg (Figure 3.16A), the resulting ∆cobU ∆metE::hyg double 
mutant was unable to grow in minimal medium supplemented with either 
cobalt or cobinamide (alone or plus DMB) (Figure 3.16B). This strongly 
supports the conclusion that cobalt is incorporated into vitamin B12, and 
reinforces the idea that supplementation with cobalt is necessary to 
enable de novo B12 biosynthesis by MTB in vitro. In addition, it suggests 
that the full B12 biosynthetic pathway is functional in MTB, despite the 
absence of clear homologoues for every biosynthetic step (discussed in 
1.6.3).  
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Figure 3.17: Genotypic confirmation of methionine and B12 
deletion mutants. Genomic DNA was isolated from H37Rv, ∆metE::hyg, 
∆cobK ∆metE::hyg, ∆PPE2 ∆metE::hyg, ∆cobU ∆metE::hyg, and ∆Rv0306 
∆metE::hyg and digested with restriction enzyme BamHI before probing 
with specific metE, cobK and cobU probes, listed in Table 2.3. Adjacent to 
each Southern blot is a diagrammatic representation of parental and 
mutant allele plus restriction sites. The probe is represented by an open 
black box in each case. (A) Construction of the ∆cobK allele eliminated 
214 bp of cobK coding sequence and hybridization with cobK probe 
identified a 5068 bp fragment in the parental H37Rv and a 3459 bp 
fragment in the ∆cobK mutant. (B) Construction of the ∆cobU allele 
eliminated 280 bp of cobU coding sequence and introduced an additional 
BamHI restriction site in the deletion allele. Hybridization with the cobU 
probe identified a 5002 bp band in the parental H37Rv and a 1835 bp 
band in the ∆cobU mutant. (C) Construction of the ∆metE::hyg allele (hyg 
cassette represented by red triangle) eliminated 1367 bp of metE coding 
sequence and introduced an additional BamHI restriction site in the 
deletion allele. Hybridization with the metE probe identified an 8016 bp 
fragment in the parental strain and a 34769 bp band in the ∆metE::hyg 
mutant. 
 
 
3.3.1 Genetic complementation of late stage (cobU) B12 
auxotroph with PPE2-cobQ1-cobU  
 
The cobU gene lies in a putative three-gene operon with PPE2 and cobQ1 
(Tundup et al., 2006) and is only 525 bp in size. A construct carrying a 
wild-type copy of the putative operon (PPE2-cobQ1-cobU) plus 688 bp 5’ 
upstream sequence was integrated at the attB site of the ∆cobU 
∆metE::hyg double mutant. As shown in Figure 3.18, complementation 
with this construct restored the ability of the double mutant to grow in 
medium supplemented with either cobalt or cobinamide, strongly 
suggesting that abrogation of CobU function eliminates the ability of MTB 
to synthesize a viable cofactor.  
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Figure 3.18: Complementation with PPE2-cobQ1-cobU restores 
growth of ∆cobU ∆metE::hyg on B12 precursors. A log-phase culture 
of ∆metE::hyg ∆cobU attB::PPE2-cobQ1-cobU was washed then 
inoculated at an OD600 of 0.1 into Sauton’s minimal medium, and grown 
for 8 to 14 days to allow internal B12 depletion. The culture was re-
inoculated into fresh media containing the same supplement and optical 
densities were measured. ∆metE::hyg ∆cobU attB::PPE2-cobQ1-cobU is 
unable to grow in unsupplemented ( ) medium, but growth is restored in 
medium containing 5 µM cobalt ( ), 10 µM cobinamide ( ), 10 µM 
cobinamide plus 10 µM DMB ( ), and 10 µg/ml B12 ( ). Data are 
representative of a single experiment from three independent biological 
replicates. Abbreviations: cbi-cobinamide, AD-adenine. 
 
 
3.3.2 Inability to supplement the ∆metE::hyg mutant with cobalt 
on solid medium 
 
To determine whether cobalt supplementation was similarly effective on 
solid medium, the ∆metE::hyg mutant was plated on 7H10/OADC plates 
containing increasing concentrations of cobalt (Figure 3.19). Surprisingly, 
even the highest concentration of cobalt failed to complement growth of 
the ∆metE::hyg mutant (Figure 3.15B). In contrast, cobinamide was able 
to support growth of the ∆metE::hyg mutant on solid medium (data not 
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shown). The reason for the failure of the ∆metE::hyg mutant to utilize 
exogenous cobalt for growth on solid media is unclear; however, it is 
possible that uptake of the metal ion – or even the synthesis of B12 - is 
inefficient and/or impaired under these conditions. 
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Figure 3.19: Inability of cobalt to complement growth of the 
∆metE::hyg mutant on solid medium. The effect of increasing 
concentrations of cobalt on growth of H37Rv, ∆PPE2, ∆metE::hyg and 
∆PPE2 ∆metE::hyg was assessed by spotting 10 µl of a 10-fold serial 
dilution of log phase cultures of each strain on 7H10/OADC supplemented 
with 500 nM, 2 µM, 5 µM, 500 µM, 1 mM and 10 mM cobalt. 
Unsupplemented 7H10/OADC and vitamin B12-supplemented 7H10/OADC 
plates were included as controls. 
 
 
3.4 Investigation of the putative role of PPE2 in B12 or cobalt 
transport/assimilation 
 
In addition to providing evidence of MTB’s inability to synthesize B12 (in 
the absence of cobalt supplementation), the B12 auxotrophy of the metE 
mutant (Warner et al., 2007) established that MTB is able to transport B12 
(Figure 3.15A). This was an important finding; unlike the majority of 
bacteria that transport B12, there is a complete lack of any identifiable B12-
specific transporter in the MTB genome (Rodionov et al., 2003). Of the 
genomes analysed by Rodionov et al. (2003), only a small proportion of 
B12-utilizing organisms lack an obvious B12 transport candidate, including 
MTB. However, the bioinformatic analysis conducted by Rodionov and 
colleagues (2003) did identify a putative cbtG-type B12-regulated cobalt 
transporter in MTB. According to their results, this function was encoded 
by PPE2.  
 
The PE/PPE’s belong to a large family of mycobacterium-specific proteins 
that consume almost 10% of the coding potential of the MTB genome but 
whose functional characterization remains elusive (Cole et al., 1998). Of 
the more than sixty PPE genes in MTB, PPE2 belongs to the PPW sub-
family (Van Pittius et al., 2006). As noted previously, PPE2 is the first gene 
in a predicted operon comprising the B12 biosynthetic genes, cobQ1 and 
cobU. It is also unusual in that its 5’ region contains one of only two B12-
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riboswitches in the MTB genome. The riboswitch is located 133 bp 
upstream of the predicted PPE2 start codon. As noted in the Introduction 
(section 1.10), B12-riboswitches typically occur upstream of genes involved 
in transport of B12 or cobalt (Richter‐Dahlfors and Andersson, 1992; Cheng 
et al., 2011), genes required for B12 biosynthesis (Lundrigan et al., 1991), 
or B12-independent enzymes with corresponding B12-dependent 
alternatives (Borovok et al., 2006; Warner et al., 2007). Therefore, the 
presence of a B12-riboswitch upstream of the PPE2-cobQ1-cobU locus was 
strongly suggestive of the involvement of PPE2 in a B12-related pathway 
(Figure 3.9). In light of these observations, the third major component of 
this study comprised an investigation of the potential ability of PPE2 to 
function in B12 or cobalt transport/assimilation in MTB.  
 
 
3.4.1 Assessment of a role for PPE2 in B12 transport in MTB 
 
 Transcriptional analysis of metE in the ∆PPE2 mutant 
 
To investigate the role of PPE2 in B12 transport, a targeted knockout was 
generated (Figure 3.22A). No difference in growth was observed between 
H37Rv and ∆PPE2 both in the presence and absence of B12 (data not 
shown). This was expected since the only B12-dependent phenotype 
identified to date in standard laboratory medium results from impaired 
methionine biosynthesis (Figure 3.15A); in the ∆PPE mutant, the B12-
independent methionine synthase, metE, is still intact. Therefore, it was 
hypothesized that if PPE2 were involved in B12 transport, the B12-mediated 
down regulation of metE (Warner et al., 2007) would not occur in the 
∆PPE2 mutant. Expression of metE was determined in vitamin B12-
supplemented 7H9/OADC medium using untreated control samples for 
each time point and normalizing results against sigA expression. Semi-
quantitative transcriptional data in Figure 3.20 indicate that metE 
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transcript levels were increased in the absence of B12 and notably 
diminished in the presence of B12 after 10 h, as was previously 
demonstrated in wild-type MTB (Warner et al., 2007). This observation 
suggested that vitamin B12 was being accessed by the ∆PPE2 mutant and, 
in turn, this suggested that PPE2 might not have a role in the transport of 
this cofactor. 
 
 
 
Figure 3.20: RT-PCR analysis of metE expression in a ∆PPE2 
mutant in response to B12. Cells were grown for 10 h in 7H9/OADC in 
the presence (+B12) or absence (-B12) of 10 µg/ml vitamin B12 before 
harvesting for mRNA extraction. The sigA housekeeping gene and no 
reverse transcriptase (-RT) controls were included. 
 
 
 Assessment of the role of PPE2 in B12 transport utilizing 
growth on valerate as a carbon source 
 
Subsequent to the inception of this study, a simple assay (described in 
section 3.2.4) for growth of MTB on odd-chain fatty acids presented the 
option of phenotypically differentiating the ∆PPE2 mutant from H37Rv. To 
investigate the possibility that PPE2 functions in B12 transport, the growth 
of the ∆PPE2 mutant was compared with wild-type H37Rv in the presence 
of 3-NP where valerate constituted the sole carbon source (Savvi et al., 
2008). The underlying rationale for this experiment was that, were PPE2 
the MTB B12 transporter, then a ∆PPE2 mutant should not be able to grow 
on valerate in the presence of 3-NP, even if supplemented with B12. 
metE
sigA
∆PPE2
+B12 -B12-RT -RT
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Growth of the ∆PPE2 mutant in valerate as a sole carbon source was 
comparable to that of H37Rv, as illustrated in Figure 3.21A. Wild-type MTB 
was unable to utilize valerate as sole carbon source in media containing 3-
NP (Figure 3.21B) in accordance with observations made by Savvi et al. 
(2008). However, supplementing media with B12 restored growth. Notably, 
the ∆PPE2 mutant achieved wild-type growth levels under the same B12-
supplemented conditions, suggesting that PPE2 does not function in B12 
transport in MTB (Figure 3.21B).  
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Figure 3.21: Growth kinetics of the ∆PPE2 mutant in valerate 
with 3-NP and B12. (A) H37Rv and the ∆PPE2 mutant were grown in 
medium containing valerate as the sole carbon source, (B) H37Rv with 3-
NP and vitamin B12 ( ) or without vitamin B12 ( ), versus growth of the 
∆PPE2 strain on valerate with 3-NP and vitamin B12 ( ), or without 
vitamin B12 ( ). Data are representative of a single experiment from 
three independent biological replicates.  
 
 
3.4.2 Assessment of the role of PPE2 in cobalt 
transport/assimilation  
 
The results above demonstrated that PPE2 does not have a role in B12 
transport in MTB. However, the possibility remained that PPE2 might 
function in cobalt transport, as predicted by Rodionov et al. (2003). 
Therefore, to investigate the potential role of PPE2 in cobalt 
transport/assimilation in MTB, an assay was developed that exploited the 
ability of cobalt to complement the ∆metE::hyg mutant (Figure 3.15B). To 
this end, a targeted knockout of PPE2 was generated in the ∆metE::hyg 
background to yield a ∆PPE2 ∆metE::hyg double mutant (Figure 3.17C & 
Figure 3.22A). This strain was unable to grow in unsupplemented liquid 
medium (Figure 3.22B), and required the addition of exogenous vitamin 
B12 for replication. In contrast to the parental metE strain (Figure 3.15B), 
the ∆PPE2 ∆metE::hyg double mutant was unable to grow in medium 
containing cobalt alone (Figure 3.22B), strongly suggesting a role for PPE2 
in cobalt/transport assimilation in MTB.   
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Figure 3.22: Genotypic and phenotypic characterization of PPE2 
deletion in H37Rv and the ∆metE::hyg mutant. (A) Southern blot 
analysis of genomic DNA isolated from H37Rv, ∆PPE2 and ∆PPE2 
∆metE::hyg digested with restriction enzyme, SalI. Hybridization with 
PPE2 probe (Table 2.3) identified a 3122 bp fragment in the parental 
H37Rv and 2043 bp in deleted PPE2 gene. Adjacent to the Southern blot is 
the schematic representation of parental and mutant allele illustrating 
restriction enzyme sites with PPE2 probe represented by black box. The 
PPE2 deletion allele eliminated 1100 bp of internal PPE2 coding sequence. 
(B) Log-phase culture of ∆PPE2 ∆metE::hyg mutant was washed then 
inoculated at an OD600 of 0.1 into Sauton’s minimal media, and grown for 
8 to 14 days to allow depletion of internal B12. Culture was re-inoculated 
into fresh media containing the same supplement(s) and optical densities 
were measured. The ∆PPE2 ∆metE::hyg double mutant was unable to 
grow when supplemented with cobalt (5 µM). Data are representative of a 
single experiment from three independent biological replicates.  
 
 
As PPE2 appears to lie in a putative operon with key B12 biosynthetic 
genes, cobQ1 and cobU, complementation of the PPE2 deletion was 
initially performed by integrating a wild-type copy of the putative operon 
(PPE2-cobQ1-cobU) plus 688 bp 5’ sequence at the attB locus. As shown 
in Figure 3.23A, complementation of the ∆PPE2 ∆metE::hyg double 
mutant with pMCPQUcomp vector containing the full-length PPE2-cobQ1-
cobU, restored the ability of the mutant to grow in medium supplemented 
with cobalt. However, the reversal of this phenotype could not be 
attributed to PPE2 alone; in particular, it remained possible that deletion 
of PPE2 (the first gene in the operon) might have had polar effects on the 
two downstream genes, cobQ1 and cobU, both of which are predicted to 
catalyze key steps in de novo B12 biosynthesis (Figure 3.9). Importantly, 
the PPE2 deletion was not in-frame, and this might have abrogated the 
function of both CobQ1 and CobU, thereby disrupting cobalt- dependent 
biosynthesis of B12. Therefore, a second complementation strategy was 
employed which entailed integration of a copy of the wild-type PPE2 ORF 
containing 5’ sequence but terminating at the native PPE2 stop codon, 
thus specifically excluding the cobQ1 and cobU genes from the 
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complementation vector. Importantly, integration of the truncated 
complementation vector, pMCPPE2comp, at the attB site of the ∆PPE2 
∆metE::hyg mutant (Figure 3.23B) restored the ability of the mutant to 
utilize cobalt for growth. This result established unequivocally the 
requirement for functional PPE2 in cobalt utilization in MTB.  
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Figure 3.23: A role for PPE2 in cobalt transport (assimilation) in 
MTB. Log-phase cultures of ∆metE::hyg ∆cobUattB::PPE2-cobQ1-cobU 
and ∆metE::hyg ∆PPE2attB::PPE2 complemented strains were washed 
then inoculated at an OD600 of 0.1 into Sauton’s minimal media, and 
grown for 8 to 14 days to allow depletion of internal B12. Cultures were re-
inoculated into fresh media containing the same supplement and optical 
densities were measured. (A) ∆metE::hyg ∆cobUattB::PPE2-cobQ1-cobU 
was able to grow when supplemented with cobalt (5 µM), and B) 
Complementation of ∆metE::hyg ∆PPE2 with the entire PPE2 gene 
restores growth when supplemented with cobalt (5 µM). Data are 
representative of a single experiment from three independent biological 
replicates.  
 
 
Further support for the role of PPE2 in cobalt assimilation is provided by 
the observation that the ∆PPE2 ∆metE::hyg mutant was able to utilize 
cobinamide for growth (Figure 3.24). In contrast, the ∆cobU ∆metE::hyg 
mutant (Figure 3.16B) was unable to utilize cobinamide, suggesting that 
the late stage of the pathway – that mediated by CobU – must be 
unaffected by the PPE2 deletion allele. That is, there appear to be no 
polar effects of PPE2 deletion on the downstream B12 biosynthetic genes. 
Together, these data provide the first direct evidence of a role for a PPE 
protein in cation transport/assimilation; specifically, they strongly suggest 
a role for PPE2 in cobalt transport/assimilation in MTB.  
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Figure 3.24: Deletion of PPE2 does not affect growth on 
cobinamide in a ∆metE::hyg mutant. Log-phase cultures of ∆PPE2 
∆metE::hyg mutant was washed then inoculated at an OD600 of 0.1 into 
Sauton’s minimal media, and grown for 8 to 14 days to allow depletion of 
internal B12. Cultures were re-inoculated into fresh media containing the 
same supplement(s) and optical densities were measured. ∆PPE2 
∆metE::hyg mutant was unable to grow without supplementation ( ), but 
was able to grow when supplemented with B12 ( ) and 10 µM cobinamide 
( ). Data are representative of a single experiment from three 
independent biological replicates. Abbreviations: cbi-cobinamide. 
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4. Discussion 
 
MTB possesses a near-complete B12 biosynthetic pathway (as discussed in 
section 1.6.3), as well as three B12-dependent enzymes (Dawes et al., 
2003; Warner et al., 2007; Savvi et al., 2008). However, previous work in 
the MMRU suggested that MTB does not synthesize B12 de novo but does 
appear to transport the vitamin despite the lack of a candidate B12-specific 
transporter (Warner et al., 2007; Savvi et al., 2008). This study 
investigated the functionality of the B12 biosynthetic pathway in MTB 
utilizing a genetic approach. In addition to vitamin B12 (CNCbl), the 
∆metE::hyg mutant could be supplemented with cobinamide or cobalt, 
thereby providing strong evidence for de novo B12 biosynthesis in MTB. 
Deletion of cobK, whose product is required in the early (CobI) phase of 
the B12 biosynthetic pathway (Figure 3.9), eliminated the ability of the 
resulting ∆cobK ∆metE::hyg double mutant to utilize cobalt - but not 
cobinamide - for growth. In contrast, deletion of the later (CobII) stage 
enzyme, CobU, in the ∆metE::hyg background, was associated with the 
inability to utilize either cobalt or cobinamide for growth. Of particular 
note was the observation that MTB requires full-length PPE2 in order to 
assimilate cobalt for growth. PPE2 is a member of the PPW subfamily of 
PPE proteins; although their function remains enigmatic, the results of this 
study provide some insight into a role for PPE proteins in the acquisition 
and assimilation of trace metals in MTB pathogenesis. 
 
This project also explored the possibility that MTB synthesizes an alternate 
B12 form, pseudo-B12. While the data suggest differential growth in the 
∆metE::hyg mutant with increasing adenine concentrations, these assays 
did not allow the synthesis of pseudo-B12 to be established unequivocally. 
This is likely to be the case because the MTB mutants applied in these 
experiments all retain the ability to generate the α-axial ligand, DMB. 
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Moreover, the ability of the ∆Rv0306 ∆metE::hyg double mutant to 
replicate in media supplemented with cobinamide alone again highlighted 
the need to determine pseudo-B12 levels in MTB directly utilizing 
alternative, biochemical techniques. 
 
 
4.1 MTB does not synthesize B12 under standard in vitro 
conditions 
 
MTB does not possess homologues of all genes required for vitamin B12 
biosynthesis (discussed in section 1.6.3). Despite similar gaps in their 
respective B12 biosynthetic pathways (discussed in section 1.6.2), earlier 
studies utilizing microbiological assays have reported de novo B12 
biosynthesis in several other mycobacterial species including M. bovis, M. 
phlei, MSM and M. fortuitum, even when grown in Sauton’s minimal 
medium (Hendlin and Ruger, 1950; Karasseva et al., 1977; Kamikubo et 
al., 1978). An earlier study detected trace amounts of B12 in the culture 
filtrate of H37Rv (Aithal and Sirsi, 1964), however this does not 
necessarily indicate de novo B12 biosynthesis. In addition, previous studies 
in the MMRU laboratory were unable to demonstrate de novo B12 synthesis 
in MTB under standard in vitro conditions (Warner et al., 2007; Savvi et 
al., 2008). In particular, the inability of the MTB metE knockout to grow 
without exogenous B12 supplementation (Warner et al., 2007) confirmed 
the in vitro essentiality of this gene inferred from genome-wide 
transposon mutagenesis (Sassetti et al., 2003). Similarly, chemical 
inhibition of the methylcitrate cycle renders MTB unable to grow in 
propionate-containing media, thereby indicating that the B12 requirements 
of the methylmalonyl-CoA mutase are not met under standard in vitro 
conditions (Savvi et al., 2008). These results suggest that insufficient (or 
no) B12 is produced by MTB to satisfy the cofactor requirements of these 
B12-dependent pathways. Quantitative assays of non-industrial bacterial 
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B12 production indicate yields of between 0.2-0.8 µM (Saunders et al., 
1952; Musílková, 1961; Kamikubo et al., 1978), which is similar to the 
levels of intracellular B12 assayed in M. bovis and M. phlei grown in 
Sauton’s medium (Karasseva et al., 1977). In turn, the failure to detect 
B12 production by MTB in vitro suggested that additional factors(s) might 
be required to stimulate (or increase) B12 production under standard 
laboratory conditions. 
 
 
4.1.1 Cobalt is a limiting factor in B12 biosynthesis in MTB 
 
The amount of B12 produced by a bacterium can be influenced by a 
number of factors, including the nature and quantity of the available 
carbon and nitrogen sources, pH, aeration, and temperature (Halbrook et 
al., 1950; Kamikubo et al., 1978; Riaz et al., 2007). In this study, it was 
demonstrated that the MTB ∆metE::hyg mutant - which is a strict B12 
auxotroph - can grow aerobically in liquid medium supplemented with 
cobalt (Figure 3.15B). This suggests that MTB has retained the ability to 
synthesize B12 provided that cobalt is not limiting. Hendlin and Ruger 
(1950) first reported that the availability of cobalt is among the factors 
that increase B12 production in microorganisms. In fact, in some enteric 
bacteria, biosynthesis is enabled (Lawrence and Roth, 1995) and even 
enhanced by the addition of this metal ion (Cauthen et al., 1966). 
Interestingly, B12 synthesizing mycobacteria including M. bovis and M. 
phlei also show increased production of B12 upon the addition of cobalt 
(Karasseva et al., 1977). However, the addition of cobalt can be inhibitory 
to growth at certain concentrations; for example, in the case of M. bovis 
which requires a lower concentration of cobalt compared to M. phlei. 
Similarly, the MTB ∆metE::hyg mutant was able to grow well in the 
presence of 5 µM cobalt (Figure 3.15B) whereas 10 µM cobalt was 
inhibitory (data not shown). It has been shown previously that the 
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provision of lower concentrations of cobalt to B12 synthesizing organisms 
results in as much as 75% of the metal being incorporated into the B12 
cofactor; however, as the cobalt concentration is increased, utilization of 
exogenous cobalt decreases sharply (Smith et al., 1952; Perlman and 
O'Brien, 1954). This is consistent with the fact that, while cobalt is 
necessary for the synthesis of B12 in bacteria, it is extremely toxic in 
excess. 
 
It was notable that the ability of the ∆metE::hyg mutant to utilize 
exogenous cobalt appeared to be specific to experiments carried out in 
liquid media. When this mutant was grown on 7H10/OADC plates 
supplemented with 5 µM cobalt, it was unable to grow (Figure 3.19). A 
range of serially-increasing cobalt concentrations between 5 µM and 500 
µM also yielded no growth (data not shown). Even when plates were 
supplemented with very high concentrations of cobalt – up to 10 mM - no 
growth was observed. The inability of cobalt to complement growth of the 
∆metE::hyg mutant on solid medium is surprising, yet analogous to the 
ability of methionine to supplement growth of the same mutant in liquid 
but not on solid medium (Warner, 2006). These observations might point 
to an alternate bacillary physiological state that prevails in the different 
growth media. Alternatively, this result might indicate that PPE2-
dependent assimilation of cobalt is inhibited on solid substrates.  
 
 
4.1.2 Precursor-mediated growth of MTB B12 auxotrophs – is the 
B12 biosynthetic pathway functional?  
 
Cobalt insertion is predicted to occur during late-stage B12 biosynthesis in 
MTB (Figure 3.9), which is consistent with aerobic pathways. Evidence 
supporting the ability of MTB to use exogenously supplied cobalt to 
synthesize B12 was provided in experiments utilizing specific deletion 
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mutants containing disruptions at certain stages of the B12 biosynthetic 
pathway, either before (cobK) or after (cobU) the predicted cobalt 
insertion step (Figure 3.16). The early stage enzyme, CobK, is predicted to 
occur in CobI of the pathway, and catalyzes the NADPH-dependent 
reduction of precorrin-6x to precorrin-6y (Blanche et al., 1992b; Raux et 
al., 1996). The CobI part of the B12 biosynthetic pathway – which involves 
the synthesis of the corrin macromolecule (Figure 3.9) – is absent in E. 
coli; therefore, this bacterium is unable to synthesize the corrin ring but, if 
provided with cobinamide, is able to synthesize and attach the α-ligand to 
form AdoCbl (Raux et al., 1996). Similarly, deletion of cobK in MTB 
∆metE::hyg eliminated the ability of the double mutant to grow in liquid 
medium supplemented with cobalt (Figure 3.16A). This is presumably 
because of incomplete synthesis of the corrin ring and, therefore, the 
inability to produce adenosylcobinamide, the precursor to AdoCbl. 
However, the ∆cobK ∆metE::hyg double mutant could still be 
supplemented with B12, as well as the late stage precursor, cobinamide 
(Figure 3.16A). Since the late stage of the pathway was intact in this 
mutant, this result suggested that MTB has retained the ability to convert 
exogenously supplied cobinamide to AdoCbl, first through adenosylation to 
adenosylcobinamide and then by attachment of endogenously produced 
DMB. 
 
Orthologues of CobK appear to fall into two distinct groups based on 
whether the enzymes are part of an aerobic or anaerobic B12 biosynthetic 
pathway; sequence alignments have identified several key residues that 
are conserved within these groups (Shearer et al., 1999). It has been 
hypothesized (Scott, 1994) that the sequence differences might reflect the 
need to bind to different substrates: anaerobic CobK enzymes act on 
cobalt-containing intermediates whereas, in the aerobic pathway, cobalt is 
inserted later. An example of this selectivity was provided by the 
demonstration that P. denitrifcians CobI – which methylates precorrin-2 to 
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precorrin-3 - was unable to replace the S. typhimurium equivalent (cbiL), 
owing to the fact that the true substrate of CbiL is cobalt-precorrin-2 
which is not recognised by CobI (Raux et al., 1996). MTB CobK possesses 
key residues that are conserved in precorrin-6x reductases from aerobic or 
facultatively aerobic bacteria, including P. denitrificans and Rhodobacter 
capsulatus (Shearer et al., 1999). Given the inferred specificity of these 
enzymes, the ability of the ∆cobK ∆metE::hyg double mutant to be 
supplemented with precorrin-6y versus cobalt-precorrin-6y would confirm 
whether cobalt was being inserted at early or late stage in the pathway in 
MTB. However, this question could not be pursued as neither intermediate 
is commercially available. 
 
The late stage of the pathway was disrupted by deletion of cobU, a gene 
encoding a multifunctional enzyme of only 174 amino acids which 
facilitates two distinct transformations. CobU possesses kinase activity to 
phosphorylate adenosylcobinamide to adenosylcobinamide-phosphate, and 
then guanylylates adenosylcobinamide-phosphate to from 
adenosylcobinamide-GDP, which is in turn converted to AdoCbl by CobS 
(Thompson et al., 1998; Thompson et al., 1999). In S. enterica, cobU 
mutants were unable to utilize cobinamide but were able to convert 
cyanocobinamide-GDP to AdoCbl (O'Toole et al., 1993). Consistent with 
this proposed function, deletion of cobU in the MTB ∆metE::hyg 
background resulted in the inability of the ∆cobU ∆metE::hyg double 
mutant to grow when supplemented with either cobalt or cobinamide 
(Figure 3.16B). CobS utilizes adenosylcobinamide-GDP and α-ribazole to 
form AdoCbl and, in S. enterica mutants of cobS were shown to be 
rescued with B12 only (O'Toole et al., 1993). The MTB ∆cobU ∆metE::hyg 
double mutant was similarly able to utilize CNCbl only, strongly suggesting 
that disruption of the dual function CobU results in the accumulation of 
adenosylcobinamide, which is not the cognate substrate of CobS, and so 
terminates B12 biosynthesis prematurely.  
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The experiments reported here also confirmed that the active form of the 
cofactor synthesized from cobinamide supplementation can be utilized to 
support functionality of another B12-dependent enzyme, the 
methylmalonyl-CoA mutase encoded by mutAB. That is, 3-NP-dependent 
growth inhibition of MTB on fatty acids can be alleviated when 
supplemented with cobinamide (Figure 3.7), owing to the enabling of 
MutAB function. It is also important to note that, while cobalt 
supplementation rescued growth of the metE mutant on minimal medium 
(Figure 3.15B) – a reaction that depends on MeCbl - this metal ion was 
not able to support the function of MutAB (data not shown), an AdoCbl-
dependent enzyme. The reason for this discrepancy is unclear. However, 
Karasseva et al. (1977) noted that, in M. phlei, B12 production was the 
highest on the 30th day and intracellular cobalt levels were highest on the 
23rd day of growth post inoculation, an observation which led the authors 
to suggest that sufficient cobalt must be accumulated first for optimal 
yields of B12 to be produced. The results reported here suggest the 
possibility that the simultaneous requirement for de novo B12 production 
against a background of accumulating propionate toxicity might exceed 
bacillary capacity for B12 biosynthesis. This interpretation is speculative, 
however, and will require further investigation utilizing a ∆prpDC mutant 
in order to minimize the potentially confounding effects associated with 
chemical inhibition of the methylcitrate cycle by 3-NP. 
 
The ability of MTB to utilize cobalt (MetE) and cobinamide (MetE and 
MutAB) to support the B12-dependent enzymes suggests that the active 
cofactor form is synthesized de novo. This in turn implies that the CobI, 
CobII, and CobIII stages of the B12 biosynthetic pathway are functional. 
That is, MTB is able to synthesize DMB (α-ligand) from a flavin precursor 
(Campbell et al., 2006; Taga et al., 2007) and then covalently link DMB to 
either endogenous (if cobalt is supplied) or exogenous cobinamide, plus a 
phosphoribosyl group, to produce B12 (Figure 3.9). Together, the results 
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generated here suggest that the previous inability to detect vitamin B12 
biosynthesis in the metH-dependent phenotypic assay could have resulted 
from cobalt limitation in standard laboratory media. However, it is 
important to reiterate that the de novo B12 biosynthetic ability is inferred 
from genetic analyses: owing to the technical complexities associated with 
B12 extraction and detection, direct (biochemical) evidence of the active 
cofactor has yet to be obtained. 
 
 
4.1.3 Why does MSM not require cobalt supplementation to 
synthesize B12? 
 
The ability of the ∆metE::hyg mutant of MSM to grow without any 
supplementation suggests that MSM is able to synthesize B12 in vitro 
(Figure 3.1). In contrast, growth of the corresponding MTB ∆metE::hyg 
requires that the same medium must be supplemented with 5 µM cobalt 
(Figure 3.15B). In a previous study, an elemental analysis of Sauton’s 
minimal medium by plasma mass spectrometry revealed a cobalt 
concentration of 5 nM (Campbell et al., 2007). It is likely, therefore, that 
traces of the metal ion were present in the medium utilized in this study. 
Analysis of the MSM genome indicates the presence of at least five 
putative cobalt transport systems (K. Gopinath, personal communication), 
three of which are homologues of well-defined cobalt transporters 
including CbiMQO, CbtAB and CorA (Nelson and Kennedy, 1971; Roth et 
al., 1993; Rodionov et al., 2003). By comparison, MTB appears to possess 
a homologue of CorA only (Agranoff and Krishna, 2004), as well as two 
other predicted cobalt transporters, Rv2325c-Rv2326c and PPE2 
(Rodionov et al., 2003; Campbell et al., 2007; Rodionov et al., 2009). This 
suggests that the different lifestyles of the non-pathogenic environmental 
saprophyte and the obligate human pathogen might require different 
cobalt scavenging capacity. In turn, the abundance of cobalt transporters 
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in MSM compared to MTB might ensure that MSM is better able to acquire 
cobalt in vitro and, therefore, does not require supplementation. 
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Table 4.1: Growth characteristics in liquid media of MTB mutants utilized in this study 
Strain Liquid medium No supplement B12 Co cbi cbi plus DMB cbi plus AD 
H37Rv S       
H37Rv VL+3-NP       
∆PPE2 S       
∆PPE2  VL+3-NP       
∆metE::hyg S       
∆cobK ∆metE::hyg S       
∆PPE2 ∆metE::hyg S       
∆cobU ∆metE::hyg S       
        
∆metE::hyg ∆PPE2attB::PPE2 S       
∆metE::hyg ∆PPE2 attB::PPE2-cobQ1-cobU  S       
∆metE::hyg ∆cobU attB::PPE2-cobQ1-cobU S       
        
∆Rv0306 S       
Rv0306D32NS167G∆metE::hyg S       
Key: S – Sauton’s minimal medium   () – indicates growth    AD - adenine 
VL – valerate     () – indicates no growth 
Co – 5µM cobalt     3-NP – 3-nitroproprionate 
cbi – cobinamide     DMB – 5, 6- dimethylbenzamidazole 
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4.2 PPE2 is required for cobalt transport/assimilation in MTB 
 
Riboswitches are mRNA elements (Vitreschak et al., 2003) that serve as 
ligand-responsive genetic controls to modulate the expression of specific 
genes in response to changing concentrations of metabolites (Nahvi et al., 
2004). These metabolites include amino acids such as lysine and S-
adenosylmethionine (Rodionov et al., 2003; Winkler et al., 2003), and 
metal ions such as magnesium (Dann III et al., 2007) and molybdenum 
cofactor (Regulski et al., 2008b). In general, B12-riboswitches occur 
upstream of genes falling into three broad categories: those involved in 
transport of B12 or cobalt (Richter‐Dahlfors and Andersson, 1992; Cheng et 
al., 2011), those required for B12 biosynthesis (Lundrigan et al., 1991) 
and, finally, those encoding B12-dependent enzymes which possess 
corresponding B12-independent alternatives (Borovok et al., 2006). In all 
cases, these riboswitches regulate expression of the associated 
downstream gene(s) in response to B12 (Borovok et al., 2006; Warner et 
al., 2007). In prior work from the MMRU, Warner et al. (2007) identified a 
riboswitch upstream of MTB metE, and demonstrated its functionality. This 
was the first riboswitch confirmed in MTB and is one of only two B12-
riboswitches that have been identified the genome of this organism. The 
second B12-riboswitch is located immediately upstream of PPE2, which is 
the first gene in a putative three-gene operon comprising two B12 
biosynthetic genes, cobQ1 and cobU. Based on its association with a B12-
riboswitch, its genomic context, and the prediction that the PPE2 protein 
possesses seven trans-membrane segments, Rodionov et al. (2003) 
predicted that PPE2 encodes a putative cobalt transporter. In S. meliloti, 
the smb20056 gene – which is similarly associated with an upstream B12-
riboswitch – was predicted to encode a btuFCD-type B12 transporter 
together with the downstream genes smb20057 and smb20058 
(Vitreschak et al., 2003). However, it was recently shown that these genes 
in fact encode a cobalt transporter (Cheng et al., 2011). In the present 
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study, the paucity of information available regarding the function of PPE 
genes, as well as the absence of a clear B12 transport candidate in the 
MTB genome (Rodionov et al., 2003; Warner et al., 2007), motivated our 
investigation of both possibilities: that is, that PPE2 might function in B12 
and/or cobalt transport.  
 
A genetic approach was used to confirm that PPE2 is not involved in B12 
transport in MTB. Firstly, transcriptional analysis demonstrated classic 
down-regulation of metE expression in a ∆PPE2 mutant in response to B12 
treatment (Figure 3.20), thereby suggesting the intracellular accumulation 
of exogenously supplied vitamin B12 even in a strain lacking functional 
PPE2. Secondly, the transport of B12 in vitro remained unaffected in a 
∆PPE2 ∆metE::hyg double mutant, as inferred from the ability of the 
mutant to grow in B12-supplemented media (Figure 3.24). Finally, in an 
assay that utilized chemical inhibition of ICL when MTB was grown on 
fatty acids, growth inhibition of the ∆PPE2 mutant was shown to be 
alleviated upon B12 addition in a manner that was identical to that 
observed for wild-type H37Rv (Figure 3.21A & B). Together, these data 
eliminated a role for PPE2 in B12 transport. Additionally, PPE2 shares no 
homology with experimentally characterized B12-specific transporters such 
as the E. coli BtuBFCD transporter. Furthermore, recent investigations in 
the MMRU (K. Gopinath et al., manuscript in preparation) have identified a 
candidate protein which, at least in vitro, appears to function as the sole 
B12 transporter in MTB. 
 
In contrast to the parental ∆metE::hyg strain (Figure 3.15B), the ∆PPE2 
∆metE::hyg double mutant was unable to grow in minimal medium 
supplemented with cobalt (Figure 3.22B). Bioinformatic analyses predict 
the existence of three putative cobalt transporters in the MTB genome, 
encoded by corA, Rv2325c-RV2326c and PPE2. For this reason, deletion of 
PPE2 in the ∆metE::hyg mutant might not be expected to affect the ability 
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of the auxotroph to assimilate cobalt for B12 synthesis, as there are two 
possible alternate transporters available. Moreover, a diversity of non-
specific metal uptake systems are present in MTB, four of which are 
predicted to transport cobalt ions in addition to other metals (Agranoff and 
Krishna, 2004). In S. meliloti, deletion of the cobalt transport system 
encoded by cbtJKL resulted in decreased accumulation of cobalt relative to 
the wild-type strain (Cheng et al., 2011). This result suggested that non-
specific transporters - for example CorA, which is predicted to transport 
magnesium, cobalt and iron (Niegowski and Eshaghi, 2007; Zhang and 
Gladyshev, 2009) - are able to take up cobalt but are probably not 
physiologically relevant as they possess a lower affinity for the metal ion.  
 
Cobalt uptake proteins in microorganisms usually exhibit shared 
architecture (Rodionov et al., 2003; Siche et al., 2010), which facilitates 
their identification in the genome. For example, Rv2325c, which is 
proposed to be an energy-coupling transporter (ECF) (Rodionov et al., 
2009), has been shown to possess a CbiQ domain. Furthermore, Rv2325c 
appears to be in an operon with Rv2326c, which itself has a CbiO domain 
(K. Gopinath; personal communication), and so is suggestive of a potential 
role in cobalt or even B12 transport. However, a similar analysis of PPE2 
does not reveal the presence of conserved structural domains 
characteristic of known or predicted cobalt transporters. 
 
Despite the lack of any conserved structural architecture for PPE2 as a 
predicted cobalt transporter, the inability of cobalt to restore growth of the 
∆PPE2 ∆metE::hyg double mutant was demonstrated in this study (Figure 
3.15B & 3.22B). In addition, the phenotypes associated with deletion of 
cobK or cobU in the ∆metE::hyg mutant background (Figure 3.16), 
strongly suggest that MTB incorporates exogenous cobalt into B12. The 
genetic data presented in this study also indicate that PPE2 is critical to 
this process. Therefore, one might speculate that PPE2 plays an integral 
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role in regulating the amount of cobalt in the bacterial cell or that it is 
required to scavenge cobalt and facilitate its delivery to cobalt uptake 
systems. In the latter option, proteins that facilitate transfer or transport 
of metal ions to the required site usually possess N-terminal or C-terminal 
metal binding motifs (Okamoto and Eltis, 2011) which have a high affinity 
for the metal ion and, in this case, would act as a cobalt store or cobalt 
trap (Raux et al., 2003). Binding of cobalt is predicted to occur by a 
histidine-rich motif (Rodionov et al., 2003) which, in the cobaltochelatase 
encoded by CbiK in Bacillus megaterium, is present in the C-terminal 
region; deletion of this region results in decreased affinity for the metal 
ion (Raux et al., 2003). However, in the PPE2 protein sequence, no 
histidine-rich N-terminal or C-terminal motif could be identified. Additional 
signatures for cobalt binding sites have been identified (Thilakaraj et al., 
2007), yet none of these appears to be present in PPE2. Interestingly, 
sequence-based analysis of PPE2 utilizing the Support Vector Machine 
server (Lin et al., 2006) indicates the highest probability of binding zinc, 
despite the absence in PPE2 of cysteine residues that are typical of zinc 
binding proteins (A. Zawaira; personal communication). 
 
The arrangement of a PPE2 gene together with an upstream B12 
riboswitch is conserved among the slow-growing mycobacterial species 
(MTB, M. ulcerans, M. marinum M. avium, M. paratuberculosis and M. 
leprae), irrespective of genomic context, but is absent in the fast-growing 
MSM. PPE2 has been identified in the cell membrane fraction of MTB 
(Mawuenyega et al., 2005), although the gene does not appear to be 
differentially expressed in macrophages or in mice infected with MTB 
(Schnappinger et al., 2003; Talaat et al., 2004; Tailleux et al., 2008). 
Microarray studies have indicated that PPE2 is down-regulated after 24 h 
of starvation and induced after 30 minutes in standing cultures of MTB 
(Betts et al., 2002; Kendall et al., 2004). It is notable, however, that 
global responses of MTB to other metals such as copper, zinc, and iron do 
142 
 
not indicate any significant up- or down-regulation of PPE2 in the 
presence of toxic or physiological concentrations of these metals 
(Rodriguez et al., 2002; Maciag et al., 2007; Ward et al., 2008). 
Therefore, aside from the prediction of Rodionov et al. (2003) and the 
data described in this study, there appears to be no other evidence to 
support a role for PPE2 in cobalt transport/assimilation. 
 
 
4.2.1 What is the function of the PE/PPE protein family? 
 
The size of the PE/PPE family suggests the possibility of functional 
redundancy, although this has not been formally demonstrated. It is 
unclear, therefore, why PPE2 should be specifically required for 
cobalt/transport assimilation in MTB. That is, why is the phenotype of the 
PPE2 knockout so profound? An analysis by van Pittius et al. (2006) 
indicates that PPE3 (Rv0280) of the PPW subfamily is very closely related 
to PPE2 and, interestingly, PPE3 has been shown to be up-regulated in 
response to zinc (Maciag et al., 2007). Another member of the PPW 
subfamily, PPE37, was up-regulated under iron-deficient conditions and 
was suggested to be a siderophore-type protein involved in iron uptake 
(Rodriguez et al., 1999; Rodriguez et al., 2002). More recently, this 
protein has also been implicated in host immune evasion by interfering 
with proinflammatory cytokines (Daim et al., 2011). Other members of the 
PPW family include PPE46, whose inactivation was shown to attenuate TB 
in mice (Camacho et al., 1999) and was shown to be essential in vitro 
(Sassetti et al., 2003); PPE47, which was up-regulated at least eightfold in 
human brain microvascular endothelial-cells and has been suggested to be 
crucial for intracellular survival and endothelial-cell invasion (Jain et al., 
2006); and PPE4 and PPE20 which are down-regulated during nutrient 
starvation (Betts et al., 2002). Thus far, however, studies of proteins 
belonging to this subfamily do not allude to any specific function in MTB.  
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Although the exact function(s) of the PE/PPEs is not known, several 
members of this family have been proposed to be virulence factors 
(Ramakrishnan et al., 2000; Brennan et al., 2001; Li et al., 2005), and 
some have even been shown to elicit strong immune responses in animals 
and humans (Dillon et al., 1999; Skeiky et al., 2000; Okkels et al., 2003; 
Singh et al., 2005). In a recent study, the SVP subfamily member, PPE17, 
was shown to augment transcription of HIV-1 by interacting with TLR2 
receptors which activated signalling pathways favourable to HIV-1 
replication (Bhat et al., 2012). It is interesting, however, that another SVP 
subfamily protein - PPE18, whose interaction with TLR2 receptors was 
demonstrated to inhibit host immune responses and thus promote 
replication of MTB (Nair et al., 2009) - was unable to augment HIV-1 
replication by this pathway (Bhat et al., 2012). These studies add to the 
accumulating evidence which suggests specific, non-redundant roles for 
the PPE proteins in modulating or altering the immune response by 
interacting with host immune components. As such, some PE/PPEs appear 
to be ideally positioned to interact with the host immune system as they 
have been shown to be cell-wall-associated (Banu et al., 2002; Okkels et 
al., 2003; Le Moigne et al., 2005) or even partially exposed on the cell 
surface (Brennan et al., 2001; Sampson, 2011). In turn, this suggests the 
possibility that they might be secreted by the bacterium into the host cell. 
Secretion of selected PE/PPE proteins occurs in an ESX-5 dependent 
manner in M. marinum (Abdallah et al., 2006; Abdallah et al., 2008; 
Abdallah et al., 2009) and, more recently, this system was shown to be 
important for cell wall integrity and virulence in MTB (Bottai et al., 2012). 
Notably, the ESX-3 cluster appears to be regulated by iron and zinc in MTB 
(Maciag et al., 2007), suggesting involvement of this system in 
maintaining homeostasis of these metal ions. Although the PE/PPEs have 
largely been implicated in antigenic variation and disease pathogenesis 
(Sampson, 2011), some members of this family were demonstrated to 
have fibronectin-binding properties (Espitia et al., 1999). There are even 
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reports of enzymatic functions, such as the phosphoglycerate mutase 
activity associated with PE_PGRS11 (Chaturvedi et al., 2010). 
 
It is tempting to speculate that the various subfamilies might be separated 
according to a broad function – that is, can a role in metabolite/metal ion 
homeostasis be generally ascribed to members of the PPW subfamily, 
whereas SVP subfamily members might be broadly involved in immune 
modulation? This might be too simplistic, and further analysis is required. 
In summary, therefore, it appears that proteins belonging to this intriguing 
family appear to have diverse functions which are not readily predicted by 
bioinformatic analyses of intrinsic properties including sequence or 
structural features, or more global characteristics such as genomic context 
or transcriptional regulation. 
 
 
4.3 A role for B12 or cobalt in MTB pathogenesis? 
 
In humans, only two enzymes require B12 for activity: methylmalonyl-CoA 
mutase and methionine synthase (Martens et al., 2002). Vitamin B12 
deficiency owing to low intake or malabsorption has been shown to cause 
pernicious anaemia and neurological dysfunction, and has also been linked 
with cardiovascular disease (McCaddon et al., 1994; Pancharuniti et al., 
1994; Clarke et al., 1998; Choi and Mason, 2002). The daily required 
intake of vitamin B12 in humans is estimated at 0.9-2.4 µg. Since this 
essential micronutrient is synthesized by selected microorganisms only, it 
is acquired through the consumption of foods like milk, eggs, fish and 
meat (Watanabe, 2007). As a result, elaborate and complex mechanisms 
of absorption, transport, and cellular uptake of B12 exist in humans to 
ensure that the cofactor is available in the sub-cellular locations in which 
the B12-dependent enzymes operate.  
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Following ingestion, food-bound B12 is released in the stomach by the 
action of hydrochloric acid, and then immediately bound by haptocorrin 
(HC), the chaperone which protects it from chemical denaturation in the 
harsh acidic environment (Banerjee, 2006). Bound B12 is transported to 
the duodenum where the B12 is liberated from HC by pancreatic protease, 
and immediately captured by another chaperone, intrinsic factor (IF), in 
an IF-Cbl complex (Banerjee et al., 2009). The IF-Cbl complex is 
subsequently transported from the duodenum and, after degradation of 
IF, B12 is taken up in the bloodstream, where it can attach to either HC or 
transcobalamin II (TCII) (Morkbak et al., 2006). Although the bulk of B12 
is bound to HC (~80%), TC bound B12 (TCII-Cbl) facilitates uptake into 
cells (Hall, 1977; Morkbak et al., 2006). From the bloodstream, the TCII-
B12 complex is taken up into the cell via receptor-mediated endocytosis 
into the lysosome (Youngdahl-Turner et al., 1978). The acidic environment 
within the endocytic lysosome digests the TCII-Cbl complex, and releases 
the B12 into the cytoplasm where it becomes available for the B12-
dependent methionine synthase and mitochondrial methylmalonyl-CoA 
mutase (Youngdahl-Turner et al., 1978; Youngdahl-Turner et al., 1979; 
Padovani et al., 2008). 
As described above, the passage of B12 through the body via multiple 
chaperones terminates with lysosome-mediated delivery of the cofactor to 
target cells. It is tempting, therefore, to speculate that B12 might 
effectively be “delivered to the doorstep” (R. Banerjee, personal 
communication) of MTB in the context of intracellular infection. In this 
regard, it is instructive to recall that the methylcitrate pathway is 
dispensable in vivo in the mouse model of TB infection, an observation 
which suggests the functioning of the B12-dependent methylmalonyl 
pathway as an alternative route for propionyl-CoA detoxification (Muñoz 
Elías et al., 2006; Savvi et al., 2008). In turn, this points to the potential 
availability of vitamin B12 during infection – at least in mice – whether 
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synthesized endogenously or acquired from the host. The amount of B12 
available in vivo varies with diet; for this reason, no specific intracellular 
B12 concentration has been determined, although the total amount of 
stored B12 is estimated at 2-4 mg in adults, of which 30-60% is stored in 
the liver (McLaren, 1981). It remains uncertain how much of this is 
available at the site of infection (if any) and whether MTB is able to access 
intracellular vitamin B12. Interestingly, in certain vegetarian populations, 
low B12 levels have been associated with increased risk of TB (Chanarin 
and Stephenson, 1988; Strachan et al., 1995; Yajnik et al., 2006). 
Conversely, enhanced growth of MTB is observed in vitro upon addition of 
B12 (Savvi, 2009). While these observations might be interpreted as having 
conflicting implications for the role of B12 in pathogenesis, it must be 
borne in mind that B12 deficiency is likely to have multiple effects on host 
immune function. Therefore, extrapolating a result from a population with 
a very specific dietary bias, as well as a hallmark B12 deficiency, is 
complicated. In this regard, it would be interesting to investigate the 
potential association with TB susceptibility of any of the eight vitamin B12 
complementation groups (Banerjee et al., 2009) which define inherited 
disorders in B12 metabolism. 
 
The demonstration in this study that cobalt can complement growth of a 
MTB B12 auxotroph (Figure 3.15B) similarly raises an important question 
pertaining to the availability of cobalt during infection. Studies on the 
elemental analysis of phagosomes have identified other metals (Wagner et 
al., 2005; Wagner et al., 2006), but cobalt is a trace nutrient and as such 
is mainly available in B12. It appears, therefore, that further work is 
required to determine the exact availability of this metal ion to MTB in 
vivo.  
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4.4 Can MTB synthesize and utilize pseudo-B12? 
 
The inferred ability of MTB to adapt to multiple environments in vivo 
suggested that the bacillus might be able to utilize alternate B12 cofactors, 
including pseudo-B12, in which adenine substitutes for DMB as α-axial 
ligand (Figure 1.1). Titrations performed with adenine and 10 µM 
cobinamide showed no differential growth in the MTB metE mutant 
(Figure 3.8B). However, it was noted that supplementing the medium with 
5 µM cobinamide resulted in reduced growth in combination with 
concentrations of 0.01 µM and 0.1 µM adenine – in contrast to 5 µM 
cobinamide alone (Figure 3.8A). Thereafter, a slight differentiation in 
growth of MTB in response to 5 µM cobinamide and increasing 
concentrations of adenine was observed (Figure 3.8A). A similar trend was 
observed in the MSM adenine titrations (Figure 3.5B), where 10 µM and 
25 µM adenine (plus 10 µM cobinamide) resulted in decreased growth 
compared to 10 µM cobinamide alone. Again, improved growth was 
associated with increasing concentrations of adenine and 10 µM 
cobinamide (Figure 3.5B). Adenine toxicity has been demonstrated in E. 
coli (Levine and Taylor, 1982), but it is unlikely that the decreased growth 
observed with low-dose adenine can be attributed to this effect: both MSM 
and MTB were able to tolerate much higher concentrations (100 µM) of 
adenine which resulted in improved growth of the B12 auxotrophs when 
provided in combination with cobinamide. It is possible that lowering the 
concentration of cobinamide further will allow better de-convolution of this 
phenotype, which is suggestive of a regulatory switch.  
 
Based on the results presented here, it is only possible to conclude that 
supplementation with adenine and cobinamide in either MSM (∆cobK 
∆metE::hyg) or MTB (∆metE::hyg) was only slightly suggestive of pseudo-
B12 synthesis. Instead, it appears that an alternative biochemical approach 
will be required to differentiate the specific chemical species; for example, 
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direct detection by HPLC (Anderson et al., 2008). This approach was not 
pursued in this project owing to the technical complexities (and associated 
health and safety risks) of B12 extraction and detection, which involves the 
use of cyanide. Furthermore, pseudo-B12 is not commercially available and 
extraction would therefore require isolation of the alternate cofactor from 
an organism that synthesizes pseudo-B12. A recent study by Szterk and 
colleges (2012) described an alternative technique of extracting B12 which, 
although not as sensitive, does offer the possibility of qualitative 
assessment of the various B12 forms in MTB. 
 
 
4.4.1. Deletion of Rv0306 in MTB  
 
The genetic approach utilized in this study to elucidate whether MTB has 
the capacity to synthesize pseudo-B12 was based on the assumption that 
abrogation of BluB function would eliminate the ability of the metE mutant 
to utilize cobinamide for growth in minimal medium. This approach relied 
heavily on the prediction that Rv0306 encodes the MTB bluB homologue 
(Campbell et al., 2006; Taga et al., 2007) and, further, that MTB does not 
possess an alternative pathway for DMB biosynthesis. The BluB enzyme 
was demonstrated both experimentally (Pollich and Klug, 1995; Campbell 
et al., 2006) and biochemically (Taga et al., 2007) to be responsible for 
the aerobic conversion of flavin mononucleotide to DMB in other 
organisms. In addition to bioinformatic searches carried out in this study, 
multiple other studies (Rodionov et al., 2003; Campbell et al., 2007; Taga 
et al., 2007) identified Rv0306 as the candidate BluB in MTB. It was 
notable that deletion of Rv0306 in the ∆metE::hyg mutant background did 
not inhibit the ability of MTB to utilize cobalt (data not shown), thereby 
invalidating the previous prediction of Rv0306 as a putative cobalt 
reductase (Figure 3.9). It was surprising, however, that the ∆Rv0306 
∆metE::hyg double mutant was able to grow when supplemented with 
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cobinamide alone (Figure 3.14), since this implied an alternative 
mechanism for DMB biosynthesis, or that MTB was able to counter the 
loss of this enzyme by producing a pseudo-B12 form (or forms) using an 
alternative, endogenous α-ligand. 
 
This observation was, however, consistent with predictions made by 
Anderson and colleagues: in their paper describing the elucidation of 
pseudo-B12 biosynthesis in S. enterica, the authors postulated that the 
phenotypic identification of the effects of disrupted DMB synthesis was 
expected to be difficult owing to the fact that, in the absence of DMB, 
corrinoid synthesis would shift to pseudo-B12 production, without any 
impairment of growth (Anderson et al., 2008).  
 
S. enterica synthesizes pseudo-B12 under anaerobic conditions (Keck and 
Renz, 2000), and “orthodox” B12 under aerobic or microaerophillic 
conditions when provided with cobinamide (Johnson and Escalante-
Semerena, 1992). S. enterica appears not to possess a bluB homologue 
(Keck et al., 1998; Anderson et al., 2008), raising the possibility that 
another enzyme might carry out this function, which might be present in 
MTB as well. M. leprae has undergone extensive genome reduction (Cole 
et al., 2001) but is in possession of the late stage B12 biosynthetic 
enzymes, including CobS and CobT, excluding a putative bluB homologue. 
M. leprae is also thought to be an excellent adenine scavenger (Wheeler, 
1987), which suggests that pseudo-B12 might be a relevant cofactor in 
different mycobacteria. As noted above, a more precise method such as 
the use of HPLC (Anderson et al., 2008) or equivalent (Szterk et al., 2012) 
to detect the exact chemical species utilized by different mycobacteria will 
be required to confirm this prediction.  
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4.5 Concluding remarks 
 
Utilizing a purely genetic approach, this study has established that cobalt 
supplements growth of the MTB metE mutant, a B12 auxotroph. However, 
fundamental questions remain, most of which relate to the role of vitamin 
B12 biosynthesis in MTB pathogenesis. These include: does MTB synthesize 
B12 in vivo? If so, how much of cobalt is available and can MTB access this 
metal ion from the host? Does MTB utilize host transporters or 
chaperones? Alternatively, if B12 is acquired from the host – how much is 
available and under what conditions is this cofactor accessed?  
 
Although the phenotypes associated with deletions of genes predicted to 
occur in early and late stages of the B12 biosynthetic pathway implied that 
cobalt was being utilized for de novo vitamin B12 synthesis, the use of 
radiolabelled cobalt would better aid in confirming accumulation and 
transport of this metal ion in MTB. This would be especially useful in the 
presence and absence of functional PPE2, to confirm the role of this gene 
in cobalt transport/assimilation. Furthermore, transcriptional analyses by 
microarray of MTB in response to cobalt could possibly elucidate 
regulation of PPE2 to this metal ion, although this is less certain based on 
similar transcriptional profiling of PPE genes (described in section 1.11.1). 
Given the inferred role of PPE2 in cobalt transport/assimilation, a 
recombinant form PPE2 might better elucidate cellular localization, and 
would offer the possibility of gaining structural insight into this unexpected 
function. Also, the predicted cobaltochelatase function of CysG could be 
explored by deleting cysG in the ∆metE::hyg background; this might be 
predicted to phenocopy the ∆cobK ∆metE::hyg and ∆PPE2 ∆metE::hyg 
mutants if cysG is required for cobalt insertion in MTB. Lastly, chemical 
differentiation of the exact species of B12 synthesized when ∆metE::hyg is 
supplemented with cobalt, and when ∆Rv0306 ∆metE::hyg is supplement 
151 
 
with cobinamide alone or in combination with adenine or DMB, will better 
resolve the exact nature of the cofactor synthesized by MTB. 
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5. Appendices 
 
Appendix A: List of abbreviations 
 
2TY Tryptone Yeast broth 
3-NP 3-nitropropionate 
AD Adenine 
AdoCbl Adenosylcobalamin 
Amp Ampicillin 
aph  Aminoglycoside phosphotransferase, confers resistance to 
kanamycin  
BCG bacille Calmette-Guérin 
bla Gene conferring resistance to ampicillin 
bp Base pair 
BSA Bovine serum albumin 
cbi Cobinamide 
Cbl Cobalamin 
CNCbl Cyanocobalamin (vitamin B12) 
CTAB Cetyltrimethylammonium bromide 
d Day(s) 
DMB 5,6-dimethylbenzamidazole 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DOTS Directly Observed Therapy – Short Course 
EDTA Ethylenediaminetetraacetic acid 
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fM femtomolar 
g Gravitational force 
g grams 
GS Glucose salt 
h Hour(s) 
HC Haptocorrin 
HCl Hydrochloric acid 
HIV Human Immunodeficiency Virus 
HPLC High-performance liquid chromatography 
hyg Gene conferring resistance to hygromycin B 
Hyg Hygromycin B 
ICL Isocitrate lyase 
IF Intrinsic factor 
IRIS Immune Reconstitution Inflammatory Syndrome 
Km Kanamycin 
LA Luria-Bertani agar 
lacZ Gene encoding β-galactosidase 
LB Luria-Bertani broth 
LTBI Latent tuberculosis infection 
MDR Multidrug Resistant 
MeCbl Methylcobalamin  
min Minutes 
ml Mililitre 
MTB Mycobacterium tuberculosis 
NaCl Sodium chloride 
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NaNO2 Sodium nitrite 
NaOH Sodium hydroxide 
NCE Non-citrate ethanolamine 
nt Nucleotide 
OAA Oxaloacetate 
OADC Oleic acid-albumin-dextrose-catalase 
OD600 Optical density at 600 nanometre wavelength 
OHCbl Hydroxycobalamin 
PCR Polymerase Chain Reaction 
PDIM Phthiocerol dimycocerosate 
PEP Phosphoenolpyruvate 
PEPCK Phosphoenolpyruvate carboxykinase 
RD1 Region of difference-1 
RNA Ribonucleic acid 
RT Reverse transcription/transcriptase 
s Seconds 
sacB Gene encoding levansucrase 
SAM S-adenosyl-L-methionine 
sdH2O Sterile distilled water 
SDS Sodium dodecylsulphate 
SL Sulfolipid 
Suc Sucrose 
TAG Triacylglycerol 
TB Tuberculosis 
TCA Tricarboxylic acid 
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TCII Transcobalamin II 
TDR Totally Drug Resistant 
TE Tris-EDTA 
TLR Toll-like receptor 
Tris Tris(hydroxymethyl)aminomethane 
Tween Polyoxyethylene sorbitan monooleate 
v/v Volume per volume 
v/w Weight per volume 
WHO World Health Organization 
XDR Extensively Drug Resistant 
X-gal 5-bromo-4-chloro-3-indolyl-D-thiogalactopyranoside 
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Appendix B: Culture media  
 
All media are made up to a final volume of 1 litre with deionised water, 
and sterilised by autoclaving at 121oC for 20 minutes, unless otherwise 
stated. 
 
Luria-Bertani Broth (LB) 
5g yeast, 10g tryptone, 10g sodium chloride 
 
Luria-Bertani Agar (LA) 
5g yeast, 10g tryptone, 10g sodium chloride, 15g agar 
 
2TY 
5g sodium chloride, 10g yeast extract, 16g tryptone 
 
Middlebrook 7H9 
2ml glycerol, 4.7g DifcoTM Middlebrook 7H9 broth 
 
Middlebrook 7H10 
5ml glycerol, 19g DifcoTM Middlebrook 7H10 agar 
 
Sauton’s minimal medium (pH 7.2) 
4 g asparagine, 0.5 g magnesium sulphate, 2 g citric acid, 0.5 g potassium 
dihydrogen orthophosphate, 0.05 g ammonium ferric citrate, 48ml 
glycerol. Sterilised by filtration. 
 
Valerate 
4.7g DifcoTM Middlebrook 7H9 broth, 0.85g NaCl, 5g BSA, 1ml valeic acid. 
pH 6.8; sterilise by filtration.  
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NCE medium 
0.2g magnesium sulphate, 10g dipotassium phosphate, 3.5g 0.2g 
magnesium sulphate, 10g dipotassium phosphate, 3.5g Ammonium 
sodium phosphate dibasic tetrahydrate, 3.9g ethanolamine hydrochloride. 
pH7.0; sterilise by filtration 
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